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Thesis	Summary.	
Ischaemia Reperfusion (IR) injury is a major cause of morbidity and mortality 
following orthotopic liver transplantation. Remote Ischaemic Preconditioning (RIPC) 
reduces IR injury in small animal models. The mechanism remains unclear. The aim 
of this thesis was to explore the mechanism of RIPC and its clinical relevance to 
liver transplant recipients.  
Following a literature review a study was performed on optimal end points for 
clinical studies modulating IR injury in liver transplantation. Day 3 AST level was 
strongly associated with early post operative morbidity and mortality.  
A pilot randomised controlled trial of limb RIPC (3 cycles 5 minutes) in 40 liver 
transplant recipients was performed. Recruitment was successful and the intervention 
found to be safe and well tolerated. There was no significant difference in day 3 
AST. CD4+T cell IFNγ and TNFα production was found to be significantly 
upregulated in patients post-reperfusion but not affected by RIPC. IFNγ and IL-2 
were produced by a CD3-ve HLADR+ve cell population. Monocyte chemoattractant 
protein-1 (MCP-1) levels were significantly elevated following reperfusion and 
correlated with clinical outcomes.  
The T cell response to RIPC was further investigated in a murine model of RIPC and 
warm liver IR injury. The model demonstrated a reduction in warm liver IR injury 
following RIPC. Intrahepatic CD4+ T cell TNFα production was significantly 
increased following reperfusion and reduced by RIPC.  Monocytes were recruited to 
the post ischaemic liver as demonstrated in the human clinical trial. MCP-1 levels 
and monocyte recruitment were significantly reduced following RIPC in the mouse.  
In conclusion clinical benefit of RIPC in OLT recipients was not achieved in this 
pilot study. The RIPC stimulus may be sub-optimal. CD4+T cells and monocytes 
were shown to have a key role in both the human and animal studies and their 
manipulation may provide new opportunities for modulating liver IR injury. 
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Thesis	Impact	Statement.	
This research performed the first ever human pilot study of remote ischaemic 
preconditioning (RIPC) on liver transplant recipients (RIPCOLT trial). We found 
although safe and feasible to perform, in its current form RIPC did not provide 
evidence of clinical benefit in the outcomes measured. A key finding was that despite 
the cuff being inflated for 5 minutes, ischaemic conditions were not achieved in the 
limb during the preconditioning period. This may be explained by the supplementary 
oxygen given to patients in the peri-operative period that could partially explain the 
poor translation of this technique to clinical practice. These results have lead to the 
design of a future study at the Royal Free aiming to identify the optimal length of 
time for the preconditioning stimulus.  
Serial peri-operative measurements of urinary Neutrophil Gelatinase Lipocalins 
(NGAL) in 28 patients from the RIPCOLT trial has identified that measurement of 
urinary NGAL levels at time of abdominal closure are an excellent and early 
biomarker to detect post-operative acute kidney injury (AKI). A grant application is 
being prepared to trial more rapid assays to measure NGAL levels than a standard 
ELISA. The measurement of urinary NGAL levels shall allow earlier diagnosis of 
AKI in liver transplant patients which will lead to better post-operative management 
of liver transplant patients and improved outcomes. This in turn has allowed for the 
design of a randomized controlled trial investigating the effect of early Renal 
Replacement Therapy (RRT) in liver transplant recipients with AKI that could 
transform the management and outcome in this cohort of patients. Patients with high 
NGAL levels will be randomized to early RRT or standard management. 
Furthermore, analysis of peri-transplant blood samples and post reperfusion liver 
biopsies from patients recruited to the RIPCOLT trial has shown clear evidence of an 
acute inflammatory response in the first 2 hours post reperfusion and that patients 
with poorer outcomes post liver transplant have evidence of greater immune 
activation in the first 24 hours post transplant. The most exciting finding was of 
infiltration of the post ischaemic liver by inflammatory monocytes and massive 
activation of likely dendritic cells with associated cytokine production. Although not 
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yet clinically applicable this work has provided the basis for further investigation of 
the monocyte/dendritic cell pathway in liver IR injury – an area that is as yet poorly 
understood. Transient inhibition of chemokines associated with monocyte 
recruitment is possible and this work may lead to the introduction of novel 
immunotherapies to ameliorate IR injury simultaneously improving outcomes for 
patients and allowing the safe implantation of more marginal grafts and ultimately 
widening the potential donor pool. 
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Chapter	1:	Introduction	
1.1: Liver Transplantation- a brief history. 
First performed in 1963 by Thomas Starzl [1], orthotopic liver transplantation (OLT) 
involves replacing a patient’s failing liver with a donor liver. Liver transplantation 
has now become the only accepted treatment for patients with both acute and chronic 
end stage liver disease and has been shown to dramatically increase not only 
recipient survival [2] but also long term quality of life [3]. In 2016, 917 liver 
transplants were performed in UK centres [4]. Liver transplantation is now 
associated with excellent outcomes with 90 day recipient survival of 90.8% and graft 
loss of 10.7% in UK centres [5]. Due to the excellent outcomes post OLT, the 
indications for liver transplantation have been widened placing even more demand 
on the availability of donor organs. As a result the number of patients active on the 
waiting list climbs annually with over 500 patients currently on the UK liver 
transplant waiting list [4]. Recent initiatives from the UK government including 
national TV advertising campaigns and the change in donor policy to an opt out 
policy in Wales have lead to an increase in the number of organ donations. However 
this increase has largely been in the group of donors following cardiac death (DCD), 
a donor group which is also associated with a high rate of organ discards following 
retrieval [4]. 
1.2: Types of liver transplant. 
There are 4 main categories of liver transplant donors which can broadly be divided 
into living donors and deceased donors. Deceased donor liver transplantation 
involves removing the liver from a recently deceased patient and transplanting it into 
the recipient and is the main method of organ procurement in the western world. 
Deceased donors can be sub divided into 2 categories depending on the mechanism 
of donor demise and therefore how the donor is to be declared dead- Donation 
following brain death (DBD) donors and donation following cardiac death (DCD) 
donors. DBD donors have functioning circulatory and respiratory systems and their 
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organs are therefore in an optimal condition until retrieval and cold storage. DCD 
donors have life support withdrawn prior to commencing the retrieval procedure and 
therefore there is a period of time when the organs are not perfused with oxygenated 
blood but remain maintained at core body temperature. This period of time is termed 
primary warm ischaemic time and it is during this period when significant damage 
can occur to the organ resulting in poorer outcomes [6]. If prolonged it is a key 
reason why organs are discarded. If a pediatric recipient requires transplantation, 
selected DBD grafts, chosen as they are of optimal quality, may be split into 2 
portions to allow simultaneous transplantation of a pediatric and adult recipient – 
optimizing organ use but unfortunately reducing the quality of the grafts and 
increasing the risk of organ failure [7]. 
Domino liver transplantation is a technique whereby patients who undergo 
transplantation for metabolic disorders such as familial amyloidotic polyneuropathy 
(FAP) can become donors themselves. This is because not all patients who receive 
these organs will progress to develop symptoms as the damage from amyloid 
deposition may take 15-20 years to occur. In a study of over 500 patients receiving a 
domino transplantation from FAP patients only 2 recipients developed symptoms due 
to amyloid disease - one patient at 7 years post transplant and the other at 8 years [8]. 
Therefore these livers can be implanted into patients with end stage liver disease 
with excellent results. 
Living donor liver transplantation involves removing part of a living donor’s liver 
and implanting it into the recipient. Although living donation constitutes the minority 
of grafts procured in the western world it is the main form of liver transplantation in 
Asian countries where the practice of donating organs following death may be 
perceived as being against religious beliefs. 
Although the grafts used in the early years of liver transplantation were from DCD 
donors, these were superseded by DBD donors. The use of DCD grafts was re-
explored in the early 2000’s to expand the donor organ pool. The use of DCD grafts 
in the UK was pioneered by Kings College London in 2001 [9] and has now become 
standard practice. In 2005, 6.9% of liver grafts transplanted in the UK came from 
DCD donors [10] but by 2016, this had climbed to 23.6% [4]. Although this has 
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successfully increased the donor organ pool and may have prevented patients dying 
on the waiting list, the use of a DCD graft from an individual recipient’s perspective 
is associated with a 2-fold increase in the risk of mortality and graft loss when 
compared to the use of a DBD graft [10]. This poorer outcome is believed primarily 
to be secondary to the increased ischaemic reperfusion (IR) injury that occurs to 
DCD grafts as a result of the initial period of warm ischaemia during circulatory 
arrest. IR injury is a major cause of post-operative morbidity and mortality and is 
believed to account for around 10% of early graft loss [11]. IR injury results in poor 
graft function and associated end organ dysfunction especially acute kidney injury 
(AKI). There is no current marker for liver IR injury. This makes both diagnosing IR 
injury and designing trials aimed at reducing IR injury challenging. Small animal 
models of liver warm IR injury or liver transplant often use a reduction in serum 
transaminases but this is a surrogate marker of liver damage and how this relates to 
clinical outcomes remains unknown. Strategies to reduce/treat IR injury would not 
only improve outcomes following liver transplantation but would also widen the 
potential donor pool as some marginal grafts which are currently discarded from 
clinical use may be suitable for transplantation 
1.3: Ischaemia reperfusion injury. 
IR injury is the injury that occurs to an organ when its blood supply is interrupted 
and reconstituted. IR injury is not a phenomenon limited to liver transplantation and 
is seen in all forms of solid organ transplantation, resectional surgery and in patients 
suffering from myocardial infarction, cerebro-vascular accidents and peripheral 
vascular disease. In the setting of liver resectional surgery, IR injury has been shown 
to occur even in the absence of inflow occlusion during mobilization and handling of 
the liver [12,13] suggesting that intra-operative tissue damage is sufficient to drive 
IR injury. This would mean that research into liver IR injury may have broader 
implications and be beneficial in all settings of surgery not just those with a defined 
ischaemic time. In the setting of transplant surgery where the liver is removed from 
one individual and placed in another, IR injury is currently unavoidable and is a 
significant cause of post-operative graft loss, morbidity and mortality [11].  
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IR injury post liver transplant can manifest as a spectrum of conditions from early 
allograft dysfunction to primary graft non-function requiring re-transplantation. It is 
also associated with end organ dysfunction including acute kidney injury and 
respiratory failure. 
When an organ loses its blood supply, the cells switch to anaerobic respiration and 
ATP stores become depleted. A key step in the pathogenesis of ischaemic injury 
(Figure 1.1) is the failure of the sodium/potassium cell membrane pump leading to 
mitochondrial dysfunction, cell swelling and membrane rupture [14]. Disruption of 
the cell membrane allows damage associated molecular patterns (DAMPs) to leak 
into the extracellular space. Several DAMPs have been identified including mRNA, 
DNA and heat shock proteins [15]. High Mobility Group Box 1 (HMGB1) has been 
identified as a key DAMP in mediating hepatic IR injury [16] which is released 
following hypoxic liver injury [17] and has been shown to interact with Toll Like 
Receptor 4 [16] in a similar fashion to lipopolysaccharide (LPS) both in monocytes 
and T cells [18]. 
 
Figure 1.1: Schematic of pathology of Ischaemia Reperfusion injury. 
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Cessation of the blood flow through the tissue and oedema leads to platelet 
aggregation [19,20] and thrombus formation in the capillaries along with activation 
of the complement system damaging the micro-vascular network. 
1.3.1: Reperfusion. 
Following reperfusion further injury occurs. The release of reactive oxygen species 
(ROS) causes cell membrane damage. Massive chemokine release results in an influx 
of inflammatory cells further injuring the already damaged micro-vascular system. T 
cells have been shown to play a key role in the pathogenesis of IR injury. Several 
studies have investigated the role of T cell subsets in liver IR injury. 
1.3.1.1: CD4+ T cells. 
There is strong evidence to suggest a role for αβ T cells in the pathogenesis of IR 
injury. A key observation by Zwacka in 1997 was that athymic mice (mice lacking T 
cells) were protected from reperfusion injury following warm hepatic IR injury [21] 
suggesting that T cell responses are crucial to the injury. Pharmacological treatment 
of mice prior to IR injury with FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-
propanediol hydrochloride), which is known to cause a lymphopaenia similarly 
reduced IR injury [22]. Further analysis has shown that selective depletion of CD4+ 
T cells provided a similar level of protection following ischaemic injury whereas 
depletion of CD8+ T cells did not [21]. This finding has been shown by other groups 
studying hepatic IR injury [23,24] and by groups studying renal [25], intestinal [26] 
and pulmonary [27] IR injury suggesting that it is a global IR phenomenon rather 
than being organ specific. In contrast one study found that depletion of CD4+ T cells 
in mice undergoing warm hepatic IR injury lead to a more significant injury [28]. 
Although these are seemingly conflicting results, they point to a key role for CD4+ T 
cells in the pathogenesis of reperfusion injury. In murine models, there is also clear 
evidence of early and transient CD4+ T cell recruitment to the post ischaemic liver 
within the first 4 hours of reperfusion [21,28,29] again indicating a role for CD4+ T 
cells in IR injury. Although it is not known which molecule attracts CD4+ T cells to 
the liver, it is specific as CD8+ T cells do not accumulate [29]. The mechanism by 
which CD4+ T cells drive IR injury remains unknown. One study treated mice with 
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anti MHC Class II antibodies to block antigen activation of T cells and demonstrated 
no effect on IR injury suggesting that CD4+ T cells are activated in a non-antigen 
dependent fashion [29]. In a similar experiment, CD4+ T cell depletion lead to 
protection against IR injury whilst prevention of antigen facilitated activation of 
CD4+ T cells did not affect IR injury [30]. Both studies also identified the CD154-
CD40 interface by CD4+ T cells as a key mechanism of injury propagation although 
they investigated different effector cells [29,30]. In contrast, one study found that 
antigen activation of CD4+ T cells was required to drive the inflammatory 
reperfusion injury [24]. However the rapid response is not typical for an antigen 
driven CD4+ T cell response which typically takes 4-7 days to become effective 
[31]. This study utilised OT-II mice in which the T cell receptor (TCR) only 
recognizes ova-albumin.  Memory T cells are known to more readily secrete 
cytokines upon stimulation than naïve T cells [32]. Although hepatic IR injury was 
attenuated, this need for TCR stimulation may reflect the lack of previously activated 
memory CD4+ T cells in these mice rather than the need for antigen recognition 
[26]. TLR4 has been highlighted as a key pathway in immune activation, both in 
CD4+ T cells and in the closely associated dendritic cells [30]. When linked with 
further studies that have identified HMGB1, which is known to interact with TLR4, 
as an essential mediator of IR injury [16,17] it is more likely that the TLR pathway 
of immune activation rather than TCR stimulation is responsible in IR injury as this 
would be in keeping with the timescale. 
There are several subsets of CD4+ T cells both pro-inflammatory and anti-
inflammatory which may explain the apparent contradictory results in CD4+ T cell 
knock out studies [21,28]. 
1.3.1.1.1: T helper 1 and T helper 2 cells. 
Once activated, naive CD4+ T helper cells differentiate into T helper 1 (Th1) cells 
which are characterized by the transcription factor T-box transcription factor (T-bet) 
and their ability to secrete Interferon gamma (IFNγ) or T helper 2 (Th2) cells which 
are characterized by the transcription factor GATA-3 and are predominantly 
involved in B cell and antibody driven immune responses. The main effector cell of 
Th1 cells are macrophages [33]. The secreted IFNγ stimulates macrophages and 
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results in iNOS driving phagocytosis. It has been shown in a murine model that mice 
lacking B cells were not protected following IR injury [34] suggesting that IR injury 
is not a Th2 response. Furthermore, they demonstrated a reduction in the number of 
intrahepatic B cells following reperfusion primarily secondary to B cell death. In 
contrast in a canine model of lung allotransplantation, significantly raised levels of 
IFNγ were measured in the bronchoalveolar fluid at 1 and 4 hours post reperfusion 
suggesting a Th1 driven CD4+ T cell response. The evidence for a Th1 response is 
further strengthened by findings in a model of ischaemic renal injury in which,    
CD4 + T cell deficient mice suffered significantly less injury that wild type mice. 
Adoptive transfer of CD4+ T cells from wild type mice reconstituted the injury 
however adoptive transfer of CD4+ T cells from mice deficient in IFNγ did not 
reconstitute the injury [25]. IFNγ is also known to strengthen the monocyte response 
following TLR4 stimulation [35]. The role of CD4+ T cells in IR injury may 
therefore be to prime and strengthen the monocyte/macrophage response. 
1.3.1.1.2: T helper 17 cells. 
T helper 17 (Th17) cells are a highly pro-inflammatory subset of CD4+ T cells. 
Stimulation of naïve T cells in the presence of IL-6 and TGF-β promotes 
upregulation of the nuclear transcription factor Retinoic acid receptor related Orphan 
Receptor Gamma T (RORγT) and differentiation of cells into the Th17 phenotype 
[36]. Th17 cells secrete the pro-inflammatory cytokines Interlukin (IL) 17, IFNγ and 
TNFα. IL-17 has been shown to recruit neutrophils to the post ischaemic liver 
[28,37] and treatment of mice with anti IL-17 antibody attenuated IR injury [37]. In a 
mouse model of intestinal IR injury, genetic knock out mice unable to produce IL-17 
experienced significantly attenuated IR injury and in wild type mice, cells expressing 
both CD3 and IL-17 were seen to rapidly infiltrate the post ischaemic tissue [38].  
1.3.1.1.3: Regulatory T cells. 
In contrast, regulatory T cells (Tregs), characterized by their expression of the 
nuclear factor Forkhead Box P3 (FoxP3), are potent anti-inflammatory CD4+ T cells. 
Stimulation of naive T cells in the presence of TGF-β promotes upregulation of 
FoxP3 and differentiation to Tregs [36]. Tregs reduce the inflammatory response 
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through the production of IL-10, CTLA-4 and TGF-β. One study carefully dissected 
the role of individual cell subsets in hepatic IR injury and found that depletion of 
Tregs by PC61 (anti CD25 antibody) did not alter the severity of IR injury [24]. 
These results are backed up by a study by Devey and colleagues [39] investigating 
the role of Tregs in ischaemic preconditioning. They found that although IPC 
protected against IR injury, it did not increase Treg numbers. Furthemore Treg 
depletion by diphtheria toxin did not affect IR injury and Treg expansion by IL-2 or 
by adoptive transfer of in vitro induced Tregs did not affect the severity of IR injury. 
In contrast, several studies have demonstrated that the adoptive transfer of induced 
Tregs (iTregs) stimulated in vitro in mice significantly attenuated hepatic IR injury 
[40,41]. All the studies used slightly different in vitro methods to stimulate the 
iTregs and this may explain the conflicting results, especially as the study by Devey 
and colleagues [39] used a process to produce iTregs that did not reduce the onset of 
experimental autoimmune encephalitis [42]. This result may be down to the 
production of ineffective Tregs Furthermore, IR injury is associated with high 
systemic levels of IL-6 [16] which is known to inhibit Treg function [43] and 
differentiation [44,45]. There appears to be a degree of plasticity between Th17 cells 
and Tregs and following IR injury, IL-6 may result in conversion of Tregs to highly 
pro-inflammatory Th17 cells [36]. Induced Tregs are Tregs that are formed either in 
the peripheral circulation or lymphatics from previously FoxP3-ve naive CD4+ T 
cells in comparison to natural Tregs (nTregs) that are formed in the thymus [46]. It 
has been shown that iTregs are significantly less susceptible to IL-6 differentiation 
into Th17 cells in inflammatory states than nTregs [47] and this may explain why a 
murine model found that Treg depletion which will have been nTregs did not affect 
liver injury [24]. The transfer of iTregs has had varying effects with 2 studies 
reporting reduced injury [40,41] and 1 not [39].  
1.3.1.2: Monocytes. 
Monocytes exist predominantly in the peripheral circulation but infiltrate tissues 
where they differentiate into dendritic cells and macrophages. In humans there are 
three main sub-groups of monocytes. Classical monocytes, identified by the presence 
of the cell surface marker CD14 and the absence of the cell surface marker CD16 
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closely resemble the murine subset of inflammatory monocytes. Monocytes are 
recruited from the bone marrow during inflammation by chemokine (C-C motif) 
ligand 2 (CCL2) or monocyte chemoattractant protein 1 (MCP1) as it is otherwise 
known [48]. The inflammatory or classical population of monocytes are highly 
phagocytic and pro-inflammatory and are known to produce IFNγ, IL-10 and 
reactive oxygen species (ROS) following TLR4 stimulation. Monocytes are key 
producers of iNOS [49] and the release of ROS is via iNOS activation. 
One study in human liver transplant patients found a correlation between serum 
levels of CCL2 measured at 1 hour post reperfusion and peak serum transaminase 
levels suggesting a relationship between monocyte recruitment and the severity of 
hepatocyte injury [50]. Another study monitoring serum cytokine levels in the post 
transplant period found that patients who developed early allograft dysfunction 
(EAD) according to the Olthoff criteria had significantly higher CCL2 levels at 24 
hours post transplant [51]. 
Monocytes have been shown to traffic to the liver following tissue injury. In one 
small animal model, 24-48 hours after carbon tetrachloride induced liver injury, 
monocytes were found to account for approximately 12% of the non hepatocyte cell 
population from a baseline of less than 1% [52]. In the liver, inflammatory 
monocytes have been shown to play a key role in the tissue injury following 
acetaminophen induced liver injury [53]. Few studies have looked at the role of 
monocytes in liver IR injury. One study depleted circulating monocytes in mice to 
investigate their role in reducing liver IR injury [54]. It was found that the depletion 
of circulating monocytes did not affect liver IR injury when compared to mice with a 
normal monocyte compartment. It is, however unclear whether monocytes in the 
bone marrow were depleted by this method. If not then circulating monocytes would 
be replenished rapidly following recruitment from the bone marrow or spleen after 
IR injury [55]. In contrast another study performed hepatic IR injury in CCL2 
genetic knock out mice and demonstrated a significant reduction in infiltration of 
inflammatory monocytes with an associated reduction in ROS induced liver injury 
[56]. A study in the murine liver found that inflammatory monocytes rapidly 
infiltrated the liver following heat induced liver injury however they were 
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reprogrammed in situ and progressed to promote tissue healing and regenesis [57]. 
This finding is strengthened by studies that have demonstrated reduced healing and 
clearance of necrotic cell debris in acute liver injury [58] in mice lacking CCL2. 
Monocytes have the potential to rapidly differentiate into macrophages and dendritic 
cells in states of inflammation. 
1.3.1.3: Macrophages. 
Macrophages are terminally differentiated monocytes and are involved in 
phagocytosis and antigen presentation to CD4+ T cells. Kupffer cells are the liver 
resident macrophage population. Macrophages can be classified as M1 or M2 
depending their effector function [59]. A M1 type response is driven by IFNγ and 
results in ROS mediated tissue damage resulting from iNOS degredation of arginine. 
M1 macrophages are the effector mechanism of Th1 differentiated CD4+ T cells. A 
M2 type response promotes tissue repair as arginine is broken down to Ornithine. 
This plasticity in the macrophage population perhaps explains why several groups 
have come to differing conclusions regarding the role of macrophages in liver IR 
injury. It has been previously shown that macrophages are activated following liver 
ischaemia [60] and drive the reperfusion injury. Inhibition of macrophage activation 
by gadolinium chloride has been shown to reduce IR injury [61]. In contrast another 
group demonstrated that Kupffer cell depletion resulted in significantly worse IR 
injury as measured by serum transaminases and found Kupffer cells mediated 
hepatoprotection via haem oxygenase-1 (HO-1) [54]. Studies investigating the role 
of macrophages in IR injury via gadolinium chloride inhibition must be interpretated 
with caution as gadolinium chloride has also been shown to significantly deplete 
circulating monocytes and therefore is not specific [62]. 
1.3.1.4: Dendritic cells. 
Dendritic cells are antigen presenting cells and are often seen as the link between the 
innate immune response and a T cell response. There are 2 main subgroups of 
dendritic cells, plasmacytoid dendritic cells that express high levels of TLR 9 and 
conventional dendritic cells that differentiate from monocytes and express high 
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levels of TLR4 [63]. In inflammatory states, monocytes can differentiate rapidly into 
inflammatory dendritic cells. Stimulation of TLR4 can induce the secretion of highly 
pro-inflammatory cytokines including IFNγ, IL-2, Il-6 and TNFα. IL-2 is a potent 
activator of T cells and is known to promote a Th1 CD4+ T cell effector response. 
IL-2 is also a potent activator of monocytes enhancing their phagocytic activity 
following TLR 4 stimulation [64]. There are only a limited number of studies 
investigating the role of dendritic cells in liver IR injury. One study in a murine 
model showed that stimulation of TLR9 on dendritic cells lead to IL-10 release and 
protection during liver IR injury [56]. Although the lineage of these cells was stated 
to be conventional, the expression of TLR9 would suggest that these cells were 
plasmacytoid in origin [63]. Another study again in a murine model found that 
circulating dendritic cells in the blood contributed to liver injury whilst liver resident 
dendritic cells were protective against liver injury [65]. Whether the blood dendritic 
cells were monocytes that have undergone differentiation was not explored in this 
study however it is known that monocytes can undergo rapid differentiation into 
inflammatory dendritic cells in inflammatory states [66]. 
1.3.1.5: Cytokines. 
IR injury has been shown to be associated with an increase in pro-inflammatory 
cytokines. In small animal models, Tumour necrosis factor α (TNFα), which attracts 
and activates neutrophils to sites of injury, has been shown to be a key driver of IR 
injury [67]. Increased TNFα levels in liver transplant donors has been associated 
with increased post-operative recipient morbidity [68]. Several groups have 
identified that both intra-hepatic and circulating levels of TNFα are significantly 
raised early following liver IR injury [16,69–71]. Treatment of rats with anti TNFα 
prior to IR injury significantly ameliorated IR injury and was associated with a 
reduction in neutrophil activity [72]. Inhibition of macrophages with gadolinium 
chloride resulted not only in a reduction of IR injury but also of TNFα levels 
following IR injury [69]. Treatment with gadolinium chloride and TNFα restored the 
IR injury. Similarly, Teoh and colleagues demonstrated significantly reduced IR 
injury in TNFα knock out mice [73] a finding which has been corroborated by other 
groups [71]. In contrast one group found that treatment of mice with a low dose of 
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TNFα 30 minutes prior to IR injury was associated with a significantly reduced liver 
injury [74] but also with significantly reduced TNFα levels post IR injury. This may 
therefore mimic IPC in which a short period of non-lethal ischaemia and tissue 
damage drives low dose TNFα release which induces a protective mechanism. 
IR injury has also been shown to result in increased levels of IL-6, a pleiotropic 
cytokine but one that plays a key role in CD4 Th17 responses [44] and blocks Treg 
function [43]. Furthermore IL-6 has been shown to play a key role in CD4+ T cell 
migration and survival [75]. Although IL-6 levels have been shown to be elevated 
following IR injury, studies using genetic knock out mice have shown that mice 
lacking IL-6 suffer a more severe IR injury [76] and exhibit reduced liver 
regeneration [77]. The effect of IL-6 knock-out on the resident CD4+ T cell 
population remains unknown and it remains unknown what transient IL-6 depletion 
at the time of reperfusion would achieve. 
One study investigating the role of CD4+ T cells in renal IR injury found that 
adoptive transfer of CD4+ T cells from IFNγ deficient mice did not reconstitute IR 
injury suggesting a key role for IFNγ in the CD4+ T cell response [25]. 
Contradictory data does exist however suggesting that IFNγ depletion did not 
influence IR severity [30]. The same study found that IFNγ was required to activate 
macrophages following IR injury. In a model of lung allotransplantation, IFNγ levels 
were found to be locally but not systemically elevated [78] and therefore systemic 
reconstitution of IFNγ may not have an effect. The same study identified local but 
not systemic increases in IL-2 a key cytokine required for CD4+ T cell survival and 
Th1 differentiation. 
1.4: Ischaemic Preconditioning: 
Ischaemic preconditioning (IPC) is the process by which short periods of non lethal 
ischaemia provide protection during a further period of sustained ischaemia. IPC can 
be performed in a direct fashion where the preconditioning stimulus is performed in 
the same vascular bed as the IR injury is going to occur or in a remote fashion. 
Remote ischaemic preconditioning (RIPC) is the process where the preconditioning 
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stimulus is performed in a different vascular bed to the one in which the subsequent 
IR injury occurs. Direct IPC was first described in 1986 in a canine model of cardiac 
IR injury [79]. In small animal models, direct IPC has been shown to ameliorate IR 
injury in several organs, including the liver [80,81]. The first trial in humans of direct 
IPC in patients undergoing liver resection was performed by Clavien and 
demonstrated a significant reduction in post operative transaminases and cellular 
apoptotsis [82,83]. Further trials have yielded mixed results and a recent meta-
analysis concluded that direct IPC in the setting of liver resectional surgery yielded 
no evidence of clinical benefit [84]. Several small studies have investigated the effect 
of direct IPC on liver transplant donors immediately prior to harvesting of the donor 
liver with mixed results [85–94]. None of the trials were adequately powered to 
demonstrate a significant reduction in post-operative mortality or graft loss but 2 
studies reported reduced post-operative transaminases in keeping with reduced liver 
injury [88,94]. One study included a subgroup analysis of steatotic grafts and found 
that IPC resulted in significantly better outcomes with fewer episodes of acute 
rejection [92]. A major drawback of direct IPC is that it can stress the target organ. 
IPC has been shown in small animal models to impair liver regeneration in small for 
size livers [95,96]. This raises the concern that direct IPC as a strategy to improve 
outcomes in marginal grafts may cause further damage. This may explain why one 
trial found that grafts that underwent IPC were associated with higher peak 
transaminases in the post-operative period suggesting increased hepatocyte injury 
[91]. There are several limitations to direct IPC. Firstly IPC cannot be performed in 
DCD donors which account for the largest group of marginal grafts. Secondly a large 
trial would be required to prove the efficacy of IPC in donors and to provide this 
infrastructure at the donor hospitals would be difficult. Both these issues would be 
overcome by performing IPC on the recipient. RIPC is a strategy that would avoid 
this stress to the target organ and could be performed on the recipient. RIPC was first 
described in 1993 again in a canine cardiac model [97]. RIPC is the process by which 
the preconditioning stimulus is applied to a distant unrelated vascular bed and 
provides systemic protection to the individual. RIPC has been shown to ameliorate 
IR injury in small animal models in the heart [97], intestine [98], kidney [99] and 
liver [100]. An initial trial of lower limb RIPC in children undergoing major cardiac 
surgery on cardiac bypass was promising with patients who were randomized to 
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RIPC requiring less post-operative inotropic support and lower post-operative serum 
troponin levels which was interpreted as indicating reduced myocardial injury [101]. 
Despite this initial success, 2 recent large clinical trials of RIPC have failed to 
demonstrate any clinical benefit in patients undergoing major cardiac surgery 
[102,103]. Both trials used a preconditioning stimulus of 4 by 5 minutes on the upper 
limb and were large including 1612 patients (801 RIPC and 811 control) [102] and 
1385 patients (692 RIPC and 693 control) [103]. There was no evidence of a 
reduction in adverse post-operative clinical complications including death, post-
operative cardiovascular events or need for inotropic support following RIPC in 
either trial. A pilot study of lower limb RIPC performed by our group in liver 
resectional surgery used a preconditioning protocol of 3 by 10 minute cycles of 
ischaemia/reperfusion and demonstrated a significant reduction in post-operative 
transaminases and a significant increase in post-operative ICG clearance indicating 
reduced liver injury and improved post-operative liver function [12]. In transplant 
surgery, there have been 3 trials performed investigating RIPC in renal transplant 
recipients with conflicting results. One trial demonstrated evidence of reduced renal 
injury as measured by neutrophil gelatinase-associated lipocalins (NGALs) and 
improved early graft function [104] whilst another failed to discern any evidence of 
improved function and measured similar NGAL levels between the groups [105]. 
One trial combined donor and recipient RIPC and found evidence of mildly 
improved graft function but no effect on the post-operative inflammatory response as 
measured by serum levels of inflammatory cytokines [106]. There has been a pilot 
study of RIPC performed on 57 DBD donors which demonstrated evidence of 
reduction in liver injury as measured by peak transaminases but this was not 
significant [107]. Performing RIPC on the recipient would mimic small animal 
models in which the preconditioning stimulus is performed in the individual that the 
reperfusion injury occurs. A study has shown that RIPC of pigs prior to implantation 
of a donor heart protected that heart during further periods of ischaemia [108] 
suggesting that RIPC may modulate the reperfusion injury. A key factor in the 
inability to translate the promising results in small animal models into clinical 
practice is a lack of knowledge about the pathways involved in the protective 
mechanisms of RIPC. Small animals used in research are primarily young healthy 
males bred in controlled circumstances. Clinical studies include many patients with 
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co-morbidities which could influence outcomes. It has been shown in small animal 
models that conditions such as diabetes, advanced age and obesity reduce the 
beneficial effect of RIPC [109]. Precise knowledge of the mechanisms of protection 
would allow targeted RIPC protocols or even the development of pharmacological 
treatments to reduce IR injury. 
1.4.1: Current knowledge of mechanisms of ischaemic preconditioning in 
hepatic ischaemia-reperfusion injury. 
IPC has been shown to provide both early and late protection which has lead to the 
terms the classical or early window of protection which lasts for up to 3 hours after 
the preconditioning stimulus [110] or the second or late window of protection which 
spans between 12 and 72 hours following the preconditioning stimulus [111–113]. 
Interestingly results from small animal models suggest that there may be an even 
later window of protection seen between 5-7 days following the preconditioning 
stimulus [114–116] although in these studies a long single preconditioning stimulus 
of between 24-30 minutes was used. IPC has been postulated to provide protection 
via 3 main mechanisms [117] (Figure 1.2). IPC has been shown to reduce apoptosis 
and promote cell survival under stress [118]. IPC has also been shown to provide a 
neuronal feedback to provide its protection [118]. The strongest evidence relates to 
the release of a soluble factor that provides systemic protection to improve cell 
survival and ameliorate the systemic inflammatory response. This factor can be 
transferred from a preconditioned animal to a naïve animal [119–121]. Studies have 
identified that the molecular mass of the factor that confers protection to be between 
3.5 and 8 kilodaltons [118] yet the factor remains unknown. This further strengthens 
the idea of preconditioning the recipient. 
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Figure 1.2: Mechanisms of IPC (direct and remote). Mechanisms identified in 
hepatic IR injury are in black whilst those not implicated/researched are in white 
[117]. 
The ischaemic conditions created during IPC causes the rapid release of adenosine 
from stressed cells [122]. Adenosine interacts with adenosine receptors of which 
there are 4 (A1R, A2AR, A2BR and A3R). Adenosine has been shown to be protective 
during IR injury in small animal models as pharmacological upregulation of 
adenosine has been shown to reduce IR injury and improve survival following warm 
hepatic IR injury in a canine model [123]. Adenosine has been shown to have several 
diverse downstream modulating pathways to provide protection (Figure 1.3). 
Adenosine improves the hepatic microcirculation in 2 ways. It has been shown to 
upregulate the release of nitric oxide (NO) a potent vasodilator which results from 
the degradation of L-arginine by endothelial nitric oxidase synthase (eNOS) [124]. 
Although administration of adenosine was shown to provide protection from IR 
injury, when it was given with a eNOS inhibitor, this protective effect was lost [125]. 
Adenosine has also been shown to work through the action of haemoxygenase-1 
(HO-1) leading to the release of carbon monoxide (another potent vaso-dilator) from 
haem [126]. No study has investigated the effect of administrating adenosine but 
simultaneously blocking HO-1 function. 
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Figure 1.3: Protective pathways of Adenosine release [117]. 
The exact receptor which is responsible remains unclear however A1R and A2AR 
have been the most extensively studied to date. Studies have focused on the 
administration of specific receptor agonist and antagonists and the results have been 
conflicting. One study demonstrated that mice administered an A1R agonist and A1R 
deficient mice suffered a more significant IR injury as measured by serum 
transaminases [127] whist another study demonstrated that administration of an 
A2AR agonist immediately prior to IR injury significantly reduced the injury [128].  
IPC has been shown to result in higher levels of intra-hepatic adenosine [129,130]. 
Administration of adenosine dehydrogenase immediately prior IPC was shown to 
ablate its protective effect [129]. Interesting this study also found that 10-15 minutes 
was the optimal length of time for the preconditioning stimulus as it resulted in the 
maximal release of adenosine but minimized the release of xanthine and other toxic 
metabolites [129]. This finding may help explain in part why the use of a 5 minute 
stimulus of donor preconditioning failed to discern any benefit [90] while the use of 
a 10 minute preconditioning stimulus demonstrated a reduction in post-operative 
transaminases in keeping with a reduction in liver injury [93]. Studies looking at the 
effect of IPC and adenosine receptors have shown conflicting results as with those 
investigating the effect of adenosine receptor manipulation in IR injury alone. One 
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study found that administration of an A1R agonist provided the same level of 
protection as IPC and that administration of an A1R antagonist immediately prior to 
IPC blocked the protection [131] whilst another study found that although depletion 
of adenosine negated the protective effect of IPC, pharmacological inhibition of A1R 
did not [132]. Similarly conflicting results exist between studies looking at the A2AR 
with one study demonstrating that inhibition of the A2AR prevented IPC providing 
protection [132] whilst in another study it did not [133] and a study using genetic 
mice to knock out each of the individual receptors in turn found that only depletion 
of the A2BR ablated the protective effect of IPC [134]. Interestingly Adenosine was 
shown in one study to inhibit NKT cell activation via the A2AR [135] and therefore 
to reduce the immune mediated  liver injury. Although several studies have 
demonstrated that adenosine is associated with a reduction in pro-inflammatory 
cytokines especially CCL2, IL-6 and TNFα [134,136] it is unclear whether this is as 
a result of reduced hepatic injury or as a result of direct manipulation of immune 
cells. One study in renal IR injury investigated the role of the A2AR on CD4+ T cells 
by adoptive transfer of CD4+ T cells into athymic mice. Transfer of cells from wild 
type mice reconstituted the IR injury and this was successfully ameliorated by 
treatment with an A2AR agonist. Transfer of CD4+ T cells from A2AR knock out 
mice again reconstituted the IR injury which was unaffected by treatment with the 
A2AR agonist [137]. This study also demonstrated that treatment of athymic mice 
with the A2AR agonist did not confer any further protection from IR injury that one 
may expect if adenosine promoted cell survival. This key study demonstrated that 
adenosine can act rapidly on CD4+ T cells to reduce the reperfusion injury. Although 
the role of IFNγ production by CD4+ T cells was investigated in this study as a 
modulator of IR injury, the experiment where the effect of A2AR agonist on CD4+ T 
cell IFNγ production was either not performed or not reported but would be 
important as it would demonstrate a clear mechanism by which adenosine may 
ameliorate IR injury. 
1.4.1.1: The effect of IPC on CD4+ T cells. 
This has only been explored in a few studies to date. In one study, splenocytes were 
transferred from wild type mice into athymic mice [116]. Mice that received 
splenocytes from mice which had undergone IPC 5 days prior suffered significantly 
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reduced IR injury compared to mice that received splenocytes from mice that had 
undergone a sham laparotomy. This study clearly identifies that T cells can be altered 
by IPC and that this can be associated with measurable benefits. In this study the 
splenocytes were not subdivided into CD4+/CD8+ T cells and as such it does not 
clarify which cell type is altered by IPC. Three studies have looked specifically at the 
effect of IPC on the Treg population in mice [39,114,115]. Two studies in the setting 
of renal IR injury found that IPC significantly increased numbers of Tregs but this 
was only demonstrated at 7 days post IPC and not at 3 or 14 days [114]. Furthermore 
IPC lead to increased IL-10 production by Tregs [114]. Depletion of Tregs ablated 
the protective effect of IPC [114,115] suggesting that IPC can manipulate Treg 
number and function and through this mechanism ameliorate IR injury. In contrast 
another study investigating IPC in warm hepatic IR injury found that although IPC 
successfully ameliorated IR injury, it did not augment Treg number [39]. Depletion 
and adoptive transfer of Tregs did not affect IR injury and this lead to the conclusion 
that the protective effect of IPC was independent of Tregs. One experiment was 
missing which was to augment Tregs and to perform IPC as IPC may improve Tregs 
function.  For instance, circulating levels of IL-6 have been shown to be significantly 
elevated following IR injury both in humans [138] and small animals [16]. IL-6 
inhibits Treg differentiation [45] and function [43] and IPC has been shown to 
reduce IL-6 levels in small animal models [139]. The 2 positive studies used a 
similar preconditioning and IR injury protocol which was very different from the 
negative study which may explain the findings and raises some very important 
questions. The length and timing of the preconditioning stimulus used was very 
different with Devey and colleagues using a 15 minute stimulus performed 
immediately prior to the IR injury. The other trials used a 28 minute preconditioning 
stimulus performed 7 days prior to the IR injury. There is clear evidence to support 
IPC modulating the T cell response. It would appear however that for Tregs to be 
augmented a period of 5-7 days may be required and this may reflect IPC causing 
tissue injury and then Tregs being recruited to facilitate tissue remodeling and 
regeneration.  
No previous study has investigated the effect of IPC on CD4+ effector T cells.  
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Cytokines are rapidly released from CD4+ T cells and are key effector mechanisms 
of CD4+ T cell function. Studies have shown that CD4+ T cell mediated cell damage 
is maximum at 6 hours post reperfusion [21] and IPC performed immediately prior to 
IR injury can provide protection. This timeframe is unlikely to be sufficient to allow 
for alteration in T cell maturation and differentiation but may allow for a different 
cytokine secretion profile from T cells. Several studies have shown that IPC is 
associated with a reduction in circulating and intra-hepatic pro-inflammatory 
cytokines following IR injury. IFNγ and TNFα are 2 key pro-inflammatory cytokines 
in IR injury. Studies have shown that intra-hepatic levels of TNFα are reduced by 
IPC when TNFα levels are measured by ELISA. However the cellular source of the 
TNFα or the target cell of IPC has not been identified. Current pharmacological 
advancements have lead to the development of biological targeted treatments 
including monoclonal antibodies to IFNγ, IL-6 and TNFα. Further knowledge of the 
protective mechanisms of IPC/RIPC would allow the protocols to be optimised for 
use in humans and for the development of targeted therapy. 
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1.5: Hypothesis. 
The hypothesis of this thesis was that inflammatory cell production of pro-
inflammatory cytokines (particularly IFNγ and TNFα) would be significantly 
upregulated following liver ischaemia reperfusion injury. Furthermore that remote 
ischaemic preconditioning would ameliorate IR injury and provide evidence of 
clinical benefit in liver transplant recipients which would be associated with a 
reduction in CD4+ T cell pro-inflammatory cytokine production. 
1.6: Aims. 
The aim of this thesis was to investigate the mechanism and clinical significance of 
remote ischaemic preconditioning in liver warm ischaemia reperfusion injury. 
The objectives were to: 
1. Perform a review of the literature and meta-analysis to ascertain the current     
evidence for ischaemic preconditioning in liver transplant. 
2. To establish appropriate surrogate endpoints for clinical trials aimed at 
reducing liver IR injury in liver transplant. 
3. To perform the first pilot study of remote ischaemic preconditioning in liver 
transplant recipients.  
4. Analysing peri-operative peripheral blood samples and post reperfusion liver 
biopsies to identify changes in CD4+ T cell cytokine production in the early 
post reperfusion period and to identify any changes resulting from RIPC. 
5. Using a murine model of RIPC and warm hepatic IR injury to identify 
immune changes in a proven model of liver protection. 
6. Analysing cytokine production by CD4+ T cells isolated from healthy 
volunteers pre and post RIPC and then stimulated in vitro. 
7. Investigate for infiltration of inflammatory monocytes in the post reperfusion 
liver and their source. 
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Chapter	2:	Materials	and	Methods.	
2.1: Systematic Review and Meta-analysis. 
This systematic review and meta-analysis was performed in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement [140]. The study protocol was registered with the University of York 
Centre for reviews and dissemination international prospective register of systematic 
reviews (2015:CRD42015016055). 
The medical literature was searched for Randomised Controlled Trials (RCTs) and 
matched cohort studies examining the effect of IPC in the clinical setting of deceased 
donor liver transplantation. 
All trials including adult patients undergoing deceased donor liver transplantation 
were included while all trials involving patients undergoing living donor liver 
transplantation were excluded. 
2.1.1: Search Strategy. 
MEDLINE, Embase and Cochrane Central Register of Controlled Trials 
(CENTRAL) databases were searched up to and including the 2nd week of January 
2015. The search algorithm is contained in table 2.1. 
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1: (hepatic or liver) adj3 (transplant$ or graft$).ti.ab. 
2: exp Liver Transplantation/ 
3: isch?emic adj(preconditioning or pre conditioning).ti.ab. 
4: exp Ischaemic Preconditioning/ 
5: 1 or 2 
6: 3 or 4 
7: 5 and 6 
Table 2.1: Search algorithm for meta-analysis 
Two authors independently reviewed the titles and abstracts of all the studies 
identified by the initial search. Once agreement was reached, the same two authors 
independently extracted data from the papers selected for full paper review to enter 
into the meta-analysis. The primary and secondary outcomes extracted are contained 
in table 2.2. 
Primary outcomes 
Early graft failure within 3 months 
Re-transplantation within 3 months 
Recipient death within 1 year 
Secondary outcomes 
Evidence of acute rejection 
Length of ICU stay 
Length of hospital stay 
Number of days ventilated 
Incidence of post-operative renal support 
Infective complications 
Aspartate transferase (AST) levels on the third post-
operative day 
Table 2.2: Primary and secondary outcomes in meta-analysis 
2.1.2: Statistical analysis 
Statistical analysis was performed on Revman 5® software (The Nordic Cochrane 
Centre, Denmark) using a random effects DerSimonian-Laird model. Dichotomous 
outcomes were analysed based on event rates using pooled odds ratios (OR) and 
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continuous outcomes were analysed using a weighted means difference (WMD). 
Heterogeneity was assess using τ2, χ2, and Ι2 measures and was deemed significant if 
p<0.10 or Ι2 was greater than 30%. Results were reported with 95% confidence 
intervals and a p value < 0.05 was considered significant. 
2.2: Identifying surrogate markers as endpoints in clinical trials of 
liver transplantation. 
A single centre prospectively collected database was analysed between the years of 
1988 and 2012 to allow a large enough cohort of patients to be analysed with 
sufficient length of follow-up. 
All patients undergoing deceased donor liver transplantation at the Royal Free 
Hospital, London were reviewed for the analysis including those who underwent re-
transplantation. All types of graft (DBD/DCD/Domino/Split) were included. Patients 
were followed up for a minimum period of 3 months or until death if earlier. 
Data collected included donor and recipient variables, pre-operative and post-
operative blood results, post-operative morbidity, mortality and the need for re-
transplantation. 
Results were analysed in Statistical Package for Social Sciences version 21 (IBM). 
Binary logistic regression analyses, linear regression analyses, and receiver operator 
characteristic (ROC) curve analyses were performed. 
A p value of less than 0.05 was accepted as significant. 
2.2.1: Correlating post-operative transaminases with short term graft loss 
secondary to liver specific causes. 
Short term graft loss was accepted to occur within 0-3 months post transplantation. 
The date of graft loss was accepted as the date of re-transplantation or date of death. 
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Liver specific graft loss was accepted as death or re-transplantation secondary to 
liver specific pathology (biliary complications/acute rejection/ductopaenic 
rejection/non-thrombotic infarction/primary graft non-function). Grafts that failed 
secondary to vascular complications were excluded from this analysis. 
Variables included in the analysis were: 
Donor and transplant – donor age, donor type, length of cold ischaemia (mins) and 
length of time taken to perform the vascular anastamoses. 
Recipient – recipient age, recipient gender, recipient pre-operative MELD score, 
ALT levels on days 1/3/7 and AST levels on days 1/3/7. 
A binary logistic regression analysis was performed to identify variables that 
correlated with early liver specific graft loss. 
A ROC curve was performed to identify the sensitivity and specificity of individual 
AST and ALT values on days 1 and 3 at predicting liver specific graft failure 
allowing likelihood values to be calculated. 
2.2.2: Correlating post-operative transaminases with late graft loss secondary to 
liver specific causes. 
Late graft loss was accepted as grafts that were lost between 3 months and 5 years. 
The date of graft loss was accepted as date of re-transplantation or date of death. For 
this analysis grafts that were lost before 3 months were excluded from the analysis. 
2.2.3: Measurement of incidence of transplant related outcomes. 
Likelihood ratios were calculated to identify AST cut off values that identified a 
moderate and significant likelihood of graft loss. The number of patients in each 
group was calculated along with incidence of total graft loss and liver specific graft 
loss at 3 months and recipient mortality at 30 days, 90 days and 1 year.  The mean 
length of time spent in ITU, requiring ventilator support and the incidence of renal 
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replacement therapy (RRT) was calculated for each group along with the incidence 
of infective complications (bacteraemia/abdominal/chest/wound/urine). 
Patients with a pre-operative serum creatinine value of greater than 150µmol/L were 
excluded from the RRT analysis to exclude the bias of pre-existing renal impairment 
and infective complications were only accepting following a positive microbiology 
culture. 
2.3: Remote Ischaemic Preconditioning in Orthotopic Liver 
Transplantation (RIPCOLT) trial. 
2.3.1: Study design and location. 
The trial was designed as a prospective single centre feasibility pilot double-blind 
randomized control trial. The trial was carried out at the Royal Free Hospital, 
London. The trial protocol was published [141]. 
2.3.2: Ethical approval, trial registration and consent. 
The trial was approved by both the ethical board of the National Research Ethical 
Service (11/H0720/4) and the Royal Free Hospital/University College London 
ethical board (8191). The trial was prospectively registered with clinicaltrials.gov 
(NCT00796588). Where possible, patients were consented for the trial during their 
index admission for liver transplant assessment. Consent was reconfirmed on 
admission for liver transplant. A copy of the consent form and patients information 
sheet is in Appendix 1. 
2.3.3: Participants and recruitment. 
Fifty-one patients undergoing liver transplant at the Royal Free Hospital, London 
were considered for recruitment to the trial. The inclusion criteria was all patients 
undergoing first elective deceased donor liver transplantation. Exclusion criteria are 
included in table 2.3. 
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Exclusion criteria: 
Re-transplantation 
Patients under 16 years of age 
Super-urgent transplantation 
Lack of informed consent 
Combined liver and kidney transplantation 
Peripheral vascular disease 
Varicose veins 
Localized limb infection 
Prior history of thrombo-embolic disease 
Inclusion in another interventional trial 
Table 2.3: Exclusion criteria for trial  
Patients were identified and recruited to the trial either during admission for 
transplant assessment or where that was not feasible on the morning of their 
transplant. 
2.3.4: Endpoints. 
As this was a feasibility trial, the primary endpoints were ability to recruit to the trial 
and to perform RIPC immediately prior to liver transplantation. Secondary endpoints 
were considered exploratory and were chosen to help design a future cost-
effectiveness study and are found in table 2.4. 
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Primary 
endpoints: 
Ability to recruit patients to the trial 
Feasibility of performing RIPC in liver transplant recipients 
Safety of RIPC in liver transplant recipients 
Secondary 
endpoints: 
AST levels on the third post-operative day [142] 
Incidence of Early Allograft Dysfunction [143] 
Incidence of Acute Kidney injury and need for Renal 
Replacement therapy 
Length of stay in Intensive Care and total hospital stay 
Incidence of vascular thrombotic events 
Incidence of biliary complications 
Incidence of post-operative infections 
Incidence of acute rejection in the first months post 
transplantation 
Circulating cytokine levels 2 hours post reperfusion of the 
liver graft 
T cell accumulation and activation in the liver 2 hours post-
reperfusion 
Urinary and serum NGAL levels 2 hours post reperfusion 
Table 2.4: Primary and secondary endpoints. 
2.3.5: Trial Protocol and follow up: 
Induction of anaesthesia was performed with intravenous propofol as the use of 
volatile inhaled induction agents such as sevofluorane has been shown to exert a 
pharmacological preconditioning effect [144,145]. Following induction of 
anaesthesia patients were randomized to either an intervention group (RIPC) or a 
control group (sham). Prior to skin incision, a layer of stockingette was applied to the 
left mid thigh with a wide pneumatic tourniquet placed over it in accordance with 
safe and recommended practices by the Association of Per-operative Registered 
Nurses (AORN) [146] and the Royal Free Hospital (RFH) departmental guidelines 
(Figure 2.1). In those undergoing RIPC, the tourniquet was inflated to 200mmHG for 
5 minutes before being deflated for 5 minutes of reperfusion. This was repeated 3 
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times and was completed in all cases prior to skin incision. In the control group, the 
sham consisted of placing the tourniquet round the middle thigh but not inflating it. 
A liver transplant was then performed as standard. 
All patients were followed up daily till discharge allowing clinical information 
including post-operative blood tests, development of infection or complications to be 
collected. The final data was collected from the 3 month assessment forms that are 
completed by the clinician reviewing them at their clinic appointment 3 months post-
operatively. 
 
 
Figure 2.1: Patient undergoing RIPC prior to transplantation. 
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2.3.6: Sample collection and processing 
2.3.6.1: Blood 
Twenty-five mls of peripheral arterial blood was collected at 4 time-points during the 
transplant period (Table 2.5). Twenty mls was collected in BD Vacutainer EDTA 
blood tubes (BD, UK) and five mls was collected in BD Vacutainer plasma blood 
tubes (BD, UK). 
2.3.6.2: Urine 
Ten mls of urine was collected directly from the foley catheter into a universal 
container to represent the freshest catch of urine possible at 3 time-points identified 
in table 3. 
2.3.6.3: Liver biopsies 
A tru-cut liver parenchymal biopsy was taken pre implantation and at 2 hours post 
portal vein reperfusion. The biopsy was immediately placed in RPMI 1640 media 
without L glutamine (Lonza, UK). 
2.3.6.4: Processing of whole blood 
20mls of whole blood was diluted with 15mls of Phosphate Buffered Saline (PBS) 
and 13mls of Phycol was layered under the diluted blood. The sample was 
centrifuged (940g, 20 minutes, 200C). The peripheral blood mononuclear cells 
(PBMCs) were then removed and counted. 5 million cells were reconstituted in PBS 
for analysis and excess cells were frozen, in aliquots of 5 million cells, in 1ml of heat 
inactivacted FCS with 10% DMSO (Sigma, UK) for later analysis. 
Plasma was obtained by centrifuging the plasma tube (10 mins, 300g, 200C). The 
plasma was then aliquoted into 750µl samples and stored at -800C till further 
analysis. 
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2.3.6.5: Processing of liver biopsy 
The biopsy was divided into smaller segments with a cell scraper and was passed 
through a 40µm filter into 30mls of RPMI 1640 media without L glutamine (Lonza, 
UK) to obtain the intrahepatic lymphocytes (IHLs). The solution was centrifuged 
(500g, 5 mins, 40C), Cells were cultured in 1ml T cell media with 5µl Brefeldin A 
added (4 hours, 5% CO2, 370C). The cells were centrifuged (500g, 5 mins, 40C) and 
resuspended in 1ml of PBS ready for staining for flow-cytometry. 
Timepoint Samples collected 
Following anaesthetic induction but 
prior to skin incision 
25 mls peripheral arterial blood  
- 20 mls cells 
- 5 mls plasma 
10 mls urine from foley catheter 
During 1st cycle of RIPC 5 mls venous blood from foot 
Following mobilization of the 
recipient liver but prior to clamping of 
the portal vein 
25 mls peripheral arterial blood  
- 20 mls cells 
- 5 mls plasma 
Pre-implantation liver biopsy 
2 hours post portal vein reperfusion 25 mls peripheral arterial blood  
- 20 mls cells 
- 5 mls plasma 
Post-reperfusion liver biopsy 
Immediately post abdominal closure 10 mls urine from foley catheter 
24 hours post operatively 5 mls peripheral arterial blood – plasma 
10 ms urine from foley catheter 
Table 2.5: Timepoints of sample collection and samples collected. 
2.4: Animal model. 
This study was performed under a project license from the Home Office in 
accordance with the Animals (Scientific Procedures) Act 1986. Male C56BL6/J mice 
(Charles River, UK) aged 8-10 weeks were used for the experiments. Animals were 
 46 
kept in a temperature controlled environment with a 12 hour light/dark cycle and 
were allowed free access to water and standard mouse chew pellets.  
48 mice were divided into 4 experimental groups (Figure 2.2). 
 
Figure 2.2: Murine RIPC and IR injury protocol. 
2.4.1: Surgical procedure. 
Animals were anaethestised with an initial dose of 0.4mls intra-peritoneal Ketamine 
Xylazine (National Veterinary Services, UK) further intra-peritoneal boluses of 
0.05mls were given as necessary. All surgery was carried out under a Ziess, OPMI, 
6MD operating microscope (Ziess, UK).  
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2.4.1.1: Remote Ischaemic Preconditioning. 
A vertical incision was made in the left lower limb from the midline to the knee. The 
femoral pedicle was exposed and under direct vision, an atraumatic microvascular 
clamp was placed across the femoral artery and vein for 5 minutes (Figure 2.3). The 
clamp was released for 5 minutes to allow reperfusion and this was repeated 3 times 
immediately prior to the hepatic IR injury. A sham consisted of exposing the femoral 
pedicle but not clamping the vessels. 
 
Figure 2.3: RIPC of left hind limb. 
2.4.1.2: Hepatic IR injury. 
A midline laparotomy was performed and the liver was retracted cranially. A 
standard model of hepatic IR injury was performed [147]. An atraumatic 
microvascular clamp was placed across the left and middle portal pedicles distal to 
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the right portal branch for 45 minutes [80] (Figure 2.4).  Portal vein occlusion was 
confirmed by blanching of the left and middle lobes of the liver. The liver was 
reperfused for 2 hours. A sham consisted of a laparotomy and exposure of the portal 
pedicles but no clamp was placed across the pedicles 
 
Figure 2.4: Blanching of the left and middle lobes of the liver (red arrows) following 
portal pedicle occlusion. Black arrow points to the right lobe. 
2.4.2: Sample collection and processing. 
2.4.2.1: Reagent preparation. 
Perfusate Buffer 1: To 20 mls of Hank’s Buffered Salt Solution (with Calcium and 
Magnesium) (Life Technologies, UK), 200µl of Collagenase VI (Life Technologies, 
UK) was added to make a 0.01% solution and 20µl of DNAse I (Roche, UK) was 
added to make a 0.001% solution. 
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Perfusate Buffer 2: To 20 mls of Hanks Buffered Salt Solution (without Calcium and 
Magnesium) (VWR, UK), 500µl of Bovine Serum Albumin was added to make a 
0.25% solution and 20µl of DNAse I (Roche, UK) was added to make a 0.001% 
solution. 
Optiprep: 3 parts of Optiprep (Sigma, UK) was diluted in 2 parts of 1640 RPMI 
media without L glutamine (Lonza, UK). 
2.4.2.2: Procedure. 
After the reperfusion period, a cardiac puncture was performed and the mouse 
circulating volume was collected in a heparin coated syringe and transferred to a 
heparin coated eppendorf. The blood was centrifuged for 10 minutes (1000g, 10 
minutes, 200C) to pellet the cells and the plasma was alliquoted into 100µl portions 
and stored at -800C until analysis. 
The portal vein was cannulated and flushed with 5 mls of PBS. The spleen and liver 
were then harvested and placed in 1640 RPMI media without L glutamine (Lonza, 
UK). In animals that underwent IR injury, the liver was divided into ischaemic and 
non-ischaemic lobes and analysed separately. A biopsy was taken from each liver 
and stored in 10% natural buffered formalin for histopathology. 
2.4.2.3: Liver. 
Buffer 1 was added to the liver which was manually homogenized between 2 scalpel 
blades. The resulting cell suspension was passed through a 70µm cell strainer (Fisher 
Scientific, UK) and centrifuged (500g, 10 minutes, 40C). The pellet was resuspended 
in 1640 RPMI media without L glutamine (Lonza, UK) and layered on top of the 
Optiprep (Sigma, UK) at a ratio of 2 volumes of cell suspension to 1 volume of 
Optiprep before being centrifuged (700g, 20 mins, 200C). The interface layer was 
collected and the cells were resuspended in Perfusate buffer 2 and centrifuged (500g, 
10 mins, 40C). The cells were resuspended in 5 mls of T cells media with 25mls of 
Brefeldin A (Sigma, UK) and cultured (4 hours, 5% CO2, 370C) before being 
centrifuged (500g, 5 mins, 40C). IHLs were resuspended in 1ml of PBS ready to be 
stained for flow cytometry. 
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2.4.4.4: Spleen. 
The spleen was manually homogenized and passed through a 40µm cell strainer 
(Fisher Scientific, UK). The cells were suspended in 20mls PBS and centrifuged 
(500g, 10 mins, 40C). The cells were resuspended in PBS with 5 mls of ACK lysis 
buffer (5 minutes) before 1640 RPMI media without L glutamine (Lonza, UK) was 
added to stop the cell lysis process and centrifuged (500g, 10 mins, 40C). The cells 
were resuspended in 5 mls of T cell media with 25mls of Brefeldin A (Sigma, UK) 
and cultured (4 hours, 5% CO2, 370C) before being centrifuged (500g, 5 mins, 40C). 
PBMCs were resuspended in 1ml of PBS ready to be stained for flow cytometry. 
2.5: Staining and analyzing samples. 
2.5.1: Reagent preparation. 
2.5.1.1: BD FoxP3 Buffer A. 
Dilute Buffer A (BD Pharminogen, 51-9005451) 1:10 in distilled H20. 
2.5.1.2: BD FoxP3 Buffer B. 
Dilute Buffer B (BD Pharminogen, 51-9005450) 1:50 in diluted Buffer A. 
2.5.1.3: Process. 
PBMCs and IHLs were divided added to a 96 well plate and the fixable viability dye 
was added to the cells (15 minutes in the dark, 40C). The cells were washed in 100µl 
of PBS, centrifuged (5 mins, 600g, 200C) and resuspended in the extracellular stain  
(Table 2.6, 2.7 and 2.8) (15 minutes in the dark, 40C). The cells were washed in 
100µl of PBS, centrifuged (5 mins, 600g, 200C) and resuspended in 100µl of FoxP3 
Buffer A (BD Pharminogen, UK) (10 minutes in the dark, 40C). The cells were 
washed in 100µl of PBS, centrifuged (5 mins, 600g, 200C) and resuspended in 100µl 
of FoxP3 Buffer B (BD, UK) (30 minutes in the dark, 40C). The cells were washed 
twice in 100µl of PBS, centrifuged (5 mins, 600g, 200C) and resuspened in 100µl of 
PBS with the intracellular stain added (Tables 2.6, 2.7 and 2.8) (30 minutes in the 
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dark, 40C). The cells were washed twice in 100µl of PBS, centrifuged (5 mins, 600g, 
200C) and the cells were re-suspended in 300µl PBS for analysis by flow cytometry. 
2.6: Flow cytometry 
Cells were analysed immediately after the staining process on a Fortessa II flow 
cytometer (Becton Dickinson, Oxford, UK) using DIVA software (Becton 
Dickinson, Oxford, UK) and FlowJo software (Tree Star, Oregon, USA). 
Antigen Conjugate Source Clone Concentration 
(µl/100µls) 
Live/Dead APC Cy7 Life 
Technologies 
n/a 0.15 
Extracellular 
CD3 PE Texas Red BD UCHT1 0.5 
CD4 PE Cy7 eBioscience RPA-T4 1 
CD8 AF 700 eBioscience OKT-8 0.5 
HLADR V500 BD G46-6 1 
CD69 FITC BD FN50 3 
PD-1 PerCP Cy5.5 Biolegend EH12.2H7 2 
Intracellular 
CTLA-4 PE BD BN13 3 
FoxP3 Pacific Blue Biolegend 259D 4 
IL-2 PerCP e-Flour 710 eBioscience MQ1-
17H12 
2 
IL-10 PE eBioscience JES3-9D7 1 
IFNγ FITC R&D systems ♯25723 3 
pS6 AF 647 Cell 
Signalling 
D57.2.2E 1 
TNFα APC Biolegend MAb11 0.5 
Table 2.6: Fluorochomes used for analysis of human cells. 
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Antigen Conjugate Source Clone Concentration 
(µl/100µls) 
Live/Dead efluor450 eBioscience n/a 0.15 
Extracellular 
CD3 APC eFluor 
450 
eBioscience SK7 0.5 
CD4 PE 610 eBioscience RPA-TL 0.5 
CD8 PE BD RPA-T8 0.5 
CD14 PerCP Invitrogen TUK4 0.5 
CD16 PE BD 3G8 0.5 
CD19 APC eFluor 
450 
eBioscience HIB1.9 1 
CD56 BV610 BD NCAM16.2 0.5 
HLA-A2 APC eBioscience BB7.2 1 
HLA-A3 FITC eBioscience GAP.A3 2 
Intracellular 
IL-6 PE Cy7 eBioscience MQ2-13AS 1 
IL-17A PE Cy7 eBioscience SHLR17 4 
IFNγ Alexa Fluor 
488 
eBioscience 4S.B3 1 
TNFα APC eBioscience MAb11 2 
EOMES PE 610 eBioscience WD1928 1 
Tbet PE Cy7 eBioscience eBio4B10 1 
Table 2.7: Fluorochromes for more detailed analysis of IHLs including monocytes 
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Antigen Conjugate Source Clone Concentration 
(µl/100µls) 
Live/Dead efluor450 eBioscience n/a 0.15 
Extracellular 
CD3 FITC BD 145-2C11 1 
CD4 PerCP BD RM4-5 0.25 
CD8 v500 BD 53.6.7 1 
CD11b FITC BD M1/70 0.25 
F4/80 APC eFluor780 eBioscience BM8 1 
Ly6c APC BD AL-21 1 
Ly6g APC Cy7 BD IAS 2 
Intracellular 
FoxP3 APC eBioscience FJK-16s 2 
IL-6 APC Biolegend MP5-20F3 1 
IL-10 BV650 BD JES5-16E3 2 
IL-17A PE-CF594 BD TC11-18H10 1 
IFNγ PE Cy7 BD XMG1.2 2 
TNFα PE BD MP6-XT22 1 
Table 2.8: Fluorochromes used for analysis of murine cells 
2.7: LEGENDplex analysis of human plasma samples. 
Plasma concentrations of IL-2, IL-6, IL-10, IFN-γ and TNF-α were measured by 
multi-analyte flow assay LEGENDplex human Th cytokine 5 plex mix and match 
subpanel (Biolegend, UK). The LEGENDplex was performed according to the 
manufacturers guidelines. 
The beads were analysed on a Fortessa II flow cytometer (Becton, Dickinson, UK) 
using DIVA software (Becton, Dickinson, UK). 
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2.8: LEGENDplex analysis of murine plasma samples. 
Plasma concentrations of GM-CSF, IL-1β, IL-6, IL-10, IL17A, IL-23, IFNγ, MCP-1 
and TNFα were measured by multi-analyte flow assay LEGENDplex murine 
inflammation panel (Biolegend, UK). The legndplex was performed according to the 
manufacturers guidelines. 
The beads were analysed on a Fortessa II flow cytometer (Becton, Dickinson, UK) 
using DIVA software (Becton, Dickinson, UK). 
2.9: Measurement of murine plasma transaminase levels. 
The plasma was thawed and plasma transaminase levels were measured by COBAS 
Integra 400 plus biochemistry analyser (ROCHE, UK). 
2.10: ELISA for CCL2, CCL 5, IL-8, IL-17A and NGALs. 
Plasma concentrations of CCL2 (Biolegend, UK), CCL5 (Biolegend, UK), IL-8 
(Biolegend, UK), IL-17A (Biolegend, UK) and urine and plasma concentrations of 
NGAL levels (Biolegend, UK) were measured by ELISA according to the 
manufacturer’s guidelines. The plates were read on a plate reader (Multiskan, UK) at 
450nM (Thermo Scientific, UK). Standard curves and sample concentrations were 
calculated on Microsoft Excel. 
2.11:Statistics. 
Continuous variables were expressed as median (+ range) or mean (± standard 
deviation) as appropriate and comparisons between the groups were performed by 
Mann Whitney U test or Students’ T-test as appropriate. Binary outcomes were 
expressed as frequency counts and percentages and comparisons between the groups 
were analysed by Chi-squared tests on Statistical Package for Social Sciences  
(SPSS) (IBM, Chicago, IL, USA) and Prism 5 (Graphpad, USA). 
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Chapter	 3:	 Systematic	 review	 and	
meta-analysis	 of	 Ischaemic	
Preconditioning	 of	 donor	 livers	 in	
liver	transplantation.	
3.1: Introduction. 
IPC has been shown to reliably ameliorate warm hepatic IR injury in small animal 
models [80,100,148–150]. Whether IPC can reduce IR injury in patients undergoing 
liver resection or transplantation remains unproven. Several small trials have 
investigated the effect of IPC performed on human donor livers prior to retrieval in 
the setting of liver transplantation. All of these trials have been small and were not 
powered to demonstrate a significant effect on hard clinical outcomes such as 
recipient mortality and graft loss. An audit of UK transplant outcomes has shown 
that 90 day patient and graft survival is 90.8% and 89.3% respectively [5]. 
Meta-analysis in which data from several studies is combined to increase the 
statistical power of the data analysis is of interest as it can unmask significant 
differences in these hard clinical endpoints. A Cochrane review performed in 2008 
included 3 trials and concluded that there was insufficient evidence to support or 
refute the use of IPC in liver transplantation [151]. As additional trials are published, 
particularly in an active research field, further evaluation may be justified as the 
accumulated data may provide statistical significance to the primary end points of the 
study or suggest that further trials and studies should not be funded. This is 
recognized by Cochrane who recommend a detailed literature update with further 
meta-analysis every 5 years. Since 2008 several further trials have been published 
and an updated meta- analysis has therefore been performed. 
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3.1.2: Aim. 
The aim of this chapter was to evaluate the current knowledge of the clinical effect 
of IPC in liver transplant surgery. 
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3.2: Methods. 
The medical literature was searched for trials involving IPC in the setting of 
deceased donor liver transplantation. Trials involving living donor liver 
transplantation were excluded. MEDLINE, Embase and Cochrane Central Register 
of Controlled Trials (CENTRAL) databases were searched up to and including the 
2nd week of January 2015. The search algorithm is contained in table 3.1. Studies 
involving animal models were excluded. Randomised controlled trials and matched 
cohort studies were included. Manuscripts in a foreign language and published 
abstracts were excluded. 
Data was extracted from the identified manuscripts and statistical analysis was 
performed on Revman 5® software (The Nordic Cochrane Centre, Denmark) using a 
random effects DerSimonian-Laird model. 
1: (hepatic or liver) adj3 (transplant$ or graft$).ti.ab. 
2: exp Liver Transplantation/ 
3: isch?emic adj(preconditioning or pre conditioning).ti.ab. 
4: exp Ischaemic Preconditioning/ 
5: 1 or 2 
6: 3 or 4 
7: 5 and 6 
 Table 3.1: Search algorithm for meta-analysis 
Primary endpoints were recipient mortality within the first year post transplant, 
incidence of primary graft non-function and incidence of re-transplantation. 
Secondary endpoints were selected as AST levels on the 3rd post-operative day, 
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length of ITU stay, length of total hospital stay on index admission and number of 
episodes of acute rejection. 
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3.3 Results 
The initial search identified 458 studies (Figure 3.1). Following electronic removal 
of duplicates 305 studies remained. The 305 titles and abstracts were reviewed by 2 
independent authors and 19 studies were selected for full paper review. Reasons for 
study exclusion were animal model (125), review, editorial or reply (73), irrelevant 
topic (64), no full text or abstract available (20) and evidence that the patient data set 
was similar to an already published study (4). 
Of the 19 studies selected a further 9 studies were excluded. Reasons for exclusion 
included conference abstract as there was insufficient published data (7), duplicated 
patient set (1) and living donor study (1). Ten studies were included in the final 
analysis [86–91,93,94,152,153] which included 593 patients (286 IPC; 307 control). 
The characteristics and results of each study are included in Tables 3.2 and 3.3. 
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Figure 3.1: PRISMA flow chart.  
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Table 3.2: Summary of included trials. 
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Table 3.3: Summary of included trials ctd. 
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3.3.2: Primary endpoints. 
The primary endpoints chosen were the hard clinical outcomes of recipient mortality, 
and graft loss, which was divided up into incidence of primary graft non-function 
(PGNF) and the incidence of re-transplantation. 
3.3.2.1: One year mortality. 
Seven studies [86–91,152] (475 patients: 232 IPC, 243 control) included data on 1 
year mortality (Figure 3.2). There was significant variability between the studies 
regarding the timepoint that recipient mortality was measured at. This ranged from 3 
months to 1 year and to allow pooling of data, mortality was defined as mortality 
occurring within the first year post operatively. There was no significant 
heterogeneity between the study results for recipient mortality (I2=0%, p=0.85). IPC 
was associated with a 45% reduction in post-operative mortality (6% vs 11%) but 
this was not statistically significant (OR 0.54, 95% C.I. 0.28 to 1.04, p=0.06).  
Figure 3.2: Forest plot comparing mortality between the groups. 
3.3.2.2: Primary graft non-function. 
Five studies [86–88,91,152] (322 patients: 152 IPC, 170 control) provided data on 
the incidence of PGNF (Figure 3.3). There was no significant heterogeneity between 
the studies (I2=0%, p=0.91). The IPC group had an 82% lower incidence of PGNF 
(0.7% vs 4%) but this was not statistically significant (OR 0.35, 95% C.I. 0.009 to 
1.31, p=0.12).  
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Figure 3.3: Forest plot comparing incidence of PGNF between the groups. 
3.3.2.3: Re-transplantation. 
Six studies [86–88,90–92] (274 patients: 182 IPC, 192 control) commented on the 
incidence of re-transplantation (Figure 3.4). There was no significant heterogeneity 
between the studies (I2=0%, p=0.99). IPC was associated with a reduction in the 
incidence of re-transplantation (3% vs 4%) but this was not significant (OR 0.83, 
95% c.i. 0.28 to 2.41, p=0.73).  
Figure 3.4: Forest plot comparing incidence of re-transplantation between the groups. 
3.3.3: Secondary endpoints. 
Secondary endpoints chosen were post-operative variables that are associated with a 
poorly functioning graft or post-operative complications. Previous work has 
identified Aspartate Transferase (AST) levels on the 3rd post operative day as a 
strong indicator of graft and recipient outcome [142]. Other secondary outcomes 
chosen included incidence of renal replacement therapy and post-operative infective 
complications. However there was insufficient data in the studies to analyse these 
additional secondary outcome measures. 
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3.3.3.1: AST level on the 3rd post operative day. 
Three studies [87,88,94] (149 patients: 68 IPC, 81 control) included data on day 3 
AST levels (Figure 3.5). There was no significant heterogeneity between the studies 
(I2=0%, p=0.46). AST levels on the 3rd post operative day were significantly lower in 
patients who had been transplanted with grafts from IPC treated donors compared to 
controls (WMD -66.41 (-129.92 to -2.89) iU, p=0.04). 
 
Figure 3.5: Forest plot comparing AST levels on the 3rd post-operative day between 
the groups. 
3.3.3.2: Length of ITU stay. 
Four studies [86,89,92,152] (240 patients: 121 IPC, 119 control) included data on 
length of ITU stay (Figure 3.6). There was no significant heterogeneity between the 
studies (I2=0%, p=0.74). IPC was associated with an increase in length of ITU stay 
of 1.2 days on average but this was not statistically significant MWD 1.21 (-1.02 to 
3.45) days (p=0.29).  
Fig 3.6: Forest plot comparing length of ITU stay between the groups. 
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3.3.3.3: Length of hospital stay. 
Six studies [86–89,92,152] (362 patients: 174 IPC, 188 control) included data on 
length of hospital stay (Figure 3.7). There was significant heterogeneity between the 
studies (I2=56%, p=0.06). IPC was associated with an average increase in length of 
total hospital stay of less than 1 day which was not statistically significant MWD 
0.56 (-4.77 to 5.9) days (p=0.84).  
Fig 3.7: Forest plot comparing length of hospital stay between the groups. 
3.3.3.4: Incidence of acute rejection episodes. 
Seven studies [88,89,91–94,152] (435 patients; 210 IPC, 225 control) included data 
on number of patients experiencing an episode of acute rejection (Figure 3.8). There 
was significant heterogeneity between the studies (I2=37%, p=0.14). IPC was 
associated with a reduction in the number of patients experiencing an episode of 
acute rejection (20% vs 25%) but this was not statistically significant (OR 0.71 95% 
c.i. 0.39 to 1.31, p=0.28). 
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Figure 3.8: Forest plot comparing incidence of acute rejection episodes between the 
groups. 
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3.4: Discussion. 
IPC is an inexpensive technique that has been shown to ameliorate warm partial 
hepatic IR injury in small animal models [80,100,148–150] but its role in human 
liver transplantation remains unclear. The results of this meta-analysis demonstrate 
that IPC of human donor livers prior to retrieval is associated with major although 
not statistically significant reduction in the majority of key primary and secondary 
end points following liver transplantation. 
IPC produced a 45% reduction in 1 year recipient mortality following liver 
transplantation (6% vs 11%). This large reduction in recipient mortality was not 
significant (p=0.06). IPC was similarly associated with a large reduction (82%) in 
the incidence of PGNF (0.7% vs 4%) but again this reduction was not significant 
(p=0.12). IPC was associated with a smaller reduction in the incidence of re-
transplantation from 4% to 3%. However the incidence of PGNF is a more reliable 
indicator of graft non function as a patient may be relisted following PGNF but may 
die as no organ becomes available.  
As regards the secondary end points of this study, AST levels on the 3rd post 
operative day have been shown to be an excellent indicator of graft survival [142] 
and AST levels in patients who received a graft that underwent IPC were on average 
66iU lower that in patients who received a graft that did not undergo IPC. This 
difference was significant (p=0.04). The reduction in recipient mortality and 
incidence of PGNF combined with the significant reduction in AST day levels 
suggest that with the benefit of an updated and pooled data set from multiple studies 
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there is strong evidence that donor IPC reduces damage to the liver and reduces graft 
loss and recipient mortality. 
However many of the end points failed to achieve statistical significance, IPC has not 
been introduced into routine clinical practice and only 2 of these studies were carried 
out within the infrastructure of the UK NHS. This would suggest that a UK 
prospective randomized controlled trial (RCT) under the direction of the National 
Organs Retrieval Service (NORS) adequately powered to demonstrate a significant 
reduction in these important clinical end points is essential to allow donor IPC to be 
introduced into routine clinical guidelines. Using the data analysed in this study, a 
power calculation with an α error of 0.05 and a β error of 0.2 would suggest that 660 
patients (330 patients in either arm) would be required to demonstrate a significant 
reduction in PGNF and a sample size of 974 (487 patients in each arm) would be 
required to demonstrate a significant reduction in 1 year mortality. A trial aimed at 
reducing 1 year mortality recruiting 30% of the 650 patients undergoing OLT each 
year in the UK could be completed within 5 years. Such a trial would be feasible in 
the UK. An initial feasibility study could evaluate UK recruitment rates to such a 
study, the most appropriate primary end point and hence trial duration. 
A key factor influencing the AST levels on the 3rd post-operative day is the cold 
ischaemic time and implantation time (secondary warm ischaemia) [142]. Recent 
work has shown that the development of ischaemic acute kidney injury predisposed 
patients to the future development of end stage renal failure [154] and is associated 
with the infiltration of monocytes and the development of fibrosis [155]. Ischaemic 
cholangiopathy, fibrotic stricturing of the biliary tract, is a devastating complication 
resulting in the need for multiple endoscopic treatments and often re-transplantation. 
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It is of particular concern in the use of DCD grafts with reports from the literature of 
an occurrence rate of 13% compared to 1% in DBD grafts [156]. A key risk factor 
for the development of ischaemic cholangiopathy is increased ischaemic time and 
therefore increased ischaemic injury [156,157]. This meta-analysis has demonstrated 
that patients who received grafts that underwent IPC had significantly lower day 
AST levels suggesting reduced ischaemic injury. Although it would be neither 
feasible nor ethical to perform direct IPC on DCD grafts, it would be feasible to 
perform Remote Ischaemic Preconditioning (RIPC) on the donor prior to withdrawal 
of life support or on the recipient prior to transplantation. There has been a recent 
pilot study investigating the effect of RIPC in DBD donors which demonstrated 
evidence of a reduction in IR injury [107]. RIPC would be feasible in DCD donors 
prior to withdrawal of life support. Reduction of the ischaemic injury in DCD grafts 
may therefore reduce the incidence of ischaemic cholangiopathy and improve 
outcomes following implantation of these grafts – the use of which is increasing.  
No trial followed patients up for longer than 1 year and therefore the effect of IPC on 
late biliary complications or long term survival is unknown. 
Interestingly although IPC was associated with a large reduction in incidence of graft 
loss and recipient mortality, patients receiving a graft that had undergone IPC stayed 
on average 1.21 days longer in ITU and 0.56 days longer in hospital. Neither of these 
increased stays was significant (p=0.29 and p=0.84 respectively) but both of these 
variables are generally associated with poorer graft function and a greater need for 
organ support and greater incidence of post-operative complications. There was 
insufficient data contained within the manuscripts to ascertain the effect of IPC on 
these post-transplant complications. Hospital and social factors or insufficient 
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community support may delay discharge from ITU and hospital and as such it is 
difficult to identify the cause of these contradictory results. This further strengthens 
the need for a larger prospective RCT including these important clinical outcomes as 
secondary endpoints. 
All of the included studies were performed on grafts from DBD donors and only one 
study included a cohort of marginal grafts [153]. This study analysed marginal grafts 
separately and demonstrated that IPC reduced liver injury as measured by peak 
transaminase levels in non steatotic grafts but not in steatotic grafts when compared 
to controls. In patients who received steatotic grafts IPC reduced the number of 
episodes of acute rejection (2/12 vs 6/10, p=0.048). There was no difference in 
episodes of acute rejection between the groups in patients who received optimal 
grafts (2/14 vs 5/14, p=0.15). This data raises the question of the mechanism of IPC. 
Monocyte infiltration into ischaemic kidneys has been shown to lead to progressive 
fibrosis and end stage chronic renal disease [157] although the effect of IPC was not 
explored in this study, these results would suggest that IPC may modulate the 
immune response post transplantation and may therefore reduce the development of 
immune activation in the implanted grafts. IPC has been shown in small animal 
models to reduce immune activation [114]. 
In conclusion the results of this meta-analysis demonstrate that IPC is associated 
with a large reduction in recipient mortality and incidence of PGNF that are not 
statistically significant even with the current meta-analysis which included 286 
patients undergoing IPC compared with 307 controls. Furthermore IPC results in a 
significant reduction in day 3 AST levels which have been shown to be an excellent 
marker of graft and patient outcomes. A large prospective RCT of donor IPC is 
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warranted to ensure the benefits of donor IPC are introduced into routine clinical 
practice. A power calculation has shown that 974 patients would need to be enrolled 
to demonstrate a significant reduction in recipient mortality and incidence of PGNF. 
Such a trial would be feasible in the UK. 
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Chapter	 4:	 Identifying	 endpoints	 in	
clinical	trials	of	liver	transplantation.	
4.1: Introduction. 
A key difficulty in designing clinical trials in liver transplantation is a lack of 
validated endpoints. A recent audit by the Royal College of Surgeons of England into 
outcomes following liver transplantation in UK found that currently 90 day graft loss 
and patient mortality following elective first liver transplant is 6.9% and 3.5% 
respectively [5]. To identify a reduction in mortality or graft loss with a single 
intervention would require a huge number of patients and is not feasible in pilot 
trials. Unlike in cardiology [158] (troponin/HDL) and HIV medicine [159,160] 
(CD4+ T cell number), there are no validated surrogate markers of outcome in liver 
transplantation. NIH defines a surrogate endpoint as a biomarker intended to 
substitute for a clinical endpoint that should predict clinical benefit or harm or lack 
of both [161]. One current method in liver transplantation is Early Allograft 
Dysfunction [143] (EAD) but this is binary and does not reflect global outcomes. 
The identification of a marker of IR injury which correlated with global outcomes 
post liver transplantation would allow for small pilot trials to demonstrate evidence 
of a reduction in IR injury and identify drugs or interventions to be further evaluated 
in trials of efficacy and cost benefit. 
4.1.2: Aim. 
The aim of this chapter was identify a potential surrogate marker of outcome 
following liver transplant surgery to use as a secondary endpoint in the pilot 
feasibility study of remote ischaemic preconditioning in liver transplant recipients. 
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4.2: Serum transaminases. 
A reduction in serum transaminase levels at 48 hours post reperfusion is an accepted 
endpoint in animal models of liver IR injury. Serum transaminase levels are also 
measured daily in the first week post transplantation. Aspartate transferase (AST) 
and Alanine transferase (ALT) are intracellular enzymes released from damaged 
hepatocytes into the circulation and are accepted to reflect the degree of liver damage 
following liver resection and transplantation. Whether raised transaminase levels 
reflect outcomes in patients undergoing liver transplantation is not yet known. The 
aim of this study was to assess whether serum transaminase levels in the first week 
post transplant reflect general and graft specific outcomes following liver 
transplantation. 
4.2.1: Methods. 
A prospectively collected, single centre, transplant database was reviewed for the 
period 1988 to 2012 at the Royal Free Hospital. Serum transaminase levels were 
measured daily post-operatively but were collected on the 1st, 3rd and 7th post-
operative day. 
4.2.1.1: Liver specific graft loss following transplantation. 
Liver specific graft loss included graft loss due to primary graft non-function, non-
thrombotic infarction, acute rejection, ductopenic rejection and biliary complications 
(excluding anastamotic stricture or bile leak). Hepatic artery thrombosis (HAT) and 
portal vein thrombosis (PVT) were excluded as a cause of graft loss from the 
analysis as it would be difficult to rule out a technical failure as contributing to graft 
loss under these circumstances.  
Date of graft loss was accepted as date of death or date of re-transplantation. 
Grafts lost within the first 3 months following liver transplantation were defined as 
early graft loss and those lost after 3 months were defined as late graft loss. 
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4.2.1.2: Clinical outcomes. 
Patients were grouped according to their AST level on the 3rd post operative day as 
day 3 was identified by multi-variate analysis as the most sensitive day to identify 
early graft loss (p=0.002). This was to allow incidence of clinically relevant 
outcomes to be calculated according to AST groups. These groups were chosen 
following a ROC analysis and the calculation of likelihood ratios to identify cut-off 
of patients most at risk and least at risk of graft failure based on AST day 3 levels: 
1: less than 107iU/L (201 patients) 
2: between 107 and 1213iU/L (883 patients) 
3: between 1213 and 2744iU/L (97 patients) 
4: greater than 2744iU/L (40 patients) 
The percentage graft loss at 3 months and percentage mortality at 30 days, 90 days 
and 1 year were measured along with mean number of days in ITU, mean number of 
days ventilated, percentage of patients requiring transient renal support 
(haemofiltration and haemodialysis) – to exclude the bias of pre-existing renal 
impairment, patients with a creatinine of greater that 150µml/L prior to 
transplantation were excluded from the analysis on requirement for renal support- 
and the percentage of patients that developed a bacteraemia or a site specific 
infection (chest, wound and intra-abdominal). Infective complications were only 
accepted after a positive microbiology culture. 
4.2.1.3: Statistical analysis. 
Results were analysed on the Statistical Package for the Social Sciences (SPSS) 
version 21, IBM. Transaminase levels were correlated with both short term (3 
month) and long term (5 year) outcomes. Transaminase levels were adjusted for cold 
ischaemic time, secondary warm ischaemic time, donor and recipient age, recipient 
gender and pre-operative MELD score using a binary logistic regression analysis. 
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When statistical analyses were performed to analyse transaminase levels with long 
term graft loss, grafts that had been lost in the first 3 months post transplant were 
excluded from the analysis. 
As this was historical data, patients with missing data were excluded from the 
analysis. 
Binary logistic and linear regression models were performed to analyse transaminase 
levels and ROC curves were produced illustrating the sensitivity and specificity for 
each AST value for predicting early liver specific graft loss.  
A p value of <0.05 was considered to be significant. 
4.2.2: Results. 
Data was analysed on 1272 patients (640 Male/628 Female/4 Unspecified) 
undergoing liver transplantation at the Royal Free Hospital between the years of 
1988 and 2012. Minimum follow up was 3 months or until graft failure. 181 patients 
were excluded due to missing data. The median donor age was 43 (31-53). The 
majority of grafts were from donors after brain death (DBD) (97%). The mean cold 
ischaemic time was 604 (454-744) minutes. 99% of grafts were preserved in 
commercial University of Wisconsin preservation fluid (Organ Recovery Systems, 
Chicago). Further donor details are provided in table 4.1. The median recipient age at 
time of transplantation was 50 years (41-57) and the median pre-operative Model for 
End-stage Liver Disease (MELD) score was 16 (12-22). Further recipient 
characteristics are given in table 4.2. The main indications for transplantation were 
hepatitis C virus related cirrhosis (22%) and alcohol liver disease (17%). Other 
indications are given in table 4.3. The median AST levels peaked on the 1st post-
operative day with a median value of 651(375-1146)iU/L. 55 grafts (5.9%) were lost 
due to liver specific pathology in the first 3 months and a further 59 grafts (9.9%) 
were lost due to liver specific pathology between 3 and 5 years. The pathology and 
incidence of all grafts lost is contained in table 4.4. 
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Table 4.1: Donor and transplant characteristics. 
 
 
Gender Male 640 
Female 628 
Unspecified 4 
Age 50 (41-57) 
Length of time in ITU (days) 3 (2-6) 
Pre operative MELD score 16 (12-22) 
Pre-operative creatinine (micromoles/L) 85 (70-107) 
Preoperative haemoglobin (g/dL) 11 (9.6-12.5) 
Table 4.2: Recipient characteristics 
 
 
 
 
 
Age 43 (31-53) 
Type of Donor Deceased brain death 1228 
Deceased cardiac death 33 
Domino 8 
Split 3 
Number of grafts analysed 
at each time point 
0-3 months 1062 
3months-5 years 623 
Length of time in ITU (days) 3 (2-5) 
Cold ischaemic time (minutes) 604 (454-744) 
Implantation warm ischaemic time (minutes) 43 (37-49) 
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Table 4.3: Indication for transplantation 
 
 
 
Indication for transplantation Number percentage 
Hepatitis C Cirrhosis 280 22.0% 
Alcohol Liver Disease 221 17.4% 
Primary Biliary Cirrhosis 149 11.7% 
Hepatitis B Cirrhosis 114 9.0% 
Primary Sclerosing Cholangitis 109 8.6% 
Acute Liver Failure (unknown cause) 69 5.4% 
Cryptogenic Cirrhosis 62 4.9% 
Hepatic Artery Thrombosis 39 3.1% 
Auto-immune Hepatitis 34 2.7% 
Metabolic Diseases 24 1.9% 
Acute Liver Failure (paracetamol) 23 1.8% 
Wilson’s Disease 20 1.6% 
Primary Graft Non-Function 20 1.6% 
Other 20 1.6% 
Biliary Complication 16 1.3% 
Chronic Rejection 13 1.0% 
Budd Chiari Syndrome 12 0.9% 
Familial Adenomatous Polyposis 11 0.9% 
Hepato-Cellular Carcinoma (non-
cirrhtoic) 
8 0.6% 
Other Malignancy 8 0.6% 
Non-Thrombotic Infarction 6 0.5% 
Ductopenic Rejection 3 0.2% 
Polycystic Disease 1 0.1% 
Biliary Atresia 1 0.1% 
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Pathology of graft failure 1-3 months 3 months – 5 years 
Extra-hepatic cause 95 157 
Vascular occlusion 56 5 
Non-thrombotic infarction 23 2 
Primary graft non-function 23 0 
Acute rejection 1 0 
Chronic rejection 3 25 
Ductopenic rejection 0 14 
Biliary complications 4 16 
Others 1 2 
Table 4.4: Pathology and period of liver specific graft failure. 
4.2.2.1: Transaminase levels and graft failure between 0 and 3 months. 
For this analysis 1062 grafts were analysed. On the first post-operative day median 
AST levels were 651(375-1146)iU/L and median ALT levels were 474(257-
865)iU/L. In uni-variate analysis, on the first post-operative day, AST levels were 
significantly higher in grafts that were lost within the first 3 months than those that 
were still functioning [755(406-1450)iU/L vs 633(371-1097)iU/L, p=0.011]. 
Although ALT levels on the first post-operative day were higher in grafts that were 
lost within the first 3 months compared to those that were still functioning, this 
difference was not statistically significant [550(263-1037)iU/L vs 463(257-845)iU/L, 
p=0.52]. By the 3rd post-operative day, median AST levels had fallen to 272(143-
588)iU/L and median ALT levels had fallen to 425 (210-834)iU/L. Univariate 
analysis found that both AST [508(195-1255)iU/L vs 257(137-527)iU/L, p<0.001] 
and ALT [618(289-1325)iU/L vs 402(204-782)iU/L, p<0.001] levels on day 3 were 
significantly higher in grafts that were lost within 3 months than those that were still 
functioning. By the 7th post-operative day, median AST levels had fallen to 61(39-
102)iU/L and median ALT levels had fallen to 175(104-290)iU/L. On univariate 
analysis, both AST levels [78(45-171)iU/L vs 59(39-96)iU/L, p<0.001] and ALT 
levels [217(128-359)iU/L vs 172(101-275)iU/L, p=0.001] on day 7 were 
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significantly higher in grafts that were lost within 3 months than those that were still 
functioning. 
A binary logistic regression model showed that both AST levels on the 3rd post-
operative day (p=0.002) as well as AST (p<0.001) and ALT (p=0.006) levels on the 
7th post-operative day were strong predictors of early graft loss. Transaminase levels 
on the 1st post-operative day were not indicative of early graft loss (AST p=0.645, 
ALT p=0.363). Although AST levels on the 3rd post-operative day correlated 
strongly with early graft failure, ALT levels did not (p=0.710) (Table 4.5). 
The binary logistic regression model was rerun including only transplants performed 
between the years of 1998 and 2012 to ensure that the model was not affected by 
changes in clinical practice over the years. 796 grafts were included in this analysis. 
AST levels on the 3rd post-operative day (p=0.003) but not ALT levels on the 3rd 
post-operative day (p=0.548) correlated with early graft loss in this recent but 
reduced size cohort. 
4.2.2.2: Transaminase levels and liver specific graft failure within 3 months of 
transplant. 
For this analysis, 151 grafts that failed within 3 months for a non liver specific 
reason were excluded and 940 grafts were therefore included in this analysis. AST 
levels on the 1st post-operative day were significantly higher in grafts that failed 
within 3 months that those that survived [840(416-1530)iU/L vs 633(371-1097)iU/L, 
p=0.009] whilst ALT levels on the 1st post-operative day were higher but not 
statistically different [572(289-1336)iU/L vs 463(257-845)iU/L, p=0.09]. By day 3 
both AST levels [780(227-1309)iU/L vs 257(137-527)iU/L, p<0.001] and ALT 
levels [680(285-1359)iU/L vs 402(204-782)iU/L, P=0.006] were significantly higher 
in grafts that failed for a liver specific reason within 3 months than those that were 
still functioning. At the 7th post-operative day, both AST levels [101(47-363)iU/L vs 
59(39-96)iU/L, p=0.001] and ALT levels [308(120-590)iU/L vs 172(101-275)iU/L, 
p=0.003] were significantly higher in grafts that were lost due to liver specific 
pathology than in those that were still functioning after 3 months. 
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A binary logistic regression model showed that AST levels on the 3rd post-operative 
day (p=0.005) and the 7th post-operative day (p=0.001) were strong predictors of 
early liver specific graft failure. Transaminase levels on the 1st post-operative day 
(AST p=0.092, ALT p=0.962) were not predictive of early liver specific graft loss. 
Although AST levels on the 3rd post-operative day correlated strongly with early 
liver specific graft failure, day 3 ALT levels did not (p=0.966). 
4.2.2.3: Transaminase levels and late graft failure between 3 months and 5 
years. 
A binary logistic regression model was used to analyse transaminase levels in grafts 
that were lost between 3 months and 5 years. For this analysis, grafts that were lost 
before 3 months were excluded from the analysis and therefore 623 grafts were 
analysed. There was no correlation between AST and ALT levels on the 1st, 3rd and 
7th post-operative days and grafts lost between 3 months and 5 years post 
transplantation. 
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 Grafts lost 0 - 3 months Grafts lost 3 months - 5 years 
MELD .000 .903 
AST day 1 .634 .935 
ALT day 1 .351 .468 
AST day 3 .002* .703* 
ALT day 3 .622 .804 
AST day 7 <.001 .402 
ALT day 7 .005 .901 
Rec gender .137 .657 
Rec age .732 .965 
Don age .447 .287 
CIT .014 .625 
Reperfusion Time .434 .243 
Table 4.5: Binary logistic regression model showing correlation between day 3 AST 
levels(*) and early but not late graft loss 
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4.2.2.4: AST levels on the 3rd post-operative day and clinical outcome measures. 
Having identified that AST levels on the 3rd post-operative day and that AST and 
ALT levels on the 7th post-operative day correlated with early graft loss, ROC curves 
were performed to calculate the area under the curve for predicting total graft loss 
and liver specific graft loss with transaminase levels on day 1,3 and 7 post tranpslnat. 
AST on the 3rd post-operative day was the best diagnostic test with an AUROC of 
0.644 (0.597-0.691) for total graft loss and an AUROC of 0.739 (0.663-0.814) for 
liver specific graft loss (Figure 4.1). As day 3 AST was the best diagnostic marker 
according to ROC curves, further more detailed analysis was performed using day 3 
AST levels against liver specific graft loss. 
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Figure 4.1: ROC curve of AST levels against 3 month graft failure. 
1A: day 3 AST levels against total graft loss - AUROC 0.644 (0.597-0.691) 
1B: day 3 AST levels against liver specific graft loss – AUROC 0.739 (0.663-
0.814) 
1C: day 7 AST levels against total graft loss – AUROC 0.600 (0.549-0.651) 
1D: day 7 AST levels against liver specific graft loss – AUROC 0.654 (0.551 -
0.757) 
 
Likelihood ratios, positive and negative predictive values were calculated for 
different day 3 AST levels. An AST level of below 106.5iU/L was identified as the 
best fit to predict graft survival with a negative likelihood ratio of 0.13 and a 
negative predictive value of 99.54%. This would mean that a recipient with an AST 
of below 106.5iU/L on day 3 has a 1 in 200 chance of developing graft failure. An 
AST level of above 2744.5iU was identified as the best fit to predict graft failure 
with a positive likelihood ratio of 13.1 and a positive predictive value of 34.62%. 
This would mean that a recipient with an AST level of > 2744.5iU/L on day 3 has a 
greater than 1 in 3 chance of developing graft failure. 106.5iU/L and 2744.5iU/L are 
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both extreme values and to ensure that middle range values could also be diagnostic, 
the central group was further divided again based on likelihood ratios. An AST level 
of 1213iU/L was chosen as the positive likelihood ratio was 4.1 identifying this level 
as a moderate predictor of graft failure. Patients were therefore divided into 4 groups 
according to the AST level on the 3rd post-operative day (<107iU/L, 107-1213iU/L, 
1213-2744iU/L and >2744iU/L). 
On day 3, 201 patients had an AST level of less than 107iU/L, 883 patients had an 
AST level of between 107iU/L and 1213iU/L, 97 patients had an AST level of 
between 1213iU/L and 2744iU/L and 40 patients had an AST level of greater than 
2744iU/L. In patients with AST levels of below 107iU/L the incidence of 3 month 
graft loss was 9.6% and mortality was 5.5%. This climbed to 13.7% and 8.2% 
respectively in patients with AST levels between 107iU/L and 1213iU/L and to 
26.5% and 18.4% in patients with AST levels of between 1213iU/L and 2744iU/L. In 
patients with AST levels of greater than 2744iU/L the incidence of 3 month graft loss 
was 58.5% and 90 day patient mortality was 48.8%. This incremental increase 
amongst the groups was observed in incidence of liver specific graft loss at 3 
months, 30 day and 1 year mortality (Table 4.6) (Figure 4.2). 
The need for organ support and length of stay in ITU similarly increased among the 
groups from a mean of 7 days in patients with AST levels of less than 107iU to 15 
days in patients with AST levels of greater than 2744iU. The incidence of renal 
replacement therapy (RRT) in the group of patients with an AST of less than 
107iU/L was 13.3% and in the group of patients with AST levels of greater than 
2744iU/L was 57.1% (Table 4.6). 
There was a greater incidence of proven bacteraemias and site specific infective 
complications in the groups of patients with higher AST levels (Table 4.6). 
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Day 3 AST levels (iU) <107 107-1213 1213-2744 >2744 
No.in group 201 882 98 41 
Liver specific graft loss 0.5% 3.2% 7.7% 34.6% 
Total graft loss 10% 13.7% 26.5% 58.5% 
30 day mortality 3.5% 5.1% 15.3% 34.1% 
90 day mortality 5.5% 8.2% 18.4% 48.8% 
1 year mortality 12.2% 12.4% 27.2% 62.2% 
Days in ITU (mean) 7 (±13) 7 (±14) 9 (±12) 15 (±21) 
Days ventilated (mean) 5 (±11) 6 (±13) 8 (±12) 14 (±20) 
Need for renal support 13.3% 12.4% 23.8% 57.1% 
Bacteraemia 0.5% 4.9% 16.3% 12.5% 
Intra-abdominal infection 1% 3.2% 16.3% 17.5% 
Chest infection 1% 4.7% 14.3% 10% 
Wound infection 0.5% 8.4% 24.5% 27.5% 
Table 4.6: Grouped AST levels (iU) on the 3rd post-operative day and incidence of 
clinical morbidity and mortality 
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A: 90 day liver specific graft loss           B: 90 day total graft loss 
 
C: 90 day recipient mortality 
 
Figure 4.2: shows the increasing incidence of 90 day graft loss and recipient 
mortality as the AST levels on day 3 climb 
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4.2.3: Discussion. 
These results show that AST levels on the 3rd post operative day accurately correlate 
with both patient and graft outcomes following liver transplantation. This is 
important for 2 reasons. Firstly studies of interventions to reduce IR injury in small 
animal models use a reduction in transaminase levels at 48 hours as a primary 
endpoint and these results suggest that this is a clinically relevant endpoint. Secondly 
it identifies a soft surrogate endpoint in clinical trials of liver transplantation for 
small pilot studies. Transaminase levels are measured daily in the post-operative 
period and therefore this simple blood test which is a marker of hepatocyte damage is 
readily available for use in all patients. Although day 3 ALT levels were significantly 
elevated in grafts that failed compared to those that still functioned after 3 months, 
when adjusted for other transplant factors, ALT levels were not significant. This is 
very interesting as although AST and ALT are released by damaged hepatocytes, 
ALT is liver specific while AST is also released from damaged myocardiocytes 
[162] and nephrons [163]. There are however 2 reasons that may explain this. Firstly 
mathematical models have shown that AST is more abundant in the liver than ALT 
[164], and therefore more AST is released into the circulation when the hepatic 
parenchyma is damaged - potentially masking subtle differences in ALT levels. This 
is reflected in the fact that median peak AST levels were higher than median peak 
ALT levels (651iU/l vs 452iU/l). Furthermore, in studies of organ preservation injury 
[165] and paracetamol liver injury [164], it has been shown that circulating AST 
levels reduce more rapidly than circulating ALT levels. These findings are similar to 
the current study with day 3 serum AST levels having fallen to 272iU/L from 
651iU/L whilst ALT levels had only reduced to 425iU/L from 452iU/L. Falling AST 
levels are therefore able to be identified earlier than falling ALT levels due to 
reabsorption profile of the transaminases. Grafts that are recovering with no further 
ongoing damage will therefore be identified at an earlier time point by measuring 
AST levels. This is reflected in the results from this study as by day 7 both AST and 
ALT levels were significantly higher in grafts that were lost but at day 3 only AST 
levels were higher. The use of AST levels as a surrogate marker of outcome would 
allow small pilot studies to identify drugs or interventions that demonstrate evidence 
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of clinical benefit and aid the decision to progress to further large randomized 
controlled trials. 
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4.3: Plasma and urinary Neutrophil Gelatinase Associated Lipocalin 
(NGAL) levels. 
Acute Kidney Injury (AKI) is one of the most common and serious complications 
post liver transplantation [166–171]. Documented incidence in the literature ranges 
from 14%-94% [166–171]. A recent study of our patients undergoing liver 
transplantation at the Royal Free found that 50% of patients developed AKI post 
transplant [172]. The development of AKI post liver transplant is associated with an 
increased risk of morbidity, mortality and graft loss [166,173]. Patients who develop 
AKI spend longer in ITU and hospital post transplantation and are at increased risk 
of developing End Stage Renal Failure (ESRF) requiring life long dialysis or kidney 
transplantation. 
Current methods to diagnose AKI are unreliable and rely on serial serum creatinine 
measurements over 48 hours – resulting in a delayed diagnosis. Creatinine clearance 
is a measure of renal function and several variables around the liver transplant period 
can alter the ability of the kidney to filter creatinine or measure creatinine reliably 
including jaundice, pre-operative muscle wasting and post-operative 
immunosuppressives [174] making creatinine changes difficult to interpret in liver 
transplant patients diagnosing AKI in post liver transplant patients more difficult. An 
accurate biomarker of kidney injury in liver transplant may be an excellent surrogate 
for outcome post liver transplant and could be used to monitor novel interventions 
aimed at reducing organ preservation IR injury. 
 The Acute Kidney Injury Network (AKIN) criteria classifies a patient as having an 
AKI if their serum creatinine levels rise by an absolute value of 26.4µmol/L or by 
greater than 50% of the baseline creatinine value [175] within 48 hours.  This delay 
in 48 hours for a diagnosis allows further kidney damage to occur and exposes 
patients to the potential complications of AKI including electrolyte disturbances, 
fatal arrhythmias and non-cardiogenic acute respiratory distress syndrome [176,177]. 
There is a strong correlation between the severity of AKI and the subsequent 
incidence of ESRF [178–180] and the duration of AKI has been shown to correlate 
strongly with risk of inpatient mortality in general hospital inpatients and in patients 
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undergoing major cardiac surgery [178–181]. A study investigating the effect of 
early involvement of the renal team in general inpatients patients with AKI at the 
Royal Free Hospital performed a subgroup analysis and found that early involvement 
of the critical care team and corrective physiological management on the day of 
diagnosis was associated with a significant reduction in both inpatient mortality and 
the need for RRT [182]. Furthermore there is strong evidence to suggest that a delay 
in starting haemofiltration is associated with an increased risk of inpatient mortality 
[183,184]. Although this has not been investigated in the setting of liver 
transplantation, 2 studies in the setting of poly-trauma [183] and cardiac surgery 
[184] clearly demonstrate that when the RRT is started earlier in patients who 
develop AKI, inpatient mortality was significantly reduced by 19% and 32% 
respectively. An early biomarker of AKI would therefore not only be of interest as a 
surrogate marker but would also allow for earlier treatment of AKI which may 
transform the care of these patients, reducing inpatient mortality and the 
development of ESRF.  
Neutrophil Associated Gelatinase Lipocalin (NGAL) is a 25 kiloDalton protein 
released by damaged nephrons that is believed to play a role in kidney development 
and thereafter to have a function in the innate immune system. NGALs have been 
shown to be rapidly released (within 2 hours) into both the circulation and urine 
following an ischaemic kidney injury [185]. Several studies have investigated the 
role of NGALs in predicting AKI following major cardiac surgery and have 
identified NGALs as an accurate predictor of AKI [185,186]. Furthermore urinary 
NGAL levels have been shown to be a strong predictor of graft injury and early graft 
dysfunction following renal transplantation [187]. Whether NGAL levels predict 
AKI post liver transplantation remains to be adequately investigated. 11 studies 
[188–198] have investigated the role of NGALs in predicting AKI post liver 
transplantation but the methodology employed in these trials has been varied and as 
such has resulted in conflicting results. Only 4 studies used the absolute urinary 
NGAL value in their analysis [189,197,198]. A key issue has been the timepoint at 
which NGAL levels have been measured. NGAL levels have been shown to peak 
rapidly within 4 hours and to then gradually drop. Of the 4 trials measuring uNGAL 
levels two collected urine samples at unspecified timepoints within the first 24 hours 
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post liver transplantation [189,197]. In a diagnostic test that peaks so rapidly and 
then drops it is difficult to rule out bias within the study unless the time of collection 
is stipulated and rigidly adhered to. A sick patient in multi-organ failure following 
transplant who arrives in ITU will require stabilization before trial samples can be 
collected therefore resulting in lower levels than in samples collected from patients 
who are stable. This may explain why although all studies discriminated between 
patients who developed an AKI and those that did not, the AUROC in these trials 
was extremely variable with a range of 0.5 [198] to 0.83 [197]. Furthermore, few 
trials investigated the role of serum or plasma NGAL levels with the majority 
focusing on urinary NGAL levels. Some trials struggled to collect urine samples 
from patients with a severe AKI who were anuric, further biasing their results, with 
one study only able to measure urinary NGAL levels in approximately 50% of 
patients [189]. Finally it was not clear whether the urine samples analysed were fresh 
urine samples collected direct from the urinary catheter or were collected from the 
reservoir and therefore were not an accurate representation of intra-operative renal 
damage. Samples measured at 24 hours post operatively, although earlier than serum 
creatinine changes measured at 48 hours, still result in a delayed diagnosis. A well 
designed study with strict and early sample collection time points is therefore of 
benefit as this would allow for a robust cut off diagnostic level and for earlier 
diagnosis and therefore treatment of AKI. The inclusion of plasma NGAL levels 
would also allow for a diagnostic marker to be available in anuric patients. 
4.3.1: Methods. 
Arterial blood and fresh catch urine samples were collected from 27 patients 
undergoing liver transplantation at the Royal Free Hospital. Paired blood and urine 
samples were collected following induction of anaesthesia but prior to skin incision. 
A further blood sample was collected as close to 2 hours post reperfusion as possible 
and a urine sample was collected at the time of skin closure. The mean time from 
portal vein reperfusion to collection of the urine sample at skin closure was 178(±46) 
mins. A further blood and urine sample were collected at 24 hours post reperfusion. 
To ensure that the urine was fresh it was collected from the collection port in the 
foley catheter and not from the urine reservoir. The urine sample was immediately 
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aliquoted and frozen at -800C till analysis. The blood sample was immediately 
centrifuged (300g, 10 minutes, 200C) to obtain plasma which was aliquoted and 
stored at -800C till analysis. 
Urinary and plasma NGAL levels were measured using the same commercially 
available ELISA kit (Biolegend, UK). Plasma was diluted 1 in 100 according to the 
manufacturer’s instructions. Following test dilutions, urine samples were diluted at 1 
in 200 and at 1 in 400 when samples diluted at 1 in 200 exceeded the maximal 
absorbance due to large NGAL concentrations. 
Serum creatinine levels were measured pre-operatively and daily post-operatively in 
peripheral venous blood (Clinical Chemistry analyser, Modular analytics, P module, 
Roche, USA). The AKIN score [199] was calculated for each patient. Patients were 
identified as having an AKI if the creatinine rose by >26.4micromol/L of by >50% 
from baseline within 48 hours. 
Differences between the groups were measured with Mann-Whitney U tests and 
correlations were calculated with Spearman rank correlations. 
4.3.2: Results. 
Urine was collected from all patients and no patient became anuric. 13 patients 
(48%) suffered an AKI post liver transplant and 8 patients (30%) required 
haemofiltration whilst in ITU. Patients who developed an AKI had a significantly 
shorter cold ischaemic time than those that did not (449 mins vs 601 mins, p=0.033). 
Both groups were otherwise well matched at baseline (Table 4.7). Patients who 
developed an AKI had significantly higher transaminase levels on the first post-
operative day – suggestive of a more significant IR injury (AST: 2521iU/L vs 
710iU/L, p=0.002; ALT: 1880iU/L vs 893.5iU/L, p=0.003). 
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 No AKI AKI P value 
Age 56 (±10) 54 (±8) 0.509 
Gender M:F 11:3 12:1  
Pre-operative creatinine (micromol/l) 75.5 (78.0) 81.0 (99.0) 0.402 
MELD 14 (19) 15 (19) 0.280 
UKELD 52 (±6) 56 (±5) 0.103 
Length of cold ischaemic time (mins) 601 (±159) 449 (±88) 0.033 
Length of operation (mins) 441 (±74) 440 (±90) 0.982 
Table 4.7: Baseline characteristics 
4.3.2.1: Urinary NGALS. 
Median urinary NGAL levels were significantly raised between the initial sample 
measured prior to skin incision and at the time of abdominal closure in all patients 
(160.67pg/ml vs 56.29pg/ml, p=0.018). Patients who developed an AKI post liver 
transplant had higher NGAL levels at baseline but this was not significant (p=0.085) 
(Table 4.8). Patients who developed an AKI post operatively had significantly higher 
urinary NGAL levels at the time of abdominal closure compared to those that did not 
develop AKI (1319.64pg/ml vs 46.56pg/ml, p<0.001) (Table 4.8 & Figure 4.2). At 
24 hours post reperfusion, although median NGAL levels had fallen in the AKI 
group patients that developed an AKI still had significantly higher urinary NGAL 
levels than those that did not but not to the same degree (p=0.011) (Table 4.8). 
 No AKI (ng/ml) AKI (ng/ml) P value 
Baseline 30.51 (186.44) 71.27 (1084.71) 0.085 
Abdominal Closure 46.56 (2409.71) 1319.64 (3146.69) <0.001 
24 hours post-reperfusion 49.44 (1045.9) 470.78 (2625.98) 0.011 
Table 4.8: Median urinary NGAL levels in patients who developed AKI compared 
with those that did not develop AKI. 
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Figure 4.2: Urinary NGAL levels measured at time of abdominal closure. 
Each point equals an individual patient. Bar represents median. Significance 
between the groups was measured by Mann-Whitney U test.  
 
A ROC curve was performed to analyse urinary NGALS at abdominal closure and at 
24 hours post operatively. The ROC curve at time of abdominal closure had an area 
under the curve of 0.943 (0.832-1, P<0.001) and at 24 hours post reperfusion the area 
under the curve was 0.771 (0.575—0.968, p=0.026) (Figure 4.3). Further analysis 
was therefore performed on the ROC curve at time of abdominal closure. Using 
likelihood values, 167.96ng/ml was identified as the optimal cut off to diagnose AKI 
with a positive likelihood ratio of 14.1 and a negative likelihood ratio of <0.01 
identifying this as an excellent diagnostic test for post operative AKI. 
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Figure 4.3: ROC curves for urinary NGAL levels prediction subsequent AKI. 
3A: urinary NGAL levels at abdominal closure – AUROC 0.948 (0.847-1.000) 
3B: urinary NGAL levels at 24 hours post reperfusion – AUROC 0.792 (0.614-
0.969) 
 
Whether the degree of NGAL rise from baseline reflects the degree of kidney 
damage is not known. A bivariate correlation between the change in NGAL levels 
from baseline to abdominal closure and the rise in serum creatinine levels at 48 hours 
demonstrated that there was a significant correlation between the NGAL level 
increase and the maximal increase in serum creatinine levels within 48 hours 
(p=0.001) (Figure 4.4). 
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Figure 4.4: Correlation between the increase in urinary NGAL levels from baseline 
at abdominal closure and the maximal increase in serum creatinine levels within 48 
hours from pre-op. 
4.3.2.2: Plasma NGAL levels. 
Median plasma NGAL levels were significantly raised in all patients at 2 hours post 
reperfusion when compared to baseline (921.62ng/ml vs 246.14ng/ml, p<0.001). 
There was no significant difference in median plasma NGAL levels measured at 2 
hours post reperfusion or at 24 hours post reperfusion between patients that 
developed an AKI or those that did not (Table 4.9). No further analysis was 
performed on plasma NGAL levels as there was no difference between the groups. 
 No AKI (ng/ml) AKI (ng/ml) P value 
Baseline 234.09 (954.73) 291.16 (617.14) 0.943 
Abdominal closure 892.27 (1321.92) 1134.26 (1499.73) 0.867 
24 hours post reperfusion 640.59 (1254.04) 448.45 (1053.29) 0.347 
Table 4.9: Median plasma NGAL levels in patients who developed AKI against 
those that did not. 
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4.3.3: Discussion. 
AKI is a significant problem following liver transplantation occurring in around 50% 
of patients at the Royal Free Hospital. Current methods to diagnose AKI are poor. 
The incidence of AKI in the study population was 48% which is in keeping with a 
larger study of AKI post liver transplantation at the Royal Free Hospital, London 
[172] suggesting that this study population is representative of patients undergoing 
transplantation at the Royal Free. 
This study has shown that urinary NGAL levels measured at time of abdominal 
closure are not only significantly elevated in patients who develop AKI but also that 
the level of increase in NGAL level from pre-op levels correlated with the increase in 
creatinine levels at 48 hours. Detailed analysis of urinary NGAL levels at abdominal 
closure showed that a cut off value of 168ng/ml was an excellent cut off value for 
diagnosing AKI. Only one patient with a NGAL level of more than 168ng/ml 
developed an AKI however this patient had experienced an absolute creatinine level 
rise of 25µmol/l which is just below the cut off level of 26.4µmol/l suggesting that 
this patient had a significant degree of acute renal injury which may explain the 
raised NGAL levels. 
The AUROC in this study was 0.943 rating urinary NGAL levels at abdominal 
closure as an excellent diagnostic test for AKI. This diagnostic accuracy is 
significantly higher than in previous studies (0.5-0.83) which likely reflects the early 
and standardized timing of urinary NGAL measurement. Previous studies have 
measured NGAL levels at varying timepoints post transplantation ranging from 2 
hours post reperfusion to 24 hours post-operatively. This study measured NGAL 
levels at the time of abdominal closure which was on average 178(±46) minutes post 
reperfusion of the donor liver which is within the 4 hour peak of NGAL release. 
Although urinary NGAL levels were able to diagnose AKI at 24 hours, the AUROC 
was significantly lower at 0.771 which is more in keeping with previous studies 
again suggesting that the timepoint at which the samples are collected is vital.  
Although urinary NGAL levels are able to accurately diagnose AKI post 
transplantation, plasma NGAL levels were unable to differentiate between patients 
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who developed an AKI and those that did not. This may reflect the fact that area of 
the kidney most sensitive to ischaemic injury are the proximal tubules and the 
ascending limb of the loop of Henley [200,201] and as such NGALs may be released 
more readily into the tubules rather than the circulating system. Furthermore in the 
presence of an ischaemic injury secondary to reduced renal blood flow it is 
unsurprising that NGAL release into the circulation is less than into the tubules 
which do not have a compromised flow. Few studies have investigated the role of 
plasma NGALs aswell as the role of urinary NGALs. An interesting further study 
would therefore be to compare NGAL levels between piggyback and caval 
replacement techniques. 
Three studies have investigated the effect of early introduction of RRT, one in the 
setting of poly trauma [183], one in the setting of cardiac surgery [184] and a large 
recent trial involving general hospital inpatients (ELAIN trial) [202]. All three trials 
demonstrated a reduction in inpatient mortality with early commencement of RRT. 
The ELAIN trial demonstrated a reduction in 90 mortality from 57% to 39%, p=0.02 
and in median length of hospital stay from 82 days to 51 days, p<0.001 [202]. In the 
trauma setting, earlier introduction of renal replacement therapy, as measured by 
raised blood nitrogen levels in the absence of a reduction in creatinine clearance, was 
associated with a significant reduction in inpatient mortality from 39% to 20%, 
p=0.041. In patients who developed AKI post major cardiac surgery those who were 
commenced on RRT earlier based on a drop in urine output before lab markers 
including creatinine levels rose had a mortality of 24% compared to 56% in those 
who were commenced on RRT following a rise in serum creatinine which was 
statistically significant (p=0.016). There are currently no trials investigating the 
timing of RRT in patients who develop AKI post liver transplantation.  
The identification of urinary NGAL levels as an excellent early biomarker for AKI 
has 2 key advantages. Once confirmed in a larger cohort of patients which would 
simultaneously allow for the identification of a cut of value to diagnose AKI, 
NGALs could be measured routinely in our liver transplant patients allowing early 
diagnosis and therefore post-operative optimization to reduce further renal injury and 
involvement of the renal physicians in their care which has been shown to improve 
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outcomes of patients with AKI [182]. Secondly, as all our patients have filtration 
lines inserted routinely, patients with raised urinary NGAL levels could be recruited 
into a randomized controlled trial aimed at investigated the effect of early RRT at 
improving outcomes in patients with AKI post liver transplant. This trial is currently 
being designed. 
Both these studies have identified important surrogate end points which could be 
used in interventional trials in liver transplantation. AST levels on the 3rd post 
operative day correlate with both graft and recipient outcomes up to 1 year. Once 
validated in another unrelated dataset, a reduction in day 3 AST levels would be a 
suitable general endpoint. AKI is a major problem post liver transplantation that is 
currently diagnosed late resulting in irreversible renal parenchymal damage. Urinary 
NGAL levels measured at time of abdominal closure can accurately diagnose AKI in 
patients undergoing liver transplantation and that urinary NGAL levels at this 
timepoint would be a suitable endpoint in a clinical trial aimed at reducing AKI post 
liver transplantation. 
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Chapter	 5:	 Remote	 Ischaemic	
Preconditioning	 in	 Orthotopic	 Liver	
Transplantation	(RIPCOLT)	trial.	
5.1: Introduction. 
One year mortality rates following first elective liver transplants in the UK have 
fallen from 12.5% to 8.8% between 1994 and 2012 [5]. As outcomes post liver 
transplantation have improved the number of conditions felt suitable for liver 
transplantation have been widened. This has not been matched by such an increase in 
the number of donor organs available and as such this increase in indications is 
stretching an already scarce resource. To increase the donor pool, more marginal 
grafts are being implanted which we know are more prone to IR injury. Grafts from 
donors following cardiac death (DCD) has been a key focus of this expansion in the 
UK. In 2005 6.9% [10] of grafts implanted in the UK came from DCD donors but by 
2016 this had increased to 22.4% [203]. The use of a DCD graft is associated with a 
2 fold increase in post-operative graft loss and recipient mortality in UK centres [10]. 
Strategies to reduce IR injury therefore remain a key clinical concern and a major 
research focus. 
Ischaemic Preconditioning (IPC), first described in 1986 in a canine cardiac model 
[79], is the process by which short periods of ischaemia to an organ protect that 
organ during further periods of sustained ischaemia. IPC has been reliably shown in 
small animal models to ameliorate IR injury in the myocardium, kidneys, gut and 
liver. In the setting of hepatic resectional surgery, the first trial performed by 
Clavien’s group in 2000 [82] included 24 patients undergoing major hepatic 
resection and demonstrated a significant reduction in post operative transaminases up 
to day 4 post-operatively compared to control patients. There was no significant 
reduction in the hard clinical end-points of post-operative liver failure or mortality 
but the trial was not powered to detect such a difference. Results from further trials 
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have been less encouraging and a recent meta-analysis failed to demonstrated an 
overall clinical benefit from IPC in the setting of hepatic resectional surgery [84].  
In the setting of liver transplantation, several small studies have investigated the 
effect of direct IPC on donor livers prior to retrieval. The results from individual 
studies have been varied but meta-analysis of the studies demonstrated a 45% 
reduction in recipient mortality and an 82% reduction in the incidence of primary 
graft non-function (PGNF), although neither of these reached statistical significance 
(p=0.06 and p=0.12 respectively). This meta-analysis included 593 patients (286 
IPC; 307 control) – a power calculation suggests that to adequately power a trails for 
a reduction in 1 year mortality would require 974 patients and to demonstrate a 
significant reduction in incidence of PGNF would require 660 patients. Therefore 
although impressive, these values did not reach significance. In small animal models, 
direct IPC has been shown to impair liver regeneration [95,96]. Although the risk of 
direct IPC has not been evaluated in liver transplant recipients, it is likely that the 
effects to the transplanted liver are similar to those seen with the liver remnant in 
resectional surgery. Although there appears to be a large reduction in recipient 
mortality following donor IPC this data needs to be validated in a larger cohort. 
However within the UK National Organ Retrieval Service (NORS) the retrieving 
team may not be attached to the centre transplanting the organ making the logistics 
of a donor IPC clinical trial more complex. This has prompted the search for other 
techniques to ameliorate IR injury. 
One such technique is Remote Ischaemic Preconditioning (RIPC) in which the 
preconditioning stimulus performed in one vascular bed provides protection to 
distant unrelated vascular beds [97]. RIPC has been reliably shown in small animal 
models to ameliorate IR injury in the myocardium, kidneys and liver and can be 
performed on the recipient prior to implantation of the donor liver removing both the 
ethical dilemma of the consent process and the infrastructure problems of performing 
IPC in the donor. Furthermore, performing RIPC in the recipient would precondition 
the individual in which the reperfusion injury occurs which is more in keeping with 
the situation in small animal models. However it should be noted that the 
mechanisms by which IPC and RIPC provide the protection remain unknown and if 
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the predominant mechanism of protection is by improving how the target organ 
copes with prolonged ischaemia, then performing RIPC in the recipient will be of no 
benefit. The first trial of RIPC in paediatric cardiac patients demonstrated a 
significant reduction in myocardial injury as indicated by serum troponin levels and a 
reduced requirement for post operative inotropic support [101]. Since then there have 
been two high profile negative trials of RIPC in cardiac surgery [102,103]. In the 
setting of transplantation surgery 3 trials have investigated the effect of RIPC [104–
106], all in the setting of renal transplantation, with one trial demonstrating improved 
early graft function following RIPC [104], one study reporting no change [105] and 
one yet to report the outcomes [106].  
There are no previous human clinical trials of liver transplant recipient RIPC and 
there are therefore fundamental issues to be addressed. These include the willingness 
of patients, their clinicians and the transplant anaethetists to support such a trial. 
Patients undergoing liver transplantation mainly have end stage cirrhosis and the risk 
of limb conditioning in patients with jaundice and a coagulopathy are unknown. 
Finally the conditioning protocol which has been used in other clinical applications 
may not be optimal with the altered metabolism and haemodynamics associated with 
end stage cirrhosis. 
5.1.2: Aim. 
The aim of this study was to perform a prospective randomized controlled feasibility 
study to address these issues and to obtain preliminary data on which to design a 
further prospective trial to determine efficacy and cost effectiveness. 
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5.2: Methods. 
A single centre double blind open prospective randomized sham controlled trial was 
performed at the Royal Free Hospital following approval by the National Research 
Ethics Service (11/H0720/4) and the Royal Free Hospital/University College London 
medical school ethical committee (8191). The trial involved randomization of adult 
recipients undergoing deceased donor liver transplantation and was registered with 
ClinicalTrials.gov: Number NCT00796588. The protocol was published [141]. 
Patients above the age of 18 undergoing first elective liver transplantation were 
enrolled with informed consent in the study for randomization. All graft types were 
included. Exclusion criteria are contained in table 5.1. 
Exclusion criteria: 
Re-transplantation 
 
Patients under 16 years of age 
 
Super-urgent transplantation 
 
Lack of informed consent 
 
Combined liver and kidney transplantation 
 
Peripheral vascular disease 
 
Varicose veins 
 
Localized limb infection 
 
Prior history of thrombo-embolic disease 
 
Inclusion in another interventional trial 
 
Table 5.1: Exclusion Criteria 
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Fifty-one patients undergoing assessment for liver transplantation were approached 
for recruitment to the study of which 6 patients were unwilling to enroll in the trial 
and a further 5 patients were excluded. Forty patients were randomized to a sham 
control or a RIPC group. Randomisation was performed, following induction of 
anaesthesia but before commencement of the abdominal procedure using a sealed 
envelope method by the study fellow who was not involved with the transplant 
surgery or post operative care (CONSORT flowchart, Figure 5.1). Both patients and 
the clinical team including the transplant surgeon and anaethetists were blinded as to 
which group the patient was randomized to. 
As this was a feasibility study the primary end points focused on safety and 
feasibility to recruit to the trial. Secondary endpoints were chosen to detect clinical 
benefit following RIPC and are contained in table 5.2. 
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Primary endpoints: 
Ability to recruit patients to the trial 
 
Feasibility of performing RIPC in liver transplant 
recipients 
 
Safety of RIPC in liver transplant recipients 
 
Post randomisation drop out rate 
 
 
90 day recipient mortality 
 
 
90 day graft loss 
 
Secondary 
endpoints: 
AST levels on the third post-operative day[142] 
 
Incidence of Acute Kidney injury and need for Renal 
Replacement therapy 
 
Length of stay in Intensive Care and total hospital stay 
 
Incidence of vascular thrombotic events 
 
Incidence of biliary complications 
 
Incidence of post-operative infections 
 
Incidence of acute rejection in the first months post 
transplantation 
 
Circulating cytokine levels 2 hours post reperfusion of 
the liver graft 
 
Table 5.2: Primary and secondary trial endpoints. 
5.2.1: The preconditioning stimulus. 
Following induction of anaesthesia but before skin incision, the left lower limb was 
covered with 2 layers of stockinette and a wide pneumatic tourniquet was applied to 
the left middle thigh in accordance with safe and recommended practices in 
accordance with the Association of Peri-operative Registered Nurses (AORN) [146]. 
To induce transient ischaemia, the tourniquet was inflated to 200mmHg for 5 
minutes and then deflated for 5 minutes to reperfuse the leg. This was repeated 2 
more times and was completed prior to the abdominal incision for the transplant 
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procedure. A sham consisted of placing the tourniquet as above but not inflating the 
tourniquet. 
5.2.2: Liver transplant procedure. 
Grafts were identified and retrieved through the dedicated UK National Organ 
Retrieval Service (NORS) according to national standards of organ retrieval from 
deceased donors [204] (NHSBT). Following aortic cannulation all grafts were 
perfused in situ with cold University of Wisconsin (UW) solution (Bridge to Life, 
Chicago, USA) at a maximum pressure of 200mmHg. On removal the grafts were 
further flushed with ice cold UW solution on the back bench via the hepatic artery, 
portal vein and the bile duct. The grafts were then sterile packaged in cold UW 
solution and transported to the recipient hospital on ice. Grafts which were stored 
and transported using normothermic perfusion using the OrganOx system were 
excluded. 
The recipients were monitored intra-operatively via arterial and central venous 
catheters with availability of trans-oesophageal echo as required. Implantation of the 
liver graft was performed by standard piggy-back and caval replacement techniques. 
Veno-venous bypass was not employed in any patient randomized in this trial. Grafts 
were flushed with 500-1000mls warm 4.5% human albumin solution (Bio Products 
Laboratory) via the portal vein immediately prior to blood re-perfusion to remove 
residual UW solution and waste material accumulated during cold ischaemia. 1g of 
methylprednisolone (Pharmacia) was given intravenously during the anhepatic phase 
as part of standard anaesthetic protocol. 
5.2.3: Post operative management. 
Post-operatively all patients were managed in the intensive care unit. 
Haemoglobin levels were maintained below 10g/L. Platelets and fresh frozen plasma 
were administered if there was a coagulopathy associated with active blood loss. 
Patients were routinely started on subcutaneous thromboprophylaxis on the first post 
operative day. All patients underwent a Doppler ultrasound scan of the liver vessels 
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on the first, third and fifth post-operative day. Daily blood tests included clotting 
profiles, renal function, bilirubin and serum liver enzymes. 
Patients were extubated on the first post-operative day unless there was a clinical 
need for ongoing respiratory support and triple therapy immunosuppression was 
commenced on day 1 post-operatively. If there was evidence of early renal 
impairment, monoclonal antibody therapy was given in place of triple therapy 
immunosuppression. 
5.2.4: Blood oxygenation levels during preconditioning. 
Two paired 2mls blood samples were collected in 21 patients (10 RIPC, 11 Control). 
A venous blood sample was collected from the recipients left foot in lithium heparin 
gas syringes (BD Preset, Wolkingham, UK), after 4.5 minutes of lower limb vascular 
occlusion while the tourniquet was still inflated or at the same time point in the sham 
group. A simultaneous peripheral arterial blood sample was collected by the 
anaesthetic team from the arterial line and identically managed. Oxygen levels, 
lactate levels and acid base status were measured instantly from both samples on a 
RAPIDPoint 500 blood gas analyser (Siemens, Surrey, UK). 
 
 
 
 
 
 
 
 
 109 
 
Figure 5.1: CONSORT flow diagram (PVD peripheral vascular disease; TED 
thrombo embolic disease) 
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5.3: Results. 
5.3.1: Feasibility and recruitment. 
Fifty-one patients were approached of which 45 (88%) were willing to enroll in the 
trial. Five patients were subsequently excluded due to risk factors for complications 
of the limb conditioning. Four of the five patients had a prior history of thrombo-
embolic disease and 1 patient had varicose veins of the left lower limb. The 
remaining 40 patients were randomized with 20 patients allocated to undergo RIPC 
and 20 patients allocated to the sham control. 
Preconditioning was feasible in the period following anaesthesia and prior to 
commencement of the transplant. During this period the anaesthetist was inserting 
the lines. All patients randomized to undergo preconditioning successfully completed 
the preconditioning protocol prior to the abdominal incision. In no patient was the 
commencement of the transplant procedure delayed due to the patient undergoing 
preconditioning. There was no evidence of systemic haemodynamic instability or a 
vagal response either during the preconditioning stimulus of following reperfusion of 
the limb. The tourniquet was removed prior to commencement of the abdominal 
procedure and visual inspection of the limb showed no evidence of bruising nor 
haematoma formation. No patient complained of post-operative limb pain, 
paraesthesia or limb weakness post-operatively. There was no clinical evidence of 
Deep Vein Thrombosis (DVT) or episodes of Pulmonary Embolism (PE) in any 
patient. 
5.3.2: Secondary end-points. 
The donor patient groups were well matched including donor age (Table 5.3) (RIPC 
43 vs control 47, p=0.376) and donor type (RIPC 15 DBD grafts vs Control 17 DBD 
grafts). The median graft cold ischaemic time was similar (RIPC 470mins vs Control 
455mins, p=0.75) and median time to perform the portal vein and hepatic artery 
anastomoses (RIPC 44mins vs Control 42mins, p=0.546) were similar between the 
groups. The recipient patient groups were well matched at baseline in all aspects 
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(Table 5.4) including severity of liver disease as measured by the MELD (RIPC 15 
vs Control 13, p=0.190) and UKELD (RIPC 55 vs Control 52, p=0.085) scores. 
 
Variable Preconditioned Control P value 
Gender (M:F) 16:4 13:7 0.731 
Age 43 (±14) 47 (±16) 0.376 
Donor ITU days 3 (2-4) 2 (1-4) 0.583 
Donor risk index 1.479 (1.242-
1.695) 
1.652 (1.041-
1.479) 
0.165 
Type of graft   0.723 
DBD 15 17  
DCD 3 2  
Domino 1 0  
Split 1 1  
Cold ischaemic time (mins) 470 (±140) 455 (±157) 0.750 
Warm ischaemic time (mins) 44 (±14) 42 (±11) 0.546 
Table 5.3: Donor and Transplant characteristics (mean ± SD/median + IQR) 
 
 
Variable Preconditioned Control P value 
Gender (M:F) 18:2 16:4 0.661 
Age 55 (±10) 54 (±9) 0.758 
MELD 15 (±5) 13 (±5) 0.190 
UKELD 55 (±5) 52 (±5) 0.085 
Indication for transplantation    
Alcoholic liver disease 7 3  
Hepatitis + HCC 3 8  
PSC 3 4  
Hepatitis C cirrhosis 4 2  
Hepatitis B cirrhosis 1 1  
NASH 1 1  
Polycystic liver disease 0 1  
Auto-immune hepatitis 1 0  
Bilirubin (µmol/L) 49 (43-107) 27 (17-65) 0.074 
ALT (iU/L) 50 (33-69) 54 (30-74) 1.00 
AST (iU/L) 77 (58-142) 76 (35-116) 0.751 
Alkaline Phosphatase (iU/L) 151 (100-195) 104 (84-194) 0.224 
Albumin (g/L) 32 (29-36) 33 (30-40) 0.369 
INR 1.5 (1.2-1.7) 1.2 (1.1-1.7) 0.253 
Creatinine (µmol/L) 80 (71-92) 72 (65-84) 0.253 
Need for pre operative RRT 0 0 1.00 
Table 5.4: Recipient characteristics (mean ± SD/median + IQR). 
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5.3.3: Ninety day mortality and graft loss. 
One patient in the control group died intra-operatively from excessive haemorrhage 
combined with primary graft non-function. No patient in the RIPC group died within 
90 days. One further graft was lost in the Control group due to the incidental finding 
of an adenocarcinoma in the donor gallbladder at routine pathology. This patient was 
relisted compassionately on the super-urgent waiting list and was retransplanted on 
the 4th post operative day. No grafts were lost in the RIPC group within 90 days post 
transplantation. 
5.3.4: Early transaminase levels and incidence of early allograft dysfunction. 
Post operative AST and ALT levels are shown in figure 5.2. Recipients that 
underwent RIPC had a higher median day 3 AST levels (221(82-434)iU/L vs 
149(103-370iU/L), p=1.00) although this was not statistically significant. AST 
immediately post-operatively (Figure 2) and on day 1 post operatively were higher to 
a greater degree with recipients undergoing RIPC having lower AST levels by day 4 
post operatively and this trend towards lower AST levels continuing up to 90 days by 
which point recipients who underwent RIPC had significantly lower AST levels 
(21(15-40)iU/L vs 37(23-50)iU/L, p=0.035). ALT levels were similarly higher in 
recipients who underwent RIPC immediately post operatively and at day 1 post 
operatively (Figure 5.2). Recipients who underwent RIPC had a faster fall in ALT 
levels than those who did not and by day 6 median ALT levels were similar between 
the groups (RIPC 220iU/l vs Control 217iU/L). By day 15, median ALT levels in 
recipients who underwent RIPC were trending to being lower and this was 
maintained to day 90 although this was not significant.  
Bilirubin levels and Alkaline Phosphatase in the first week post operatively are 
shown in figure 5.2. There was a trend towards a higher incidence of early graft 
dysfunction in the RIPC group (10 vs 7, p=0.523) although this again was not 
significant.  
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A                                                                   B 
     
C                                                                   D 
     
Figure 5.2: Serum Bilirubin and Transaminase levels within the first week post 
transplantation. 
Each point represents the median reading for the group. Figures A and B show 
reduced median bilirubin and Alkaline Phosphatase levels in recipients who 
underwent RIPC. Figures C and D show higher peak transaminase levels in 
recipients who underwent RIPC that recovered quicker. 
5.3.5: Complications 
There was no significant difference in number of patients in each group who 
developed a complication (15 of 20 RIPC patients vs 15 of 20 control patients, 
p=1.00). There was no significant difference in the median number of complications 
per patient in each group [RIPC 2(1-2) vs control 2(1-3), p=0.557]. Complications 
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were further analysed according to Clavien Dindo classification. There was no 
significant difference in complications of any kind between the groups (Table 5.3). 
 Preconditioned Control P value 
3 month mortality 0 1 1.00 
3 month graft loss 0 2 0.487 
Day 3 AST 221 (82-434) 149 (103-370) 1.00 
EAD 10 7 0.523 
Mean days ventilated 2 (±1) 2 (±1) 0.758 
Mean ITU stay (days) 4 (±2) 3 (±3) 0.372 
Mean hospital stay (days) 31 (±46) 21 (±14) 0.409 
Complications    
No per patient 2 2 0.557 
Grade I    
Wound infection 4 7 0.303 
Urine infection 2 3 0.517 
Grade II    
Chest infection 0 1 0.349 
Bacteraemia 3 2 0.549 
Abdominal infection 3 2 0.549 
Fungal infection 1 0 0.368 
Portal vein thrombosis 0 0 1.00 
Hepatic artery thrombosis 0 0 1.00 
Grade IIIa    
Bile leak 1 1 1.00 
Biliary stenosis 3 1 0.37 
Grade IIIb    
Bile leak 1 1 1.00 
Biliary stenosis 0 0 1.00 
Grade IV    
Acute Kidney Injury 10 7 0.523 
Need for haemofiltration 5 3 0.695 
Retransplanted 0 1 1.00 
Grade V    
Death 0 1 1.00 
  Table 5.3: Clinical outcomes in RIPC and control groups 
 
5.3.6: ITU and total hospital stay. 
Patients in the preconditioning group had a longer ITU [4(±2) days vs 3(±3) days, 
p=0.372] and hospital stay [31(±46) days vs 21(±14) days, p=0.409] but this was not 
statistically significant. 
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5.3.7: Limb oxygenation during RIPC. 
Preconditioning did not affect systemic arterial oxygen levels. Arterial oxygen levels 
were measured from the radial artery of 21 patients during the preconditioning 
stimulus showing similar oxygen levels between the groups [28.87(±9.73)kPa vs 
30.43(±12.63)kPa, p=0.757, RIPC vs control]. In the same patients, venous oxygen 
levels measured from the preconditioned limb at the same time were significantly 
lower in the preconditioning group than in the control group (7.53(4.94-9.28)kPa vs 
15.06(8.67-19.00)kPa, p=0.004) (Figure 5.3). Median limb venous oxygen levels in 
the preconditioned group were above 3-4kPa in all patients. 
 
Figure 5.3: Venous oxygen levels in the limb and systemic arterial oxygen levels 
during the preconditioning cycle. 
Each dot represents a reading from a single patient. Bar represents median. 
Statistical significance was confirmed or refuted with Mann-Whitney U tests. 
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5.4: Discussion. 
This is the first trial to prospectively investigate RIPC in liver transplant recipients. It 
has demonstrated that RIPC is feasible, acceptable and safe in liver transplant 
patients with end stage cirrhosis. 
Recruitment to the trial was satisfactory with a consent rate of 88% and no post 
randomization drop out. The RIPC protocol was successfully completed in all 
patients randomized to the RIPC group and did not delay surgery. No patient 
suffered a localized or systemic complication secondary to RIPC and therefore this 
study has satisfied its primary objectives. 
A feasibility study is not powered to look at the efficacy of the intervention but 
secondary end points were defined in the published protocol to help quantify the size 
of subsequent trial which would be required to demonstrate effectiveness. Ninety day 
patient survival was 100% in the RIPC group and 95% in the control group and 90 
day graft survival was 100% in the RIPC group and 90% in the control group. 
Neither of these were significantly different. 
Other secondary endpoints were chosen which are more frequent events and hence 
more likely to demonstrate evidence of benefit or harm following RIPC. Recent 
work from our group has shown that AST on the third post operative day is a strong 
predictor of graft and recipient outcome [142]. RIPC was not associated with a 
reduction in AST day 3 levels or a reduction in the incidence of early graft 
dysfunction as calculated according to the Olthoff criteria [143]. Interestingly 
recipients who underwent RIPC had higher AST and ALT levels immediately post 
operatively and on the first post operative day but with a more rapid fall in serum 
transaminase levels than patients who underwent a sham. The significance of this 
observation is unclear in such a small cohort of patients and whether this reflects that 
grafts inserted into the RIPC group had a larger ischaemic injury and RIPC helped 
them recover faster or that RIPC caused a greater reperfusion injury would need to 
be investigated in a larger trial however data from small animal models would not 
support RIPC causing increased liver injury.  
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During the first post operative week recipients who underwent RIPC had non-
significant but lower bilirubin and alkaline phosphatase levels possibly reflecting 
improved bile production and better early graft function. 
The number and severity of complications were similar between the two groups. As 
complications closely correlate with graft and patient survival this would again 
suggest that RIPC produced no harm but did not provide major benefit. 
As regards the studies on limb and systemic oxygenation, the limb venous pO2 was 
significantly reduced by RIPC but the limb did not become severely hypoxic 
(pO2<3kPa). It is unlikely that this is secondary to errors in cuff inflation as the inter 
quartile range is low. The explanation for this level of venous oxygenation may be 
that patients undergoing liver transplantation are administered high concentration 
supplementary oxygen throughout the procedure including during the 
preconditioning stimulus. This level of oxygen may have impaired the 
preconditioning stimulus. A recent pilot study of RIPC performed by our group in 
patients undergoing major liver resection for colorectal liver metastases used a 
preconditioning protocol of 3 by 10 minutes and showed a reduction in liver IR 
injury with significantly reduced post operative serum transaminases and 
significantly increased indocyanine green clearance [12]. Trials of direct IPC of 
donor livers found that 5 minutes of donor IPC had no effect [90] whilst trials of 10 
minutes of donor IPC have shown evidence of a reduction in recipient post operative 
transaminases [92] in keeping with reduced IR injury. During the retrieval process, 
donors are also maintained on a high inspired oxygen concentration.  It is possible 
that a successful ischaemic preconditioning stimulus requires severe limb hypoxia 
and that 5 minutes of inflow occlusion to a vascular bed is not sufficient time to 
create these conditions in recipients on high flow oxygen. Furthermore, although the 
initial trial of RIPC in humans demonstrated successful reduction in cardiac injury 
whilst on cardiopulmonary bypass [101] , trials of RIPC in renal transplantation have 
been varied with one trial demonstrating improved early graft function [104] and one 
trial failing to discern any clinical benefit within the first post operative year [105]. 
Neither manuscript documented whether the recipients were administered high flow 
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oxygen during the preconditioning stimulus but further trials with longer cycles are 
warranted to test this hypothesis. 
In conclusion this pilot study has demonstrated that RIPC is safe and feasible in 
patients with end stage cirrhosis undergoing liver transplantation. We have not 
demonstrated evidence to support that limb RIPC is likely to provide clinical benefit. 
Alterations to the preconditioning protocol with longer periods of limb ischaemia 
should be explored and consideration given to providing physiological levels of 
oxygen during the preconditioning period. 
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Chapter	6:	 Immunological	 changes	 in	
the	 early	 period	 following	 liver	
transplant	 and	 the	 influence	 of	
remote	 ischaemic	 preconditioning	
(RIPCOLT	trial).	
6.1: Introduction. 
Ischaemia Reperfusion (IR) injury is a form of sterile inflammation. Evidence from 
several small animal models has shown that mice lacking CD4+ T cells, although 
suffering the same ischaemic insult as immune competent mice, are protected from 
the reperfusion injury [21,25,27]. One study found that mice lacking CD4+ T cells 
suffered a more significant IR injury [28]. The reason behind this conflict in findings 
is unclear. CD4+ T cells certainly play a key role in the pathogenesis of early IR 
injury. Ischaemic tissues are rapidly infiltrated by CD4+ T cells. The term CD4+ T 
cell encompasses a broad group of diverse cell populations that display the CD4 
marker on their cell surface. This group of cells includes not only pro inflammatory 
effector cells but also a potent anti inflammatory subset of cells known as regulatory 
T cells (Tregs). This may explain the different results seen with CD4+ T cell 
depletion. 
Small animal studies have shown that augmentation of activated Tregs prior to IR 
injury can ameliorate IR injury [40,41] and depletion impairs graft healing following 
ischaemic injury [205,206]. It has therefore been postulated that IPC may exert its 
effect by manipulating the Treg component either by increased recruitment of Tregs 
or by increased activation. 
Three studies have investigated the effect of direct IPC on the Treg population in a 
murine model following IR injury with conflicting results [39,114,115]. Two studies 
used a model of renal IR injury [114,115] and one model investigated this in the liver 
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[39]. Along with different target organs, there were significant key methodological 
differences between the studies. The liver model involved performing IPC 15 
minutes prior to IR injury in what could be described as the classical model [39]. In 
the renal model however, both groups used a delayed preconditioning model in 
which IPC was performed 7 days prior to the IR injury [114,115]. Both renal studies 
of delayed IR injury clearly demonstrated a reduction in renal IR injury as measured 
by serum creatinine levels. Furthermore they demonstrated increased Treg number 
both in the renal parenchyma and in the periphery (spleen) 7 days after IPC. 
Depletion of Tregs ablated the protective effect gained by IPC suggesting that the 
protective effect of IPC in these models was conferred by the Treg population. When 
IPC was performed immediately prior to IR injury in a murine hepatic model [39], 
although IPC successfully ameliorated IR injury, it did not alter Treg recruitment to 
the liver. Treg depletion had no effect on the benefit of IPC when it was performed 
in this model. It is unclear why these studies have shown such different results but 
possible explanations include the different target organs. The most plausible 
explanation however is the different time frame involved as it takes roughly 7 days to 
mount a classical, antigen driven, effective T cell response [31]. It is more likely that 
the model of delayed IPC results in tissue injury and then repair and that by day 7, as 
tissue modeling and repair is occurring Treg number is augmented. As it is not 
feasible to deplete CD4+ T cells in humans, to our knowledge the effect of CD4+ T 
cell function in humans following reperfusion has not been investigated. Key 
differences exist between human and murine immunology and therefore it is 
important to have an understanding of the immunological changes that occur in 
humans post reperfusion to direct further murine studies. As CD4+ T cells have been 
shown to play a key role in murine models, it is therefore appropriate to investigate 
the early changes that may occur in CD4+ T cells post reperfusion. 
A key and early effector mechanism of CD4+ T cells is cytokine production. Pro-
inflammatory cytokines including IL-2, IL-6, IL-8, IL-17A, IFNγ and TNFα have 
been shown to be raised in small animal models following IR injury [67,78,207,208]. 
TNFα a potent anti inflammatory cytokine, released by CD4+ T cells and 
macrophages is believed to play a key role in IR injury and has been shown to be 
elevated following IR injury [16]. Antibody depletion of TNFα prior to IR injury has 
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been shown to reduce IR injury [67,209] and in some small animal models, IPC and 
RIPC have been shown to reduce TNFα production following IR injury both in the 
heart [210] and the liver [207]. Studies of direct IPC in liver transplant donors prior 
to retrieval have shown no effect on recipient circulating levels of IL-6 or TNFα 
three hours post reperfusion [91]. Interestingly, recipients who received a graft from 
a donor that underwent IPC had significantly higher circulating levels of IL-10 at 3 
hours post reperfusion but this was associated with significantly higher peak 
transaminases [91]. The source of these cytokines was not sought. Whether RIPC in 
human liver transplant recipients has the potential to alter CD4+ T cell recruitment or  
activation and cytokine production by CD4+ T cells remains to be elucidated. The 
hypothesis of this study was that RIPC would alter cytokine production by CD4+ T 
cells reducing levels of IL-2, IL-6, IL-8, IL-17, IFNγ and TNFα whilst increasing 
levels of IL-10 at 2 hours post reperfusion. We therefore analysed peripheral blood 
and post reperfusion liver biopsies collected from patients recruited to the RIPCOLT 
trial to analyse for circulating cytokine levels and CD4+ T cell cytokine production 
in the peripheral circulation and the post ischaemic liver. 
6.1.2: Aim. 
The aims of this study were to: 
1. Measure the circulating levels of key pro-and anti-inflammatory cytokines in 
the per-operative period and to correlate these levels with measurement of 
clinical outcomes post liver transplant and pre-operative variables. 
2. Identify changes in CD4+ T cell number and cytokine production in the per-
operative period in both the peripheral blood and the liver itself. 
3. To identify changes in the cytokine levels or CD4T cell population resulting 
from remote ischaemic preconditioning. 
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6.2: Methods. 
6.2.1: Ethical Approval and consent. 
Ethical approval was obtained from both the National Research Ethics Service 
(11/H0720/4) and the Royal Free Hospital/University College London medical 
school ethical committee (8191) to perform the RIPCOLT trial. This included 
collecting and analyzing peripheral blood and an additional post reperfusion liver 
biopsy to analyse for markers of liver damage and inflammation. Informed consent 
was obtained from patients during their index admission for liver transplant 
assessment and was reconfirmed where possible on the day of admission for the liver 
transplant. 
6.2.2: Blood collection and processing. 
In 28 patients undergoing liver transplant, 25 mls of peripheral arterial blood was 
collected at the following time intervals: 
• Baseline (following induction of anaesthesia but before abdominal incision). 
• Immediately before the recipient’s liver was removed. 
• 2 hours post reperfusion of the donor graft. 
• 24 hours post operatively (5 mls plasma only). 
6.2.2.1: Measurement of cytokines. 
Five mls of peripheral arterial blood was collected in BD vacutainer plasma tubes 
(BD, UK). Samples were immediately centrifuged (1000g, 10 minutes, 200C). The 
plasma was stored at -800C until analysis. IL-2, IL-6, IL-10, IFNγ and TNFα levels 
were measured by legendPLEX (Biolegend, UK) – Human Th Cytokine Mix and 
Match Subpanel. CCL2, CCL5, IL-8 and IL-17A were measured by ELISA via 
commercial kits (Biolegend, UK). 
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6.2.2.2: Analysis of CD4+ T cells. 
Twenty mls of peripheral blood was collected into BD vacutainer EDTA tubes (BD, 
UK). Samples were diluted with 15 mls PBS and centrifuged with Ficoll Paque (GE 
healthcare, UK) density gradient (to isolate peripheral blood mononuclear cells 
(PBMCs) which were immediately stained and analysed by multi channel flow 
cytometry. Excess cells were frozen to -80 0C and stored in liquid nitrogen in case 
further analysis was necessary. The fluorochromes used are contained in table 6.1. 
 
Antigen Conjugate Source Clone Concentration 
(µl/100µls) 
Live/Dead APC Cy7 Life 
Technologies 
n/a 0.15 
Extracellular 
CD3 PE Texas Red BD UCHT1 0.5 
CD4 PE Cy7 eBioscience RPA-T4 1 
CD8 AF 700 eBioscience OKT-8 0.5 
HLADR V500 BD G46-6 1 
CD69 FITC BD FN50 3 
PD-1 PerCP Cy5.5 Biolegend EH12.2H7 2 
Intracellular 
CTLA-4 PE BD BN13 3 
FoxP3 Pacific Blue Biolegend 259D 4 
IL-2 PerCP e-Flour 
710 
eBioscience MQ1-
17H12 
1 
IL-6 PE Biolegend MQ2-13A5 2 
IL-8 APC eBioScience 17-8088-42 2 
IL-10 PE eBioscience JES3-9D7 1 
IFNγ FITC R&D systems ♯25723 3 
pS6 AF 647 Cell Signalling D57.2.2E 1 
TNFα APC Biolegend MAb11 0.5 
Table 6.1: Fluorochromes used for staining Peripheral Blood Mono-nuclear Cells 
and Intra-hepatic Leukocytes. 
6.2.3: Post reperfusion liver biopsy. 
In 22 patients, a tru cut biopsy was obtained 2 hours post portal vein reperfusion. The 
biopsy was mechanically dissociated and passed through a 70µm filter (BD, UK). 
Intra hepatic leukocytes (IHLs) were stained immediately (Table 6.1) and analysed 
by multi channel flow cytometry (Fortessa BD, UK).  
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6.2.4: Perfusate. 
In 18 patients, the fluid the liver was transported in was collected and processed 
immediately. The fluid was aliquoted to 50ml tubes and centrifuged (750g, 20 
minutes, 200C). The pellet was resuspended in 1ml of RPMI (chapter 3) and layered 
on top of 1ml Ficol-Paque before being centrifuged (400g, 20 minutes, 200C). The 
cell layer was pipetted and added to 50mls of PBS before a further centrifuge (750g, 
15 minutes, 200C). The supernatant was discarded and the pellet was resuspended in 
a further 50mls of PBS and centrifuged (750g, 15 minutes, 200C). The supernatant 
was discarded and the cells were resuspended and stained immediately (Table 6.1). 
6.2.5: Statistical analysis. 
Changes in circulating cytokine levels and percentage of CD4+ T cells producing 
cytokines at different peri-operative time points were analysed by Kruskall-Wallis 
test and confirmed by Mann-Whitney U tests. 
Circulating cytokine levels were analysed against important donor variables that 
identify the quality of the donor organ including the type of graft (DBD vs DCD), the 
Donor Risk Index and length of ischaemic time. Cytokine levels were further 
analysed against recipient outcomes including post-operative graft injury and 
dysfunction as measured by day 3 AST levels [142] and early allograft dysfunction 
[143], acute kidney injury and post-operative infective outcomes. Outcomes with 
continuous measurement were compared by Spearman Rank correlations and 
categorical outcomes were compared by Mann Whitney U tests. 
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6.3: Results. 
6.3.1: Cytokines. 
6.3.1.1: Circulating cytokine levels before and after liver transplant. 
Circulating levels of CCL2, CCL5, IL-6, IL-8, IL-10 and IL-17A (Figure 1) were 
raised significantly from baseline following mobilization of the recipient liver and at 
2 hours post reperfusion. Circulating levels of these cytokines returned to pre-
operative levels within 24 hours following the surgery. Circulating levels of IL-2, 
IFNγ and TNFα were not significantly raised at any time point during the transplant 
procedure or in the first 24 post operative hours (Table 6.2). 
6.3.1.2: Pre-operative cytokine levels and recipient variables. 
There was no correlation between the pre-operative level of any cytokine measured 
and recipient age, MELD or UKELD score (Appendix 2, Table 1). There was no 
significant difference between the median values of any cytokine level measured pre-
operatively between recipient’s gender or indication for transplant (Appendix 2, 
Table 1). 
 
 
 
 
 
 
 
 
 126 
                                
 127 
A: CCL2                                                               B: CCL5 
                    
C: IL-6                                                                  D: IL-8                             
                                  
  E: IL-10                                                                  F: IL-17A                              
                  
Figure 6.1: Circulating cytokine levels that showed a significant increase during liver 
transplant and at 24 hours post op. 
Each dot represents a single patient. Bar represents median. Statistical 
significance was demonstrated with Kruskal-Wallis test and confirmed with 
Mann Whitney U tests. Figures A (CCL2), C (IL-6) and D (IL-8) demonstrate a 
significant increase in circulating cytokine levels following mobilization of the 
recipient liver but prior to hepatectomy and a further significant increase in 
cytokine levels at 2 hours post reperfusion. Levels returned to near baseline 
levels at 24 hours post operatively. Figure B (CCL2) demonstrated significantly 
increased levels following mobilization of the recipient liver only. Figures E (IL-
10) and F (IL-17A) demonstrate significantly elevated cytokine levels at 2 hours 
post reperfusion only. 
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6.3.1.2: The effect of RIPC on post reperfusion circulating cytokine levels. 
Patients who underwent RIPC had significantly lower median IL-6 levels than 
patients in the control group at 2 hours post reperfusion [487.99(221.65-
1232.37)pg/ml vs 1062.3(221.5-25903.85)pg/ml, p=0.013] (Figure 6.2). Median 
levels of all other cytokines measured were similar between both control and 
preconditioned patients (Figure 6.2). 
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A: CCL2                                                       B CCL5 
      
C: IL-6                                                          D: IL-8                             
                 
E: IL-10                                                               D: IL-17A          
               
Figure 6.2: Circulating cytokine levels in patients who underwent RIPC vs controls.                               
Only IL-6 levels (Figure A) were significantly reduced in patients undergoing 
RIPC when compared to controls. Each dot represents an individual patient. 
Bar represents medium. Statistical significance was confirmed or refuted by 
Mann-Whitney U tests. 
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6.3.1.3: Cytokine levels and correlation with outcomes. 
Twenty patients suffered from Early Allograft Dysfunction (EAD) [143]. These 
patients had significantly higher plasma levels of IL-10 at 2 hours post reperfusion 
than those who did not suffer from EAD [747.69(462.15-1336.7)pg/ml vs 
420.43(338.05-561.39)pg/ml, p=0.008]. Patients who suffered from EAD had 
significantly higher levels of CCL2 at 24 hours post reperfusion [105.96(70.61-
238.45)pg/ml vs 53.49(35.77-77.73)pg/ml, p=0.013] There were no correlations 
between circulating cytokine levels post reperfusion and aspartate transferase levels 
on day 3 [142] however CCL2 levels measured at 24 hours post-reperfusion 
significantly correlated with AST levels on day 3 [p=0.009]. Six patients developed a 
graft specific complication with the 3 months post transplantation (portal vein 
thrombosis, hepatic artery thrombosis, bile leak, biliary stricture). These patients had 
significantly higher circulating levels of IL-10 at 2 hours post reperfusion 
[1507.22(951.87-343.72pg/ml vs 462.15(343.72-718.3)pg/ml, p=0.006] but 
significantly lower IL-10 levels at 24 hours post operation [4.39(3.34-5.1)pg/ml vs 
10.10(4.92-38.23)pg/ml, p=0.027]. 
6.3.1.4: Cytokine levels and correlation with donor and transplant variables. 
IL-6 levels post reperfusion, had a significant correlation with the donor risk index 
value (p=0.003) but there was no correlation with recipient MELD score (p=0.383) 
or UKELD score (p=0.373). Five patients received a DCD graft. These patients had 
significantly higher levels of IL-10 post reperfusion than those who received a DBD 
graft [853(777.07-1257.76)pg/ml vs 457.16(338.05-641.87)pg/ml, p=0.01]. 
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6.3.2: T cells. 
6.3.2.1: Per-operative T cell population size changes in circulating blood in all 
patients. 
The gating strategy for the peripheral blood mono-nuclear cells is contained in figure 
6.4. The lymphocyte gate was selected based on accepted FSC and SSC 
characteristics of lymphocytes (Figure 6.4). The percentage of CD3+ cells in this 
lymphocyte gate fell significantly post reperfusion [60.1(42.8-70.3)% vs 41.8(29.4-
53.6)%, p=0.003] (Figure 6.5). More detailed analysis of the ratios of CD4+:CD8+ T 
cells demonstrated that the percentage of CD4+ T cells (p<0.0001) significantly fell 
and the percentage of CD8+ T cells (p<0.0001) significantly increased both during 
mobilization of the liver and after reperfusion (Figure 6.5). 
6.3.2.2: T cell activation during the transplant procedure. 
Three markers of T cell activation were analysed - HLADR, CD69 and CTLA-4. The 
median levels of circulating CD4+ T cells expressing these markers of activation 
increased significantly as the transplant progressed. Both CD69 [0.52(0.25-1.29)% 
vs 0.82(0.43-0.82), p=0.002] and CTLA-4 [5.89(3.5-16.1)% vs 8.48(3.84-17.5)%, 
p=0.002] expressions were significantly increased during mobilization of the liver 
(Figure 6.6). Median levels of CD69 [0.52(0.25-1.29)% vs 2.04(1.09-3,53)%, 
p=0.0001], CTLA-4 [5.89(3.5-16.1)% vs 16.8(9.51-26.9)%, p<0.0001] and HLADR 
[2.93(2.208-4.31)% vs 5.45(2.66-9.81)%, p=0.004] were significantly raised post 
implantation from baseline. 
Median levels of both CD69 [3.16(0.78-5.56)% vs 3.48(1.46-10.2)%, p=0.001] and 
CTLA-4 [0.98(0.53-1.9)% vs 1.9(0.49-3.54)%, p=0.003] by CD8+ T cells were 
significantly raised after mobilization of the liver and post reperfusion [3.16(0.78-
5.56)% vs 11.9(4.08-19)%, p<00001] and [0.98(0.53-1.9)% vs 4.21(2.33-8.41)%, 
p<0.0001] respectively. HLADR expression by CD8+ T cells did not vary during the 
per-operative period (p=0.784) (Figure 6.7). 
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A                                                               B 
      
C                                                                       D 
          
Figure 6.5: Changes in the T cells populations during the per-operative period. 
Figure A demonstrates that the percentage of circulating CD3+ cells fall 
significantly following reperfusion and figure B-D show that the ratio of 
CD4:CD8 T cells alters significantly during mobilization of the liver and more 
significantly post reperfusion. Each dot represents a single patient. Bar 
represents median. Statistical significance was demonstrated by Kruskal Wallis 
tests and confirmed by Mann-Whitney U tests. 
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A                                                                        B 
          
C 
 
Figure 6.6: Changes in activation markers on CD4+ T cells in the per-operative 
period. 
Each dot represents a single patient. Bar represents median. Statistical 
significance was demonstrated by Kruskal Wallis test and confirmed by Mann-
Whitney U tests. Figures A and B show that expression of CD69 and CTLA-4 by 
CD4+ T cells are significantly increased from baseline both following 
mobilization of the liver and post reperfusion. Figure C shows that HLADR 
levels although increased following mobilization of the liver they are only 
significantly increased following reperfusion. 
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A                                                                     B 
         
C 
 
Figure 6.7: Changes in activation markers on CD8+ T cells in the per-operative 
period. 
Figures A and B show significantly raised expression of CD69 and CTLA-4 by 
CD8+ T cells following mobilization of the liver and after reperfusion. Figure C 
shows no change in HLADR expression by CD8+ T cells in per-operative 
period. Each dot represents a single patient. Bar represents median. Statistical 
significance was demonstrated or refuted by Kruskal-Wallis test and confirmed 
by Mann-Whitney U tests. 
 
 
Timepoints
%
 C
D
8+
 T
 c
el
ls
 C
D
69
+
Ba
se
lin
e
Pr
e i
mp
lan
tat
ion
Po
st 
rep
erf
us
ion
0
10
20
30
40
50
p=0.001
p<0.0001
Ba
se
lin
e
Pr
e i
mp
lan
tat
ion
Po
st 
rep
erf
us
ion
0
5
10
15
Timepoints
%
 C
D
8+
 T
 c
el
ls
 C
TL
A
4+
p=0.003
p<0.0001
Timepoints
%
 C
D
8+
 T
 c
el
ls
 H
LA
D
R
+
Ba
se
lin
e
Pr
e i
mp
lan
tat
ion
Po
st 
rep
erf
us
ion
0
10
20
30
p=0.784
 136 
6.3.2.3: Changes in T cell population sizes in the hepatic microenvironment. 
There was no significant difference between T cell populations in terms or number or 
ratio between the perfusate collected pre-implantation and the post reperfusion 
biopsy (Appendix 2, Table 2). 
6.3.2.4: Changes in intra-hepatic T cell activation markers. 
CD4+ T cells isolated from the post reperfusion biopsy had significantly higher 
surface levels of HLADR than those isolated from the perfusate [10.42(6.47-13.4)% 
vs 5.4(3.47-9.57)%, p=0.012] and intracellular CTLA-4 levels were non significantly 
higher in CD4+ T cells isolated from the biopsy than those from the perfusate 
[19.8% vs 14.8%, p=0.232]. There was no significant difference in activation 
markers between CD8+ T cells isolated from the perfusate and the biopsy. 
6.3.2.5: Effect of RIPC on circulating T cell populations and activation in the 
per-operative period. 
Of 28 patients analysed, 16 (57.1%) underwent RIPC pre-operatively. There was no 
significant difference in the T cell populations at any time point in the per-operative 
period (Appendix 2, Table 3). 
There was no significant difference in activation markers expressed on CD4+ T cells 
(Appendix 2, Table 4) of CD8+ T cells (Appendix 2, Table 5) at any time point in 
the per-operative period. 
There was no significant difference in levels of CD4+ HLADR expression in the post 
reperfusion biopsy between patients that underwent RIPC than those that did not 
[10.53(7.628-13.4)%, vs 10.42(4.453-14.14)%, p=0.558]. 
6.3.2.6: Cytokine production by circulating and intra hepatic CD4+ T cells. 
The gating strategy for intrahepatic mononuclear cells is contained in figure 6.8. A 
very low proportion of viable CD4+ T cells were actively producing IL-2, IL-8, IL-
10, or TNFα both in the circulation and in the hepatic environment however 
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production of the cytokines IFNγ and TNFα were significantly higher in the hepatic 
environment than in the circulation (Figure 6.9). Production of IFNγ by CD4+ T cells 
was significantly upregulated post reperfusion both in the circulation and in the 
hepatic micro-environment (Figure 6.10). TNFα production by CD4+ T cells 
isolated from the liver post reperfusion was significantly greater than in CD4+ T 
cells isolated from the liver prior to implantation (p=0.008). Although IFNγ 
production by CD4+ T cells was higher following reperfusion, this was not 
significant (p=0.983). In three patients, a fluorochrome for IL-6 was included and 
this was the prominent cytokine produced by CD4+ T cells both in the liver and in 
the circulation. CD4+ T cell IL-6 production in the liver was significantly higher in 
the post reperfusion liver than in perfusate and than in the circulating CD4+ T cells 
(Figure 6.10).  
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Baseline                               Pre implantation                 Post reperfusion 
 
    
                               
      Perfusate                                                         Biopsy 
    
 
 
Figure 6.9: Production of cytokines by hepatic T cells before and after perfusion of 
the graft. 
Figure 6.9 shows that circulating cytokine production was lower in the 
periphery than in the liver environment. IL-6 is the predominant cytokine to be 
released by CD4+ cells in hepatic microenvironment and its production 
increased following reperfusion. Each point represents an individual patient. 
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A: IFNγ                                                            B: TNFα  
          
C: IL-6 
 
Figure 6.10: CD4+ T cell production of IFNγ, TNFα and IL6 in all samples 
collected. 
Figure A shows increased IFNγ  production significant increased in following 
reperfusion. Post reperfusion the percentage of CD4+ T cells producing IFNγ  in 
the circulation and the hepatic micro environment were similar. Figure B shows 
increased TNFα  production in the hepatic micro environment and significant 
increase in production following reperfusion. Each point represents an 
individual patient. Bar represents median. Statistical significance was 
demonstrated with Kruskal Wallis test and confirmed with Mann-Whitney U 
tests. Figure C shows a clear increase in IL-6 production in the liver and 
following reperfusion. Statistics not performed due to low sample numbers. 
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6.3.2.7: Cytokine production by circulating and intra hepatic CD8+ T cells. 
Cytokine production by both circulating and intra hepatic CD8+ T cells was low. 
Production of IL6 by intra hepatic CD8+ T cells was higher than in the periphery but 
unlike CD4+ T cells, production of IL-6 was not higher by intrahepatic T cells 
following reperfusion. Intracellular production of IL-2 and TNFα by intrahepatic 
CD8+ T cells was higher following reperfusion but this was not significant (p=0.092 
and p=0.234 respectively). 
6.3.2.8: Effect of RIPC on TNFα  production in the post reperfusion liver 
biopsy. 
There was no significant difference in TNFα production by CD4+ T cells in the post 
reperfusion biopsy between patients who underwent RIPC and those that did not 
(0.73(0.57-2.97)% vs 0.58(0.34-1.24)%, p=0.495). 
6.3.2.9: Regulatory T cells and their function. 
Regulatory T cell (Treg) number in the circulation did not change significantly 
throughout the per-operative period (p=0.22). There were similar numbers of Tregs 
in the circulation as there were in both the perfusate and the post reperfusion liver 
biopsy. There was no significant increase in number of cells producing CTLA-4 or 
IL-10 throughout the per-operative period. There was an increase in the number of 
circulating Tregs expressing CD69 post reperfusion but this just failed to reach 
significance (p=0.052). There were significantly more Tregs in the biopsy and 
perfusate that expressed CD69 (p<0.0001) however there was no increase in CD69 
expression in the liver following reperfusion (p=0.588). As there were no significant 
changes in the Treg population, the effect of RIPC on them was not explored. 
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6.4: Discussion. 
This is the first study to look in depth at T cell populations both in the periphery and 
in the post ischaemic graft in liver transplant recipients along with circulating 
cytokines in the per operative period. It has shown that circulating levels of the pro 
inflammatory cytokines CCL2, IL-6, IL-8 and IL-17A are significantly raised at 2 
hours post reperfusion as well as circulating levels of IL-10. Furthermore it has 
demonstrated that T cells and specifically CD4+ T cells leave the peripheral 
circulation following reperfusion. In the peripheral circulation, early activation 
markers on CD4+ and CD8+ T cells are significantly increased following reperfusion 
and there was a significant increase in IFNγ production by CD4+ T cells post 
reperfusion. There was a further subtle but significant increase in TNFα production 
by CD4+ T cells. Patients who underwent RIPC had significantly lower circulating 
IL-6 levels post reperfusion but no other difference was seen in this group of patients 
as a result of RIPC. 
IL-6 is a highly pro inflammatory cytokine that plays a key role in the acute 
inflammatory response [211]. It is rapidly secreted following TLR4 stimulation by 
Damage Associate Molecular Patterns (DAMPS) by hepatocytes, macrophages and T 
cells [212]. IL-6 has been shown to play a key role both in effector CD4+ T cell 
activation, proliferation and survival and to block Treg differentiation from naïve 
CD4+ T cells and Treg function [75,213]. In this group of patients, plasma IL-6 
levels were significantly raised at 2 hours post reperfusion. Recent evidence would 
suggest that immune activation following IR injury is driven by release of DAMPS, 
of which High Mobility Group Box 1 (HMGB1) [16,214] is one, which stimulates 
Toll Like Receptor (TLR) 4 in a fashion similar to Lipopolysaccharide and leads to 
early IL-6 secretion within 4 hours [16,211]. This timescale is in keeping with our 
results. Furthermore, the concentration of plasma IL-6 levels post reperfusion 
significantly correlated with the Donor Risk Index, a marker of the quality of the 
graft prior to implantation but not with any recipient factors such as MELD or 
UKELD score again suggesting that the more damage a graft has the greater the IL-6 
production. IL-6 levels post reperfusion did not correlate with any outcome post 
transplantation however it should be noted that the one patient who died secondary to 
 143 
PGNF had huge levels of IL-6 (>25000pg/ml) post reperfusion. Previous studies 
have shown that post operative IL-6 levels do correlate with complications post liver 
resection [215] and the development of AKI and prolonged ventilation in children 
undergoing major cardiac surgery [216]. Studies in liver transplantation have 
demonstrated that raised IL-6 levels in the donor prior to organ retrieval are 
associated with worse recipient outcomes [68,217] and that in patients who 
developed a complication post liver transplant, this was preceded by a spike in 
plasma/serum IL-6 levels [218]. One study however has found similar results to our 
results in both the kinetics of IL-6 release and that IL-6 levels post reperfusion did 
not correlate with graft or patient outcome [219]. 
Monocytes are rapidly recruited from the bone marrow to areas of inflammation by 
CCL2 [48]. The increased levels seen post reperfusion in this study are in keeping 
with an inflammatory response. Interestingly, although levels peaked post 
reperfusion there was no correlation seen between the post reperfusion levels and 
outcome measures post transplant. This is contrary to one previous study that found a 
correlation between CCL2 levels post reperfusion and peak transaminases [50]. 
Interestingly although median CCL2 levels at 24 hours post reperfusion were lower 
than levels measured immediately following baseline, in grafts that developed EAD 
the levels were significantly higher than pre-operative levels and were significantly 
higher than in grafts that functioned well immediately. Similarly CCL2 levels at 24 
hours post op correlated with AST day 3 levels another good marker of graft 
function. This would indicate that there is ongoing unresolved inflammation in these 
grafts and certainly implicates monocyte infiltration in graft damage and the 
development of graft dysfunction. One study to our knowledge has investigated the 
role of CCL2 in warm hepatic IR injury using CCL2 knock out mice and 
demonstrated that CCL2 knock out mice had significantly less hepatic injury than 
wild type mice and that this was associated with a reduced infiltration of 
inflammatory monocytes into the reperfused liver. CCL2 is known to attract other 
cell types including CD4+ T cells, dendritic cells and macrophages and therefore 
further work is required to dissect the exact role of CCL2. CCL2 was not included in 
the panel of intracellular antibodies in the analysis of ex vivo cells and therefore the 
source of CCL2 can not be commented on however it would be useful to identify 
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this. If it is identified as CD4+ T cells it may help further explain the role of CD4+ T 
cells in IR injury. 
Circulating levels of IL-10 were significantly elevated in all patients post 
reperfusion. This has been shown in previous studies [220,221]. It was initially 
believed that this may be secondary to the administration of intravenous methyl 
prednisolone [138], however IL-10 levels at 2 hours post reperfusion display a 
striking correlation with poor outcome measures, both short term (EAD) and long 
term (bile duct strictures and leaks). Furthermore patients who received a DCD graft 
had significantly higher levels of IL-10 than those who received a DBD graft. It is 
known that human monocytes release both IL-10 and ROS following TLR4 
stimulation [222] and it is likely therefore that the IL-10 release may reflect 
monocyte stimulation. This would explain why higher IL-10 levels are related with 
poorer outcomes as they reflect monocyte driven damage to the graft. 
Analysis of cell populations in the periphery clearly demonstrate that the CD4+ T 
cell population in the circulating blood significantly decreases in number following 
reperfusion. Furthermore early cell makers of cell activation (CD69 and CTLA-4) 
were significantly upregulated during hepatic mobilization and following reperfusion 
whilst HLADR expression by CD4+ T cells was significantly upregulated following 
reperfusion. The drop in circulating CD4+ T cells would suggest that CD4+ T cells 
are being recruited to areas of inflammation. Unfortunately this can not be confirmed 
as pre-implant biopsies were not collected in this group of patients. Although the 
perfusate was analysed, it is collected from the intravascular space and is likely a 
mixture of both liver and circulating T cells from the donor. The CD4+ T cell 
activation and evidence of CD4+ T cell recruitment from the periphery is in keeping 
with small animal models that clearly demonstrate rapid infiltration of the post 
ischaemic tissue by CD4+ T cells and the key role that CD4+ T cells play in driving 
IR injury [21,25]. RIPC had no effect on either T cell reduction in the peripheral 
circulation or upregulation of activation markers on CD4+ T cells. This is keeping 
with the clinical results from the trial demonstrating that RIPC did not appear to 
result in a reduction in IR injury. 
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Cytokine production by both CD4+ and CD8+ T cells was low. The cells obtained 
from these patients were not stimulated as the aim was to analyse what CD4+ T cells 
were actively secreting in vivo at time of collection. IL-6 was the main cytokine 
produced by both CD4+ and CD8+ T cells both in the periphery and in the liver 
biopsies. Although circulating cells were only stained for IL-6 in 2 patients, IL-6 
production in the periphery by both CD4+ and CD8+ T cells did not alter during the 
per-operative period. CD4+ T cells in the liver were producing a larger amount of 
IL-6. Furthermore, more CD4+ T cells in the post reperfusion liver biopsy were 
secreting IL-6 than in the perfusate. There was no difference in IL-6 production by 
CD8+ T cells between the perfusate and post reperfusion biopsy. IL-6 has been 
shown to play a key role in activated CD4+ T cell migration to sites of inflammation 
and can be released by hepatocytes [213] and therefore may be involved in the 
recruitment of CD4+ T cells to the post ischaemic liver however this was not 
analysed in this study. Antibody blockade of IL-6 would therefore present an 
interesting therapeutic target for IR injury. IL-6 knock out mice have been shown to 
resistant to antigen induced rheumatoid arthritis [223] and treatment of animals with 
anti IL-6/anti IL-6 receptor has significantly reduced the progression of rheumatoid 
arthritis [224,225]. There are drugs that target IL-6 – siltuximab. An ongoing trial of 
its use in Castleman’s disease has reported promising results [226] with a low 
incidence of adverse events and minimal toxicity. There is no published animal study 
involving IL-6 blockade in the setting of liver IR injury and this would certainly be 
of merit as there is a drug already available on the market. 
Although TNFα production was less than IL-6 production, TNFα production in the 
liver biopsy was significantly higher than by CD4+ T cells in the periphery at all 
time points. Furthermore TNFα production in the post reperfusion liver biopsy was 
significantly higher than TNFα production by CD4+ T cells in the perfusate 
suggesting that TNFα production was upregulated following reperfusion. TNFα 
production by CD8+ T cells meanwhile, was unchanged. These results would 
indicate that TNFα production by CD4+ T cells is upregulated following IR injury in 
liver transplant recipients. Previous studies in small animal models have 
demonstrated upregulation of TNFα in the liver following hepatic IR injury [16,70], 
however they have analysed TNFα upregulation primarily by PCR and therefore 
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have been unable to identify the source of the production. Anti TNFα treatment may 
be beneficial in treating IR injury [67]. Infliximab, a monoclonal antibody to TNFα, 
is licensed for use in the treatment of rheumatoid arthritis but more importantly is 
also used in the treatment of severe and refractory Crohn’s disease and ulcerative 
colitis. Studies have shown that despite initial concerns, Infliximab can safely be 
given in the peri-operative period without a significant increase in the incidence of 
post-operative complications – including delayed wound healing [227]. Analysis of 
circulating plasma cytokine levels however, would suggest that although TNFα 
production is increased locally, it is not increased systemically. This is in keeping 
with a model of canine lung transplantation which demonstrated significantly 
increased levels of TNFα post reperfusion in the bronchoalveolar lavage but not in 
the peripheral circulation [78]. The recent advance of machine perfusion may allow 
for the graft to be treated in transit prior to implantation avoiding the risk of drug 
side effects to patients. 
The most striking upregulation of CD4+ T cell cytokine production was in IFNγ. 
IFNγ produced by CD4+ T cells plays a key role in driving a M1 macrophage 
response [33] and is a potent activator of monocytes [64]. One study investigating 
renal IR injury in a mouse model has shown that adoptive transfer of CD4+ T cells 
from IFNγ deficient mice into athymic mice was unable to reconstitute the IR injury 
[25]. Further evidence from this study has identified that cytokines associated with 
monocyte recruitment (CCL2) and possible with monocyte activation (IL-10) 
correlate with injury. This would therefore suggest an interplay between CD4+ T 
cells and monocytes that requires further analysis as this may identify key steps in 
the pathognenesis of IR injury that can be interrupted to prevent it. 
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Chapter	 7:	 The	 effect	 of	 remote	
ischaemic	preconditioning	on	CD4+	T	
cells	 following	 warm	 hepatic	
ischaemia	 reperfusion	 injury	 in	 a	
murine	model.	
7.1: Introduction 
The effector mechanisms by which Remote Ischaemic Preconditioning (RIPC) 
provides protection during hepatic ischaemia-reperfusion (IR) injury remain unclear. 
CD4+ T cells have been shown to play a key role in the pathogenesis of IR injury 
and mice lacking CD4+ T cells although suffering the same ischaemic injury are 
protected from reperfusion injury, particularly the late stage [21] (6 hours post 
reperfusion). Although both direct ischaemic preconditioning (IPC) and RIPC have 
been shown to reduce apoptosis and necrosis which is associated with the 
upregulation of adenosine and the upregulation of the function and level of 
haemoxygenase-1 in hepatocytes, the effect of IPC/RIPC on the CD4+ T cells 
population remains poorly understood [117]. Several studies have addressed the 
immunological effect of RIPC by measuring cytokine levels or intrahepatic cytokine 
levels, as measured by PCR of homogenised tissue following IPC/RIPC. Although 
CD4+ T cells have been shown to play a key role in IR injury the mechanism of this 
remains unknown [21]. In the time frame of significant T cell mediated IR injury, 
cytokines secreted by CD4+ T cells are likely to be a dominant effector mechanism 
driving the tissue injury.  
Three studies in small animal models have investigated the effect of IPC on 
regulatory T cells (Tregs), a subset of CD4+ T cells characterized by their expression 
of the transcription factor forkhead box P3 (FoxP3). Tregs are potent anti-
inflammatory cells and have been postulated as potential effectors of IPC/RIPC. Of 
the three studies, 2 involved renal IR injury [114,115] and 1 hepatic IR injury [39]. 
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The results from the studies are conflicting. Two studies showed that RIPC increased 
Treg function and number and that Treg depletion ablated the protective effect of 
IPC. In the liver study, direct IPC reduced liver IR injury but had no effect on Treg 
recruitment and Treg depletion/augmentation had no effect on IR injury [39]. There 
were significant differences in the methodology between the studies specifically that 
in the 2 positive studies, IPC was performed 7 days prior to IR injury and it was 
clearly shown that the effect of IPC on the Treg population was not present when the 
IR injury was performed less than 5 days post IPC or at day 14 [114]. IPC was 
shown not to effect the Treg population when performed immediately prior to the IR 
injury [39]. Taken together and when combined with the fact that IPC/RIPC likely 
works by creating limited tissue injury, these results suggest that although Tregs can 
be increased following preconditioning, this happens during the healing process 
following the preconditioning stimulus within a specific time frame of around 7 
days. Although it may be feasible to perform RIPC on patients 7 days prior to 
elective major resection, this is not feasible in liver transplant recipients. 
Mechanisms by which IPC/RIPC provide immediate protection therefore may be 
different and must be identified. It is perhaps unrealistic to expect IPC/RIPC to have 
such a rapid effect expanding a cell population. No prior studies have focused on the 
effect of RIPC on the effector CD4+ T cell population. 
Studies have shown that CD4+ T cells rapidly and transiently infiltrate the post 
ischaemic liver in the first 4 hours post reperfusion [21,28]. Cytokines are a key 
effector mechanism of T cells and can be released by T cells following Toll Like 
Receptor (TLR) stimulation [228,229]. TNFα in particular has been shown to play a 
role in the pathogenesis of IR injury [70,71]. Whether IPC/RIPC alters CD4+ T cell 
function during this time remains to be elucidated. In the RIPCOLT trial, RIPC in 
liver transplant recipients was not associated with evidence of clinical benefit. 
Analysis of plasma collected from patients showed increased levels of CCL2, IL-6, 
IL-8, IL-10 and IL-17A post reperfusion. CCL2 and IL-10 levels were elevated in 
patients with poorer outcomes post transplant. Analysis of CD4+ T cells 
demonstrated that CD4+ T cell production of IFNγ, IL-6, and TNFα were 
significantly elevated post IR injury. The effect of RIPC on CD4+ T cell function 
 149 
was negligible however RIPC did not provide evidence of clinical benefit in this 
model. 
7.1.2: Aim.   
The aim of this study was to analyse changes in circulating cytokine levels and 
CD4+ T cell cytokine production following warm hepatic IR injury and remote 
ischaemic preconditioning in a murine model. This would allow for human and 
mouse immunology to be compared and to identify changes following RIPC in a 
model already validated to ameliorate IR injury. 
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7.2: Methods. 
All experiments were performed under a project license from the Home Office (PPL: 
70/7765) and in accordance with the Animals (Scientific Procedures) Act 1986. Male 
C56BL6/J mice (Charles River, UK) were used for the experiments. Animals were 
kept in a temperature controlled environment with a 12 hour light/dark cycle and 
were allowed free access to water and standard mouse chow pellets. 
48 mice were divided into 4 experimental groups (Figure 7.1). 
 
Figure 7.1: Flowchart of experimental groups clamp on liver for group 4 
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7.2.2: Surgical procedure. 
Animals were anaesthetised with intra peritoneal Ketamine Xylazine (National 
Veterinary Services, UK). All surgery was carried out under a Zeiss, OPMI, 6MD 
operating microscope (Zeiss, UK). A warm hepatic IR injury was induced by placing 
an atraumatic microvascular clamp across the left and middle portal pedicles for 45 
minutes [80,147]. Lobar inflow occlusion was confirmed by blanching of the left and 
middle lobes of the liver (Figure 7.2). The liver was reperfused for 2 hours and the 
animal was sacrificed. The sham consisted of a laparotomy and exposure of the liver 
for 3 hours but no clamp was placed on the portal pedicles. All mice underwent 
exposure of the left femoral pedicle prior to the laparotomy. RIPC was performed as 
previously described [100]. An atraumatic vascular clamp was placed across the 
femoral pedicle for 5 minutes and removed for 5 minutes to allow reperfusion 
(Figure 7.1). This was performed immediately prior to the IR injury. The sham 
consisted of exposing the femoral pedicle but not placing a vascular clamp. 
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Figure 7.2: Blanching of the left and middle lobe of the liver (red arrows) during 
portal vein occlusion. The blood supply to the right lobe was not interrupted (black 
arrow). 
Termination of the animal was performed by cardiac puncture at the end of the 
experimental procedures which also allowed collection of blood for measurement of 
plasma cytokine levels and transaminases. The blood was immediately centrifuged 
(1000g, 10 minutes, 200C) to obtain plasma. The spleen and livers were harvested 
and immediately placed in T cell buffer at 40C to allow isolation of lymphocytes for 
analysis. Livers harvested from mice that underwent a hepatic IR injury were divided 
into ischaemic lobes and non-ischaemic lobes which were handled and analysed 
separately. A sample of each liver (including from the ischaemic and non-ischaemic 
lobes) was added immediately to 10% natural buffered formalin for Hematoxylin and 
Eosin (H&E) staining and histopathological analysis. 
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7.2.3: Measurement of hepatic IR injury and protection by RIPC. 
Plasma was thawed and transaminase levels were measured by COBAS Integra 400 
plus biochemistry analyser (ROCHE, UK). 
Liver samples were fixed in 10% natural buffered formalin for 24 hours and were 
processed using a Shandon Citadel 200 Automatic Processor (Thermo Scientific™, 
UK). Samples were paraffin embedded using a Tissue Tek II™ tissue embedding 
centre (Sakura, The Netherlands). H&E staining was performed by the pathology 
department at Northwick Park Hospital, London and the pathology samples were 
analysed by a consultant histopathologist specializing in hepatico pancreatico biliary 
surgery and liver transplantation who was blinded to the group allocation of each 
mouse. 
7.2.4: Plasma cytokines. 
Frozen plasma was thawed and plasma levels of Granulocyte Macrophage Colony 
Stimulating Factor (GM-CSF), IFNγ, IL-1β, IL-6, IL-10, IL-17A, IL-23, CCL2 and 
TNFα were measured by LEGENDplex (Biolegend, UK) bead multi array as 
previously described. Circulating levels of free TGFβ were measured by ELISA 
(Biolegend, UK). 
7.2.5: Flow cytometry. 
7.2.5.1: Liver. 
Intrahepatic mononuclear cells were isolated from the fresh liver samples. The 
process is described in detail in the methods section (Chapter 2). In brief, the livers 
were manually homogenised and the resulting cell suspension was passed through a 
70µm cell strainer (Fisher Scientific, UK) and centrifuged (500g, 10 minutes, 40C). 
The pellet was resuspended, layered on Optiprep solution (Sigma, UK) and 
centrifuged (700g, 20 mins, 200C, without breaking). The interface layer was 
removed and resuspended before a final centrifuge (500g, 10 mins, 40C). The cells 
were resuspended in 5 mls of T cell media with Brefeldin A (1µg/ml; Sigma, UK) 
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and cultured (4 hours, 5% CO2, 370C) before being centrifuged (500g, 5 mins, 40C). 
IHLs were resuspended in 1ml of PBS ready to be stained for flow cytometry using 
the antibodies in Table 7.1. The cells were analysed on a Fortessa II flow cytometer 
(Becton Dickson, Oxford) using DIVA software (Becton Dickson, Oxford) and 
FlowJo software (Tree Star, Oregon, USA). 
Antigen Conjugate Source Clone Concentration 
(µl/100µls) 
Live/Dead efluor450 eBioscience n/a 0.15 
Extracellular 
CD3 FITC BD 145-2C11 1 
CD4 PerCP BD RM4-5 0.25 
CD8 v500 BD 53.6.7 1 
F4/80 APCeFluor780 eBioscience BM8 1 
Intracellular 
FoxP3 APC eBioscience FJK-16s 2 
IL-6 APC Biolegend MP5-20F3 1 
IL-10 BV650 BD JES5-16E3 2 
IL-17a PE-CF594 BD TC11-18H10 1 
IFNγ PECy7 BD XMG1.2 2 
TNFα PE BD MP6-XT22 1 
Table 7.1: Fluorochromes for staining murine T cells from both liver and spleen. 
7.2.5.2: Spleen. 
The spleen was similarly manually homogenised and the resulting cell suspension 
was passed through a 40µm cell strainer (Fisher Scientific, UK) and centrifuged 
(500g, 10 mins, 40C). The cells were resuspended and treated with ACK lysis buffer 
to lyse red blood cells and then centrifuged (500g, 10 mins, 40C). The cells were 
resuspended in 5 mls of T cell media with Brefeldin A (1µg/ml; Sigma, UK) and 
cultured (4 hours, 5% CO2, 370C) before being centrifuged (500g, 5 mins, 40C). 
PBMCs were resuspended in 1ml of PBS ready to be stained for flow cytometry 
using the antibodies in table 7.1. The cells were analysed on a Fortessa II flow 
cytometer (Becton Dickson, Oxford) using DIVA software (Becton Dickson, 
Oxford) and FlowJo software (Tree Star, Oregon, USA). 
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7.2.6: Statistics. 
Continuous variables were expressed as median (+ inter quartile range) or mean (± 
standard deviation) as appropriate and comparisons between the groups were 
performed by Kruskall Wallis and Mann Whitney U test or ANOVA and Students’ 
T-test as appropriate. Binary outcomes were expressed as frequency counts and 
percentages and comparisons between the groups were analysed by Chi-squared tests 
on Statistical Package for Social Sciences  (SPSS) (IBM, Chicago, IL, USA) and 
Prism 5 (Graphpad, USA). 
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7.3: Results. 
7.3.1: Confirmation of hepatic IR injury and protective effect of RIPC. 
Plasma transaminases were significantly raised following hepatic IR injury when 
compared to controls [AST 699.1(605.9-724.2)iU vs 390.9(152-478.4)iU, p=0.001; 
ALT 299.8(219-428.7)iU vs 54.4(41.8-63.2)iU, p<0.001] (Figure 7.3). Mice that 
underwent RIPC + hepatic IR injury had significantly lower serum transaminases 
than those that underwent hepatic IR injury only [AST 399.2(300-439.7)iU vs 
699.1(605.9-724.2)iU, p=0.0007; ALT 169.3(105.2-244.9)iU vs 299.8(219-428.7)iU, 
p=0.008] (Figure 7.3). 
A                                                                  B 
          
Figure 7.3: Plasma transaminases of mice at 2 hours post reperfusion or after 3 hours 
of sham laparotomy. 
Each point represents a single mouse (n=12 per group). Bar represents median. 
Statistical significance was determined using Kruskall-Wallis followed by 
Mann-Whitney U Tests. 
There was no histopathological evidence of IR injury seen in any group. 
 
Sh
am
RI
PC
 on
ly
IR
 in
jur
y
RI
PC
 +I
R 
inj
ur
y
0
200
400
600
800
1000
Groups
A
ST
 le
ve
ls
 (i
U
)
p=0.013
p<0.001
Groups
A
LT
 (i
U
/L
)
Sh
am
RI
PC
 on
ly
IR
 in
jur
y
RI
PC
 +I
R 
inj
ur
y
0
200
400
600
800
1000
p<0.001
p=0.04
 157 
7.3.2: Circulating levels of cytokines. 
Circulating levels of IL-6 [442.2(177.1-1370)pg/ml vs 87.26(63.86-117.5)pg/ml, 
p=0.002] and CCL2 [125.1(53.78-155.6)pg/ml vs 48.6(27.5-60.2)pg/ml, p=0.008) 
were significantly raised in mice that underwent hepatic IR injury (Figure 7.4). In 
mice that underwent RIPC prior to hepatic IR injury, circulating levels of both IL-6 
[132.8(34.7-369.6)pg/ml vs 442.2(177.1-1370)pg/ml, p=0.02] and CCL2 [53.8(22.2-
63.3)pg/ml vs 125.1(53.78-155.6)pg/ml,p=0.02] were significantly lower than in 
those that underwent hepatic IR injury only (Figure 7.4). Circulating plasma levels of 
GMCSF, IFNγ, IL-1β, IL10 and TNFα were undetectable in all mice. TGFβ levels 
were detectable but not significantly raised following IR injury or RIPC (Figure 7.4). 
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A                                                                        B 
          
C 
 
Figure 7.4: plasma levels of IL-6, CCL2 and TGFβ at 2 hours post reperfusion or 
after 3 hours of sham laparotomy. 
Each point represents a single mouse (n=12 per group). Bar represents median. 
Statistical significance was determined using Kruskall-Wallis followed by 
Mann-Whitney U Tests. 
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7.3.3: Cells. 
7.3.3.1: Splenic T cell populations. 
The gating strategy for the splenic T cell is contained in figure 7.5. The CD4+ and 
CD8+ T cell numbers calculated as a proportion of CD3+ cells were similar between 
the groups (Figure 7.6). There was no difference in the Treg population size between 
the groups (Figure 7.6).  
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A                      CD4+ T cells                        B                            CD8+ T cells 
         
C                            Tregs 
 
Figure 7.6: Circulating T cell populations. 
Each point represents a single mouse (n=12 per group). Bar represents median. 
Lack of statistical significance was determined using Kruskall-Wallis test. 
The percentage of circulating CD4+ T cells actively producing cytokines was low 
and was unchanged by hepatic IR injury and RIPC (Figure 7.7). 
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A                          IL-6                                      B                         IL-10 
             
C                        IL-17                                       D                       IFNγ 
              
E                       TNFα 
 
Figure 7.7: Cytokine production by splenic CD4+ T cells. 
Each point represents a single mouse (n=12 per group). Bar represents median. 
Lack of statistical significance was determined using Kruskall-Wallis test. 
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Similarly cytokine production by circulating CD8+ T cells was low and was not 
significantly changed by hepatic IR injury or RIPC (Figure 7.8). 
A                           IL-6                                   B                    IL-10 
               
C                           IFNγ                                    D                    TNFα 
                 
Figure 7.8: Cytokine production by splenic CD8+ T cells. 
Each point represents a single mouse (n=12 per group). Bar represents median. 
Lack of statistical significance was determined using Kruskall-Wallis test. 
 
7.3.3.2: Hepatic T cell populations. 
The gating strategy for intrahepatic T cells is contained in Figure 7.9. The CD4+ and 
CD8+ T cell number as calculated by a proportion of CD3+ cells were similar 
between the groups (Figure 7.10). There was no difference in the Treg population 
size between the groups (Figure 7.10). 
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A                      CD4+ T cells                       B                            CD8+ T cells 
     
C                            Tregs 
 
Figure 7.10: Intrahepatic T cell populations. 
Each point represents a single mouse (n=12 per group). Bar represents median. 
Lack of statistical significance was determined using Kruskall-Wallis test. 
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7.3.3.3: Intra hepatic CD4+ T cell cytokine production. 
The percentage of CD4+ T cells actively secreting TNFα was significantly higher in 
the non-ischaemic lobe of the liver following IR injury than in sham animals 
[13.1(8.72-15.2)% vs 5.0(4.22-5.97)%, p=0.002] (Figure 7.11). RIPC resulted in a 
significantly lower median percentage of CD4+ T cells isolated from the non-
ischaemic lobe producing TNFα  [6.84(4.34-12.11)% vs 13.1(8.72-15.2)%, p=0.046]. 
The percentage of CD4+ T cells isolated from the ischaemic lobe of the liver 
following IR injury producing TNFa however was similar in number to the sham 
control [4.84(3.05-6.91)% vs 5.0(4.22-5.97)%, p=0.662]. Although the percentage of 
CD4+ T cells isolated from the ischaemic lobe of the liver from mice undergoing 
RIPC was higher than from those not undergoing RIPC, this was not significant 
[6.87(2.4-4.46)% vs 4.84(3.05-6.91)%, p=0.436]. There was no difference in CD4+ 
T cell production of IFNγ, IL-6 or IL-17A (Figure 7.11). 
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A                               IL-6                    B                               IL-10 
          
C                            IL-17A                  D                               IFNγ 
          
E                             TNFα 
 
 
Figure 7.11: Intrahepatic CD4+ T cell cytokine production. 
Each point represents a single mouse (n=12 per group). Bar represents median. 
Statistical significance was determined using Kruskall-Wallis test followed by 
Mann-Whitney U tests. 
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7.3.3.4: Intra hepatic CD8 + T cells production. 
The median percentage of CD8+ T cells isolated from the non-ischaemic lobe of the 
liver following IR injury actively producing TNFα was significantly higher than 
those actively producing TNFα in the control mice [11.7(7.64-13.2)% vs 6.25(5.23-
7.14)%, p=0.003] (Figure 7.11). The proportion of intrahepatic CD8+ T cells 
producing TNFα was unaffected by RIPC [10.35(6.36-13.83)% vs 11.7(7.64-13.2)%, 
p=0.866] (Figure 7.12). 
 
 
Figure 7.12: TNFα production by intrahepatic CD8+ T cells. 
Each point represents a single mouse (n=12 per group). Bar represents median. 
Statistical significance was determined using Kruskall-Wallis test followed by 
Mann-Whitney U tests. 
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7.4: Discussion. 
The results of this study confirm that RIPC can reduce warm hepatic IR injury in a 
murine model and show that TNFα production by intra hepatic CD4+ T cells is not 
only upregulated following IR injury but is also significantly attenuated in the 
murine liver following RIPC. Furthermore the immune changes seen in mice 
following IR injury reflect in some degree those seen in human liver transplant 
recipients at a similar time point post reperfusion. 
 
7.4.1: Cytokines. 
At 2 hours post reperfusion only IL-6 and CCL2 levels were significantly elevated in 
the hepatic IR injury group. This is in keeping with results from the human patients 
in the RIPCOLT trial who had significantly elevated circulating levels of IL-6 and 
CCL2 at 2 hours post reperfusion. Other cytokines raised following reperfusion in 
the trial patients were IL-8 (which is not present in mice [230]), IL-10 and IL-17A. 
IL-10 levels were not raised in the mice following IR injury. The most likely 
explanation for the raised levels of IL-10 seen in patients is that activated 
inflammatory monocytes are releasing the IL-10. Murine inflammatory monocytes 
do not release IL-10 in the same fashion [222] and this may therefore explain why 
IL-10 is not raised in this model. The murine LEGENDplex measured circulating 
levels of IL-17F not IL-17A as measured in the humans. This may explain the 
discrepancy noted between the 2 models especially as IL-17 has been shown in other 
small animal models to play a key role in recruiting neutrophils to the liver following 
IR injury [28]. However yet again the specific clone of IL-17 involved in hepatic IR 
injury would need tested in another model. 
Although TNFα has been postulated as a key cytokine in the pathogenesis of IR 
injury [69], and has been identified as being raised in small animal models [70], 
circulating levels of TNFα and IFNγ were not detected in our model. This is in 
keeping with a small animal model of lung transplantation that clearly demonstrated 
that localized TNFα levels were elevated in the bronchoalveolar lavage whilst not in 
the circulation [78]. 
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Mice that underwent RIPC had significantly lower circulating IL-6 and CCL2 levels 
at 2 hours post IR injury compared to those that underwent IR injury only. CCL2 is 
the chemokine that promotes monocyte recruitment to sites of inflammation from the 
bone marrow [48]. Monocytes are a key producer of inducible Nitric Oxide Synthase 
(iNOS) which is a key driver of IR injury [231]. Only one study has investigated the 
role of CCL2 in hepatic IR injury and there was clear evidence that mice lacking 
CCL2 via genetic knock out were protected from IR injury [56]. Monocytes have 
also been implicated in acetaminophen induced liver injury in mice and have been 
shown to be recruited following liver injury [232,233] and to drive chronic fibrosis 
following liver injury [52] which may impair long term graft function and survival. 
However, monocytes have been shown to display plasticity and an elegant study has 
shown that once recruited to sites of inflammation, monocytes can undergo further 
differentiation from pro-inflammatory to pro healing type cells [57] and therefore 
may play a key role in helping resolve IR injury in the later stages. This plasticity 
may also be present in CD4+ T cells and could explain the differing results seen in 
CD4+ T cells knock out mice [21,28]. A key investigation that was not performed in 
this experiment was to analyse for the cellular source of CCL2 production. If CD4+ 
T cells produce CCL2 following TLR4 stimulation, this may explain why a cell 
population that transiently infiltrates the post ischaemic liver plays such an important 
role in the pathogenesis especially as it is an atypically rapid response for CD4+ T 
cells which usually takes 5-7 days [31]. Blockade of CCL2 early on may present an 
exciting novel therapeutic approach to treating IR injury. There is an experimental 
anti CCL2 antibody for use in mice and further murine studies are essential. The only 
study of CCL2 in genetic knock out animals although useful does not reflect clinical 
practice which would involve transient inhibition of CCL2. Furthermore monocytes 
differentiate into macrophages and dendritic cells and therefore the effect of CCL2 
knock out on these populations requires further evaluation. These experiments 
remain to be done. But if confirmed would present transient CCL2 blockade prior to 
implantation as a very exciting target pathway for immune modulation. Whether 
monocytes are recruited to the liver graft post transplantation remains to proven and 
whether these monocytes are recruited in the donor during brain death/retrieval or in 
the recipient remains to be elucidated and was explored in experiments described in 
chapter 9. Furthermore the effect of RIPC on monocyte recruitment remains to be 
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adequately explored as the livers would have to be examined at a later time-point 
than in this study. 
Only 1 study has documented the effect of RIPC on IL-6 levels post hepatic IR 
injury. It demonstrated that IL-6 levels were significantly elevated at 1 hour post 
RIPC and then significantly reduced at 3 hours post IR injury [139]. This reduction 
in IL-6 levels was similarly seen in liver transplant recipients undergoing RIPC [138] 
however this was not associated with any clinical benefit. Further experiments are 
required in which mice undergoing RIPC are treated with IL-6 to test whether this 
reduced IL-6 level is involved in the protective mechanism of RIPC. IL-6 is known 
to play a key role in the recruitment and proliferation of CD4+ T cells [75,213] and 
to block Treg differientation and function [75]. As such further investigation of its 
role in hepatic IR injury is warranted. There is currently an anti-IL-6 antibody 
(siltuxibab) licensed for use in patients with rheumatoid arthritis and as such an small 
animal model in which IL-6 was depleted following IR injury is merited as this 
would facilitate early translation to a clinical trial. 
Although both IL-6 and CCL2 are worthy of further analysis, CCL2 is of more 
interest as post reperfusion IL-6 levels were found to be significantly lower in liver 
transplant recipients that underwent RIPC than those that did not but this was not 
associated with any clinical benefit. Liver transplant recipients undergoing RIPC had 
similar circulating levels of CCL2 post reperfusion and outcomes, whilst mice with 
lower levels of CCL2 also had significantly less liver injury as measured by 
transaminases. The source of this CCL2 production was not identified. When this 
experiment was designed, CCL2 and monocyte infiltration was not the focus. Further 
work is necessary but it would be interesting to analyse both the intrahepatic and 
splenic CD4+ T cell populations for CCL2 production. If the transiently infiltrating 
CD4+ T cells are shown to be key producers of CCL2 and therefore the initiators of 
the inflammatory response, it would explain the key finding of why CD4+ T cells are 
essential for IR injury [21,24]. Furthermore it would strengthen the role of targeting 
CCL2 to ameliorate IR injury. 
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7.4.2: CD4+ T cells. 
CD4+ T cells have been shown to rapidly infiltrate the post ischaemic liver [21,28] 
and have been identified as a major pathogenic pathway of IR injury, not only in the 
liver [21,24,28], but also in the kidney [25] and in the lung [27,234]. Although RIPC 
has been shown to reliably reduce IR injury in small animal models, its protective 
mechanisms remain poorly understood especially the effect on the CD4+ T cell 
population.  
Detailed analysis of the T cell population from the mice in this study showed no 
evidence of change in the percentage of T cells that were CD4+ or CD8+ either in 
the spleens or the livers of mice that underwent IR injury when compared to the 
controls. This is not in keeping with results from other studies which clearly show a 
rapid and transient influx of CD4+ T cells to the post ischaemic liver within the first 
4 hours [21,28]. It should be noted however that this study was not designed to look 
at changes in population number and in mice that did not undergo IR injury the liver 
was analysed as a whole while in mice that underwent IR injury, the ischaemic and 
non-ischaemic lobes were analysed separately. Furthermore the entire suspension of 
cells was not run through the flow cytometer and therefore a direct comparison is 
flawed. To further analyse this, immunostaining of the fixed samples to allow for 
identification of the number of CD4+ T cells per high-powered field would be 
required.  
TNFα is a key cytokine upregulated early during IR injury and specific depletion of 
which has been shown to ameliorate IR injury [67,70,235]. In keeping with the 
analysis of CD4+ T cells obtained from patients recruited to the RIPCOLT trial 
(Chapter 6), TNFα production by both intrahepatic CD4+ and CD8+ T cells was 
significantly raised following IR injury. Interestingly this was seen in the non-
ischaemic lobes only. This may reflect the fact that for 45 minutes, the vascular 
inflow to the ischaemic lobe was occluded preventing the influx of the inflammatory 
cells. To our knowledge no other study has analysed the post ischaemic livers in this 
way and as such there is nothing in the literature to compare this finding to. The 
increased TNFα production in the liver is in keeping with our current understanding 
of IR injury. HMGB1 release following IR injury leads to TLR4 activation on 
immune cells and has been shown to lead to increased TNFα mRNA levels in the 
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hepatic parenchyma [16]. This study adds to that knowledge by demonstrating that 
TNFα is produced by the T cell population. Mice that underwent RIPC prior to IR 
injury had significantly less injury as measured by serum transaminases and this was 
associated with significantly reduced CD4+ TNFα production. Although this study 
clearly demonstrates a reduction in TNFα production by CD4+ T cells it does not 
answer how this occurs and this needs further explored. Whether RIPC reduces the 
CD4+ T cell response to DAMPs or whether RIPC reduces the level of DAMPs 
released by reducing hepatocyte necrosis needs further investigated using a cell 
transfer model. One study performed adoptive transfer of splenocytes from wild type 
mice into athymic mice and then performed a renal IR injury 7 days later. Mice that 
received splenocytes from a preconditioned mouse suffered a significantly reduced 
renal IR injury as measured by serum creatinine levels and histopathological analysis 
[116] suggesting that RIPC is able to fundamentally change T cells. There was no 
sub-group analysis with transfer of pure CD4+ T cells or CD8+ T cells and as such 
there is no evidence as to which particular cell RIPC exerts its protective mechanism 
through. It is important to note that although TNFα production by CD4+ and CD8+ 
T cells was significantly upregulated following IR injury, TNFα production by CD4+ 
T cells was significantly reduced in mice who underwent RIPC whilst TNFα by 
CD8+ T cells was unchanged indicating that RIPC may have direct effects on the 
CD4+ T cell population. Postulated mechanisms include the action of extracellular 
adenosine released during the preconditioning stimulus which has been shown to 
reduce both CD4+ T cell recruitment and activation to post ischaemic kidneys [236] 
and myocardium [237]. Neither of these models involved RIPC/IPC and therefore 
the key question of the timing required to alter the CD4+ T cell response remains to 
be answered especially in the setting of transplantation where a 5 day window is not 
available. Further in vitro work may provide direct evidence of the effect of 
adenosine on immediate CD4+ T cells responses. 
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Chapter	 8:	 An	 exploration	 of	 the	
inflammatory	 response	 to	 RIPC	
evaluated	 in	 healthy	 human	
volunteers.	
8.1: Introduction. 
RIPC has reliably been shown to ameliorate IR injury in small animal models yet its 
transfer into clinical practice has been hampered by several negative clinical trials 
[138]. Recently 2 large randomized controlled trials performed in the setting of 
major cardiac surgery failed to demonstrate any clinical benefit to patients following 
RIPC [102,103]. A study of children undergoing major cardiac surgery demonstrated 
significant reduction in cardiac injury as measured as measured by a reduction in 
post-operative troponin levels and need for inotropic support [101]. One possible 
cause for negative clinical studies is that certain physiological states including 
diabetes, hypercholesteraemia, hypertension, age and gender have a negative effect 
on the preconditioning response [109]. Small animal models are tightly controlled 
often using healthy young male mice without the variability seen in human patients 
with end stage liver disease. It is not currently known if end stage liver disease could 
reduce the preconditioning response as with the above conditions but it would seem 
likely. The optimal length of cuff inflation time and limb ischaemia to adequately 
precondition humans is unknown. Five minute cycles of hind limb ischaemia has 
been shown to be adequate to successfully precondition mice [238]. However mice 
have a higher metabolic rate than humans and are maintained on room air during the 
preconditioning stimulus and the resulting IR injury. In contrast patients undergoing 
liver transplantation are intubated and maintained on high flow oxygen. Analysis of 
the PaO2 levels in venous blood collected from the patients foot 4.5 minutes into the 
first 5 minute period of cuff inflation on the lower limb demonstrated that PaO2 
levels were significantly lower in patients with the cuff inflated [7.53(4.94-9.28)kPa  
vs 15.06(8.67-19.00)kPa, p=0.004] however no patient experienced a PaO2 of <3kPa 
which would signify hypoxia in a venous sample [138]. Similarly there was no 
 175 
evidence of a lactic acidaemia which would indicate ischaemic conditions had been 
achieved in the limb. A recent pilot study of RIPC in patients undergoing major liver 
resection using 10 minute cycles of ischaemia found evidence of a significant 
reduction in liver injury as measured by post-operative transaminases and 
indocynanine green clearance [12]. This is reflected in an analysis of direct IPC of 
donor livers prior to retrieval where 5 minutes of IPC failed to discern any benefit 
[90] yet 10 minute cycles demonstrated a reduction in post-operative transaminases 
in keeping with reduced injury [92]. 
To determine the immunological response to RIPC in the absence of a concomitant 
disease process and high flow oxygen, healthy volunteers underwent RIPC and blood 
was analysed for changes in the inflammatory response. 
CD4+ T cells have been shown to rapidly infiltrate the liver following IR injury 
[21,28] and RIPC has been shown to provide systemic protection to the entire body 
of the individual preconditioned. Circulating CD4+ T cells were isolated from the 
blood of healthy volunteers blood pre and post RIPC and were stimulated in vitro to 
determine whether RIPC may effect CD4+ T cell cytokine production. 
Mammalian Target of Rapamycin (mTOR) is an intracellular kinase that has been 
shown to direct CD4+ T cell activation and differentiation [239]. MTOR activity is 
upregulated following CD4+ T cell stimulation both through the T cell receptor and 
through toll like receptors [239] but is suppressed by hypoxia and low nutrient 
conditions, similar to those seen during the preconditioning stimulus [240]. 
Pharmacological suppression of mTOR via rapamycin has been shown to augment 
Treg responses and promote the differentiation of activated naive CD4+ T cells into 
Tregs [241]. Furthermore, Tregs activated in vitro in culture with rapamycin prior to 
adoptive transfer into mice were able to ameliorate hepatic IR injury [41]. 
8.1.2: Aim. 
The aim of this study was to assess whether RIPC suppressed mTOR activity in 
circulating CD4+ T cells following in vitro activation resulting in reduced CD4+ T 
cell cytokine production. 
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8.2: Methods. 
Six healthy volunteers were recruited to this study and following informed consent, 
underwent RIPC of the right upper limb. Exclusion criteria for this study are 
contained in table 8.1. A similar protocol of 3 by 5 minute cycles of preconditioning 
was used as in the RIPCOLT trial [141]. Individuals were not administered 
supplementary oxygen during the preconditioning procedure. Twenty mls of venous 
blood was collected from the right arm prior to the cuff being inflated, immediately 
after the preconditioning had been performed and again 1 hour after the 
preconditioning (Figure 8.1). 
 
Exclusion criteria 
Female 
Age >50 
Diabetes 
Acute infection 
Diagnosis of chronic disease 
Table 8.1: Exclusion criteria for this study 
 
Figure 8.1: Flow chart for the preconditioning and sample collection. 
 
15 mls of peripheral blood was collected into BD vacutainer EDTA tubes (BD, UK). 
Samples of peripheral blood were diluted with 15 mls PBS and centrifuged with 
Ficoll Paque (GE healthcare, UK) density gradient (to isolate peripheral blood 
mononuclear cells (PBMCs). Samples were divided into aliquots of 2 million cells 
and were cultured in a 6 well tissue culture plate (Thermo Scientific, England) for 4 
hours (370C, 5% C02, 20% O2) under 2 different conditions: 
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1. Brefeldin A (1µg/ml). 
2. Brefeldin A (1µg/ml) + OKT 3 (1ng/ml). 
Cells were stimulated with OKT3 antibody, which activates T cells through T Cell 
Receptor stimulation, and were cultured with Brefeldin A to prevent cytokine release 
from the cell during the stimulation period unmasking small changes. Cells were 
washed and immediately stained and analysed by multi channel flow cytometry. The 
cells were analysed in a similar fashion to the cells from the RIPCOLT trial using the 
same cell markers to allow for identification of any significant differences from our 
patients. The fluorochromes used are contained in table 8.2. 
Antigen Conjugate Source Clone Concentration 
(µl/100µls) 
Live/Dead APC Cy7 Life 
Technologies 
n/a 0.15 
Extracellular 
CD3 PE Texas Red BD UCHT1 0.5 
CD4 PE Cy7 eBioscience RPA-T4 1 
CD8 AF 700 eBioscience OKT-8 0.5 
HLADR V500 BD G46-6 1 
CD69 FITC BD FN50 3 
PD-1 PerCP Cy5.5 Biolegend EH12.2H7 2 
Intracellular 
CTLA-4 PE BD BN13 3 
FoxP3 Pacific Blue Biolegend 259D 4 
IL-2 PerCP e-Flour 
710 
eBioscience MQ1-17H12 1 
IL-6 PE Biolegend MQ2-13A5 2 
IL-8 APC eBioScience 17-8088-42 2 
IL-10 PE eBioscience JES3-9D7 1 
IFNγ FITC R&D systems ♯25723 3 
pS6 AF 647 Cell Signalling D57.2.2E 1 
TNFα APC Biolegend MAb11 0.5 
Table 8.2: Fluorochromes used for staining PBMCs. 
Cells were analysed on a Fortessa II flow cytometer (Becton Dickinson, Oxford) 
using DIVA software (Becton Dickinson, Oxford) and FlowJo software (Tree Star, 
Oregon, USA). 
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Five mls of peripheral venous blood was collected in BD vacutainer plasma tubes 
(BD, UK). Samples were immediately centrifuged (1000g, 10 minutes, 200C). The 
plasma was stored at -800C until analysis. 
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8.3: Results. 
Median age of volunteers was 22 (21-45). All volunteers tolerated the RIPC protocol 
and samples were collected and analysed from all individuals at all time points. 
8.3.2: The effect of RIPC on CD4+ T cells. 
The gating strategy is contained in figure 8.2. There was no significant change in the 
size of the circulating CD4+ T cell population following preconditioning of healthy 
individuals as measured by Friedman test (p=0.0521). Analysis of CD4+ T cells 
directly ex vivo without further stimulation demonstrated an increase in the 
expression of HLADR on the cell surface following RIPC (p=0.0028) and an 
increase in the intracellular production of CTLA-4 (p=0.0082) (Figure 8.3). The 
median levels of further markers are contained in Appendix 3 Tables 1 & 2. 
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Figure 8.3: Percentage of CD4+ T cells actively producing CTLA-4. 
Each line represents an individual and demonstrates increased numbers of 
CD4+ T cells producing CTLA-4 after RIPC in all individuals (n=6). Statistical 
significance was demonstrated by Friedman test and Wilcoxon tests. 
There was no change in the expression of CD69 by CD4+ T cells following RIPC 
(p=0.7402). RIPC alone did not stimulate CD4+ T cells to produce TNFα. When 
stimulated, a greater number of CD4+ T cells collected after RIPC produced TNFα 
than those collected before RIPC (p=0.012) (Figure 8.4). 
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Figure 8.4: TNFα production by stimulated CD4+ T cells. 
Each line represents an individual and demonstrates increased numbers of 
CD4+ T cells producing TNFα after RIPC in all individuals (n=6). Statistical 
significance was demonstrated by Friedman test and Wilcoxon tests. 
RIPC had no effect on the circulating Treg population either in terms of size or 
cytokine production.. 
8.3.3: The effect of RIPC on pS6 levels. 
Stimulation with OKT3 led to significantly higher pS6 expression by CD4+ T cells 
[2.44(1.393-3.233)% vs 0.859(0.515-0.905)%, p=0.0095], RIPC did not significantly 
reduce pS6 levels following activation [1.37(1.27-5.685)% vs 2.44(1.393-3.233)%, 
p>0.999]. 
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8.4: Discussion. 
There is clear evidence in small animal models to support a key role for CD4+ T 
cells in the pathogenesis of IR injury as CD4+ T cells have been shown to rapidly 
infiltrate reperfused tissue and mice lacking CD4+ T cells are protected from the 
reperfusion injury [21]. The protective mechanisms of IPC/RIPC remain unclear 
especially the effect of IPC/RIPC on CD4+ T cells. This study has analysed the 
effect of RIPC on CD4+ T cells in healthy individuals and has demonstrated that 
RIPC stimulates CD4+ T cells. 
RIPC led to increased CTLA-4 production by CD4+ T cells. CTLA-4 is an inhibitory 
molecule that binds to CD80 and CD86 on antigen presenting cells preventing their 
binding with CD28 and therefore blocking the co-stimulatory signal required to 
promote T cell activation and proliferation following T cell receptor stimulation 
[242]. Although constitutively expressed on Tregs, CTLA-4 expression on CD4+ T 
cells is only upregulated following activation. Studies have shown that this 
upregulation of CTLA-4 on activated CD4+ T cells can occur within 1 hour [242] 
which is in keeping with the timeframe of the CTLA-4 upregulation seen in this 
study. What is not clear is whether this upregulation of CTLA-4 simply reflects 
stimulation of CD4+ T cells following RIPC or a shift towards an anti inflammatory 
phenotype. Analysis of CD69, an early activation marker, showed no change 
following RIPC however surface expression of HLADR (another activation marker) 
by CD4+ T cells was upregulated following RIPC and therefore CD4+ T cell 
activation is the most likely explanation. 
As expected, Stimulation of cells with OKT3 antibody demonstrated increased 
production of TNFα by CD4+ T cells [243]. Cells obtained following RIPC showed 
a greater predisposition towards producing TNFα following OKT3 stimulation rather 
than less. When this data is combined with the increase in HLADR and CTLA-4 
expression of CD4+ T cells following RIPC this would indicate that RIPC has 
stimulated CD4+ T cells. The result was unexpected however as the hypothesis was 
that RIPC would result in less TNFα upon stimulation. Cells were stimulated with 
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OKT3 as this was an established model for stimulating T cell cytokine production in 
our lab.  
Evidence from small animal models would suggest that TLR4 stimulation by 
HMGB1 is a key driver of the immune response following reperfusion [16] rather 
than antigen recognition [30] and therefore results from this model where cells are 
stimulated via the T cell receptor should be interpretated with caution. Further in 
vitro models of IR injury need to be developed. A key step would be measuring the 
concentration of HMGBI released following IR injury as this would allow cells to be 
stimulated in a similar fashion to that following IR injury. 
This study did not include measurement of CCL2 production by CD4+ T cells. 
Further work both in humans and mice (Chapters 3.4 and 3.5) has shown that 
circulating CCL2 levels are significantly elevated following IR injury[244] and are 
significantly reduced following RIPC in mice. Further studies in both humans and 
mice should include this chemokine as it may further delineate the role of CD4+ T 
cells in the reperfusion injury. 
Ribosomal protein S6 is a downstream kinase directly phosphorylated by mTOR 
[245] and as such is accepted as a marker of mTOR activity. Rapamycin, which 
inhibits mTOR activation, has been shown to lead to the expansion of Tregs in vitro 
and has been shown to suppress in vitro CD4+ T cell activation [245] and reduce 
warm hepatic IR injury [41]. This process takes about 7 days. In this study pS6 levels 
in CD4+ T cells showed a trend towards being higher immediately post RIPC rather 
than lower. This is in keeping with CD4+ T cells being activated by RIPC. These 
results would therefore suggest that RIPC does not suppress CD4+ T cell activation 
but that CD4+ T cells are more responsive to activation following RIPC 
A study investigating RIPC in cerebral IR injury found that treatment of animals 
with rapamycin 30 minutes prior to RIPC abolished the protective effect of RIPC 
[246]. However, pS6 levels in CD4+ T cells were not measured and therefore 
conclusions can not be drawn as to whether rapamycin interfered with CD4+ T cell 
activation following RIPC. This would however be an easy experiment to perform 
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and is of merit to further understand the effect of RIPC on CD4+ T cells following 
IR injury. 
The plasma collected from the limb during this study has yet to be analysed. A 
review of the current literature identified that adenosine is rapidly released following 
IPC and may be a potential mediator of the protection gained following ischaemic 
preconditioning [117]. As such, it would be interesting to measure adenosine levels 
in the collected plasma. This could be combined with measurement of adenosine 
levels in plasma collected and stored from the limb during preconditioning in 
patients in the RIPCOLT trial. This would answer the question whether RIPC leads 
to adenosine release in humans and whether the use of high flow supplementary 
oxygen and concomitant comorbidities in patients prevents this release and therefore 
this may be the reason for the lack of the protective effect seen following RIPC in the 
RIPCOLT trial.  
The key result of this study is that RIPC in healthy volunteers shows evidence of 
CD4+ T cell activation in humans. Studies in mice have shown that adoptive transfer 
of splenocytes 5 days following 30 minutes of renal ischaemia, into naïve mice, 
protected against renal IR injury [116]. A key next step is to further analyse the time 
frame of RIPC and CD4+ T cells. RIPC has been shown to ameliorate IR injury that 
occurs 5 minutes following RIPC and this model has shown that CD4+ T cells 
immediately following RIPC show greater evidence of activation. As such a small 
animal model of adoptive transfer of splenocytes, collected 5 minutes following 
RIPC, into naïve mice immediately prior to IR injury is necessary. Further 
knowledge of the downstream pathways in CD4+ T cells following IPC/RIPC is 
essential and more robust in vitro models mimicking IR injury are required to 
allowed targeted immuno-therapies to be developed.  
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Chapter	 9:	 A	 study	 of	 monocytes	 in	
liver	IR	injury	and	RIPC.	
9.1: Introduction. 
Monocytes are recruited from the bone marrow by Chemokine Ligand 2 (CCL2)/ 
Monocyte Chemo-attractant Protein 1 (MCP1) and rapidly infiltrate damaged tissue. 
Monocytes have been shown to play a key role in both carbon tetrachloride induced 
liver injury [247] and in acetaminophen induced liver injury [233] in small animal 
models. One study demonstrated that between 24 and 48 hours post carbon 
tetrachloride induced liver damage, the intra-hepatic classical monocyte population 
grew to account for 12% of total cells in the liver from less than 1% pre injury [52]. 
Inducible Nitric Oxide Synthase (iNOS) has been shown to be a key driver of IR 
injury and monocytes are known to produce iNOS [248]. It therefore may be that 
infiltrating monocytes are the source for the iNOS that drives the immune liver 
injury following reperfusion [249].  
Results from both the RIPCOLT trial and the mouse model show that CCL2 levels 
were significantly elevated following IR injury [142]. In chapter 3.4, analysis of 
patient samples demonstrated that circulating CCL2 levels measured at 24 hours post 
transplantation correlated with AST levels on day 3 post liver transplant (p=0.002) – 
a strong indicator of early patient morbidity and mortality [142]. Patients that 
developed early allograft dysfunction (EAD) had significantly higher CCL2 levels 
than those that did not (p=0.037) [244] . Furthermore intracellular production of 
Interferon Gamma (IFNγ) by circulating CD4+ T cells was significantly upregulated 
following reperfusion of the graft (data in Chapter 3.4). IFNγ is a potent activator of 
monocytes [250] priming the response to Toll-Like Receptor 4 stimulation [35] and 
this axis between CD4+ T cells and monocytes may explain the necessity for CD4+ 
T cells in the development of IR injury [21]. Our mouse model which confirmed that 
RIPC provides protection following liver IR injury demonstrated clearly that mice 
that underwent RIPC prior to IR injury had significantly lower CCL2 levels and were 
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protected from liver IR injury (p=0.01) suggesting that CCL2 is involved in the liver 
injury.  
The use of CCL2 knock out models has shown a reduction in tissue injury and 
improved outcomes in different organs. Genetic knock out mice lacking CCL2 have 
been shown to have a better motor functional outcome following haemorrhagic 
cerebral injury [251] indicating reduce injury. In the setting of liver injury, 
pharmacological inhibition of CCL2 reduced monocyte infiltration into the liver 
following carbon tetrachloride induced hepatic injury [247] in a non-lethal model. 
Genetic knock out mice lacking CCL2 have been shown to suffer from a 
significantly reduced reperfusion injury following warm hepatic ischaemic [56]. 
Infiltrating monocytes mature into macrophages and dendritic cells and populate the 
liver [252]. It is unclear of the effect of CCL2 knock out on these resident liver 
populations as these results were not published. As regards the relevance of this 
finding to translation into clinical practice, it would be unrealistic to deplete humans 
of a cell population however transient interruption of cell recruitment or inhibiting 
cell activation may be possible. A murine anti-CCL2 antibody does exist and 
treatment with this prior to IR injury would more accurately reflect the potential anti 
CCL2 treatment that may be given in humans and may present an exciting 
therapeutic option. Whether classical monocytes are recruited to the post-ischaemic 
liver has not previously been investigated.  
9.1.2: Aim. 
The aim of this study was to explore whether classical monocytes are recruited to the 
liver following a period of ischaemia and reperfusion. We wished to compare this 
process between mice and humans and to determine the source of any monocyte 
infiltrate. 
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9.2: Methods. 
9.2.1: Mice. 
Samples were collected for analysis from mice in the model described in detail in 
chapter 3.5. In 8 of 12 mice in each group from the murine model of partial warm 
liver IR injury and RIPC (Figure 9.1), samples were analysed for liver infiltration by 
inflammatory monocytes. The livers were harvested 2 hours post reperfusion, 
manually homogonised and passed through a 70µm cell strained (Fisher Scientific, 
UK). The solution was layered on top of Optiprep solution (sigma, UK) and 
centrifuged (700g, 20 mins, 200C without breaking) to isolate intra hepatic 
leukocytes. Cells were immediately stained for analysis by flow cytometry.  
The flow cytometry staining panel is listed in table 9.1. Classical monocytes were 
identified as CD11b intermediate/Ly6chi/Ly6gnegative (Figure 9.2). The percentage 
of classical monocytes were calculated as the number of cells as a proportion of cells 
after dead cells, doublets and debris were gated out. 
Antigen Conjugate Source Clone Concentration 
(µl/100µls) 
Live/Dead efluor450 eBioscience n/a 0.15 
Extracellular 
CD11b FITC BD Pharinogen M1/70 0.25 
Ly6c APC BD Pharminogen AL-21 1 
Ly6g APC Cy7 BD Biosciences IAS 2 
Table 9.1: Fluorochromes for staining cells from murine liver. 
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Figure 9.1: Experimental protocol of murine model including sample collection.
 
Figure 9.2: An example of the staining showing murine classical monocytes. 
 190 
9.2.2: Humans. 
As part of the RIPCOLT trial, tru-cut biopsies were obtained from 5 donor livers 
immediately prior to donor organ implantation and at 2 hours post graft reperfusion. 
The biopsies were analysed separately. The flow cytometry staining panel is listed in 
table 9.2 and the gating strategy for analyzing the human samples is in figure 9.3. 
 
Antigen Conjugate Source Clone Concentration (µl/100µls) 
Live/Dead efluor450 eBioscience n/a 0.15 
Extracellular 
CD3 APC efluor780 eBioscience SK7 0.5 
CD14 PerCP Invitrogen TuK4 0.25 
CD16 PE BD Pharminogen 3G8 0.5 
CD19 APC efluor780 eBioscience HIB19 1 
CD56 BV510 BD Horizon NCAM 16.2 0.5 
HLA-A2 APC eBioscience BB7.2 1 
HLA-A3 FITC eBioscience GAP.A3 2 
Table 9.2: Fluorochromes for staining cells from the human liver. 
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Figure 9.3: The gating strategy for identifying the source of classical monocytes in 
human patients. 
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Classical monocytes were identified as being CD3/CD19/CD56 negative and then 
CD14 positive CD16 negative. The percentage of classical monocytes in the 
intrahepatic samples was calculated after exclusion of dead cells, doublets and 
debris.  
9.2.2.2: Method for determining the source of the monocyte population. 
In liver transplantation, donors and recipients are matched on blood group (A, B, 
AB, O), size, and quality of organ/frailty of recipient. Unlike in renal transplantation, 
they do not undergo HLA tissue matching. Where there was a mismatch between 
donor and recipient at the HLA-A2 or HLA-A3 alleles (i.e. the donor was HLA-A2 
+ve and the recipient was HLA-A2 –ve) it was possible to identify whether the 
monocytes in the post reperfusion liver originated from the donor or recipient. 
9.2.3: Statistical analysis. 
Differences in the median between multiple groups were identified by Kruskall-
Wallis tests and differences in the mean between 2 groups were identified by Mann-
Whitney U tests. Statistical analysis was performed on Prism version 6 (Graphpad, 
USA). 
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9.3: Results. 
9.3.1: Mice. 
Samples of fresh liver were analysed from the murine model in described in chapter 
3.5. This model clearly demonstrated significant liver injury, following partial liver 
ischaemia for 45 minutes, as measured by serum transaminases 2 hours post 
reperfusion. Remote ischaemic preconditioning protected against liver injury. The 
liver tissue was collected at 2 hours post reperfusion and analysed immediately. 
There was a significantly higher number of intra-hepatic classical monocytes in the 
mice that underwent IR injury than controls (Figure 9.4). To help understand the 
mechanism both the ischaemic and non-ischaemic liver lobes from the IR injury 
groups were analysed separately. This increase in number of monocytes was seen in 
both the ischaemic [3.61(2.43-6.05)% vs 2.01(1.55-2.74)%, p=0.014] and the non 
ischaemic [6.27(3.12-10.44)% vs 2.01(1.55-2.74)%, p=0.003] lobes in the mice that 
underwent IR injury. There was significantly lower number of classical monocytes in 
mice that under went RIPC prior to IR injury compared to those that underwent IR 
injury alone (Figure 9.4). This was again seen in both lobes [1.89(1.36-3.69)% vs 
3.61(2.43-6.05)%, p=0.049] and [1.75(1.37-3.7)% vs 6.27(3.12-10.44)%, p=0.007]. 
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Figure 9.4: shows the number of monocytes as a percentage of total live cells 
extracted from the murine livers. 
A – sham laparotomy, B – RIPC only, C – IR injury only, D – RIPC + IR 
injury. Each point represents a mouse (8 in each group). Statistical significance 
was tested by Kruskal-Wallis test and by Mann-Whitney u tests between the 
groups.  
9.3.2: Humans. 
Paired liver graft biopsies were collected immediately pre implantation and at 2 
hours post reperfusion from 5 patients undergoing liver transplantation and were 
analysed for the presence of monocytes. The percentage of classical monocytes in 
the post reperfusion biopsies was significantly higher than in the pre implantation 
biopsies [4.18(±2.61)% vs 0.61(±0.38)%, p=0.018] (Figure 9.5). In 3 of 5 patients 
there was a mismatch between the donor and recipient at the HLA-A2 or HLA-A3 
allele. In these post reperfusion biopsies, 62.6(41.2-77.6)% of classical monocytes 
had the same HLA allele as recipient (Figure 9.6). A representative example of the 
difference from one set of paired biopsies is shown in figure 9.5. 
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A                                                                    B 
      
Figure 9.5:  
A: increased number of monocytes in the 5 post reperfusion biopsies compared 
to pre implantation. Each line joins the pre and post implant biopsy monocyte 
number in an individual patient. Statistical significance was determined by the 
Mann-Whitney U test. 
B: The majority of monocytes in the post reperfusion biopsy are of recipient 
origin. Each line joins the pre and post implant biopsy in an individual patient 
Pre-implantation                                 Post-reperfusion        
 
Figure 9.6: Shows an increase in the number of classical monocytes in the post 
reperfusion biopsy. The donor was HLA-A2 +ve and the recipient was HLA-A2-
ve. 
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9.3.3: Cytokine production by monocytes in patients undergoing liver 
transplantation. 
Peripheral blood mono-nuclear cells and post reperfusion biopsies collected from 20 
consecutive patients and analysed for CD4+ T cells cytokine production (Chapter 
3.4) were re-analysed for monocyte cytokine production. IFNγ production was 
upregulated following mobilization of the recipient liver but was not significant 
[5.61(3.77-14.2)% vs 2.27(1.44-9.31)%, p=0.071]. The percentage of CD3-
veHLADR+ve cells actively producing IFNγ was significantly upregulated following 
reperfusion [27.9(10.79-54.28)% vs 2.27(1.44-9.31)%, p<0.0001] (Figure 9.7). IL-2 
production was similarly significantly upregulated following reperfusion [20.5(3.23-
46.08)% vs 1.83(0.80-5.00)%, p=0.0003] (Figure 9.6). IFNγ and IL-2 production by 
CD3-veHLADR+ve cells in the post ischaemic liver were even higher than in the 
circulation at 60.7(29.4-78.4)% and 64.1(35.9-78.7)% respectively (Figure 9.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 197 
IFNγ 
A                                             B                                          C 
          
IL-2 
D                                             E                                          F 
       
 
Figure 9.7. 
A-C relate to IFNγ. A shows an example of the pre-op stain and B shows an 
example of the post reperfusion stain. C demonstrates a significant increase in 
IFNg production following reperfusion both in the circulation and liver (each 
dot represents a patient and significance is demonstrated by Mann-Whitney u 
test). 
D-F relate to IL-2. D shows an example of the pre-op stain and E shows an 
example of the post reperfusion stain. F demonstrates a significant increase in 
IL-2 production following reperfusion both in the circulation and liver (each dot 
represents a patient and significance is demonstrated by Mann-Whitney u test). 
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9.4: Discussion. 
These results clearly demonstrate that classical monocytes are recruited to the liver 
following IR injury. By using HLA staining where there was a donor/recipient 
mismatch it has shown that these monocytes are derived from the recipient.  
Monocytes are rapidly mobilized from the bone marrow in a CCL2 dependent 
fashion following tissue injury and have been shown to play a key role in 
paracetamol and CCL4 induced liver injury. Studies have shown that CCL2 mRNA is 
upregulated in the ischaemic lobe of the liver within 3 hours of reperfusion [253]. 
This is in keeping with the increased serum levels of CCL2 observed in both the 
mice and humans samples at 2 hours post reperfusion [244] (Chapters 3.4 and 3.5). 
Interestingly, although in previous studies, CCL2 was released only from the 
ischaemic lobe, in this murine study, there were higher numbers of classical 
monocytes in the non-ischaemic lobes. This likely reflects the fact that inflow 
occlusion performed on the ischaemic lobes prevented any blood flow to that lobe 
for 45 minutes while the venous outflow remained patent allowing mediators to be 
released into the systemic circulation. Therefore classical monocytes recruited to the 
liver during this time would only have access to the non-ischaemic lobe. Other 
studies have shown that monocytes recruitment peaks at around 12 hours post 
reperfusion [56]. This would explain why the number of monocytes recruited to the 
post ischaemic liver although statistically significant was not as large as those 
recruited following carbon tetrachloride induced hepatic injury [52]. 
There was similarly clear evidence of a recruitment of classical monocytes to the 
post-ischaemic liver following reperfusion. To our knowledge, no other group has 
shown this before. In the RIPCOLT trial, 18 patients developed early allograft 
dysfunction and these patients had significantly higher circulating levels of IL-10 
(p=0.008) than those that did not (data in chapter 3.4). Similarly the 6 patients who 
developed a graft specific complication (bile duct stricture or bile leak) had 
significantly higher circulating levels of IL-10 at 2 hours post reperfusion (p=0.006) 
(data in chapter 3.4). Human inflammatory monocytes [222,254], macrophages 
[255,256] and dendritic cells [256] are known to produce IL-10 and ROS following 
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TLR4 stimulation by LPS. Liver IR injury is believed to be driven by HMGB1 which 
stimulates TLR4 in a similar fashion to LPS [16]. Raised IL-10 levels post 
reperfusion have been noted in 2 other studies [220,221] and it is likely that this 
increase in circulating levels of IL-10 post reperfusion reflects innate immune cell 
stimulation. Interestingly patients who received a DCD graft similarly had 
significantly higher levels of IL-10 at 2 hours post reperfusion (p=0.01) again 
suggesting increased monocyte activation. Three of 5 patients who received a DCD 
graft in the RIPCOLT trial developed bile duct strictures within the first year post 
transplantation. In total 4 patients developed a bile duct stricture and these patients 
again had significantly higher levels of IL-10 post reperfusion (p=0.046). Classical 
monocytes have been shown to drive liver fibrosis [52] in a mouse model and may 
therefore not only be involved in the acute IR injury but may also drive the 
development of post-ischaemic inflammatory bile strictures – a devastating 
complication particularly associated with the use of DCD grafts. Systemic IL-10 
levels may therefore be an early marker of graft dysfunction/injury although a larger 
cohort would need to be analysed to prove this. 
Although there was clear evidence of monocyte recruitment to the post-ischaemic 
liver, the cytokine activation profile in the samples from the RIPCOLT trial suggest 
activation of dendritic cells. Inflammatory dendritic cells are terminally 
differentiated monocytes that occur during inflammatory states [252] and may occur 
rapidly. The cytokine profile of the cells from the RIPCOLT trial would suggest that 
the activated cells may have differentiated into inflammatory dendritic cells as 
monocytes are not known to produce IL-2 whilst dendritic cells are known to 
produce IL-2 upon activation [257] and iNOS [53,258]. IL-2 is a key cytokine in the 
differentiation of CD4 effector cells response promoting a Th1 differentiation 
characterized by production of IFNγ. In high doses, IL-2 can even promote this 
differentiation in the absence of T cell receptor antigen stimulation which may 
explain why CD4+ T cells can be activated during IR injury without the need for 
antigen [259]. Furthermore IL-2 when combined with CD4+ derived IFNγ is a potent 
activator of monocytes [64]. The potential complex interplay between CD4+ T cells, 
monocytes and dendritic cells is contained in figure 9.8. 
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Figure 9.8: Interplay between CD4+ T cells, dendritic cells and monocytes in IR 
injury. 
 
The main issue with this analysis is that no panel was designed specifically to 
identify dendritic cells and as such the cell population can only be inferred. The 
results are exciting as monocytes/dendritic cells remain a relatively unexplored 
pathway of the immune mediated damage that follow reperfusion.  
Both dendritic cells and monocytes are mobilized from the bone marrow in a CCL2 
[48] fashion and therefore inhibition of CCL2 is an exciting concept. Results from 
the RIPCOLT trial show that CCL2 levels at 24 hours post-operatively correlate with 
development of early allograft dysfunction and AST day 3 levels. Another study 
demonstrated a correlation between CCL2 levels 1 hour post reperfusion with and 
serum transaminases (measured at an unknown timepoint) [50] This likely reflects 
ongoing inflammatory damage and monocyte recruitment which may be blocked by 
CCL2 inhibition. One study has shown with genetic knock out mice lacking CCL2 
that they suffer from a significantly reduced hepatic IR injury [56]. Although this 
model is interesting and would allow further dissection of the exact mechanisms of 
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monocyte driven damage, this does not reflect clinical practice. Models that 
transiently inhibit chemokines are required and would more accurately reflect the 
potential treatment pathway in humans, in which chemokines may be transiently 
inhibited during the anhepatic phase prior to reperfusion. Pharmacological inhibition 
of CCL2 with mNOX-E36 has been shown in murine models to block monocyte 
recruitment [247] and has been shown in in a phase II trial to be safe in humans – 
although it took 2 weeks to reach steady state and monocyte levels were only 
measured after 1 week and its use in such an acute setting remains untested. 
Although classical monocytes have been shown to play a role in the acute immune 
driven injury, an interesting study has shown that once recruited monocytes can 
change their function from pro inflammatory to anti inflammatory and aid in 
resolution of inflammation and organ recovery [57]. Therefore longer recovery 
experiments are necessary to assess not only the effect of CCL2 blockade in the early 
reperfusion injury but also its effect on hepatic recovery following IR injury as 
experiments in knock out mice lacking IL-6 have suggested reduced recovery in the 
absence of this pro-inflammatory cytokine [76]. It may be that transient blockade of 
inflammatory cytokines at time of maximal injury when DAMP concentrations are at 
their highest may reduce injury and allow later influx of inflammatory cells to allow 
tissue healing and proliferation. Experiments with transient antibody blockade are 
therefore essential next steps to introduce a potential new treatment for IR injury. 
This should be combined with further studies in CCL2 knock out mice to identify 
further pathways of monocyte driven injury and potentially allow even more targeted 
therapies 
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Chapter	 10:	 Summary	 and	 Future	
work.	
This work has identified several key findings.  
10.1: Meta-analysis of donor IPC in liver transplant. 
Meta-analysis of current published clinical trials of donor IPC in liver transplant 
donors has shown evidence of a large reduction in incidence of recipient 1 year 
mortality (45%) and primary graft non-function (82%). Although large, neither of 
these differences were significant (p=0.06 and p=0.12 respectively) primarily due to 
insufficient patient numbers (n=593). Using the data obtained from this meta-
analysis to perform a power calculation demonstrated that to adequately power a trial 
of donor IPC to identify a significant difference in recipient mortality and primary 
graft non-function would require a total sample size of 974 patients. As 650 liver 
transplants are performed in the UK each year, assuming a recruitment rate of around 
30%, such a trial, involving all UK centres, would be feasible and could be 
completed within 5 years. 
10.2: Surrogate end-points in clinical trials modulating IR injury. 
In a retrospective analysis of patients undergoing liver transplantation at the Royal 
Free, post-operative transaminases were found to correlate well with post-operative 
graft loss and recipient morbidity and mortality within the first 3 months post 
transplant. The importance of this result is two-fold. Firstly small animal models use 
a reduction in post-operative transaminases as a key endpoint in trials to reduce 
hepatic IR injury and therefore this endpoint is clinically relevant. Secondly current 
post-operative 90 day mortality and graft loss in UK transplant centres is 3.5% and 
6.9% and therefore it is difficult to demonstrate evidence of clinical benefit in small 
pilot studies. The use of post-operative transaminases as a surrogate end-point in 
early pilot studies would provide the ability to demonstrate evidence of clinical 
benefit when determining which interventions should proceed to larger randomized 
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clinical trials. This finding now needs to be confirmed in a prospective, likely multi-
centre, clinical study to validate this finding. A further end-point identified was the 
use of urinary NGAL levels measured at time of abdominal closure in identifying the 
presence of acute kidney injury (AKI). A major issue with current methods to 
diagnose AKI is the delay of 48 hours in which significant and irreversible renal 
parenchymal damage may occur. Furthermore by the time AKI is diagnosed, a 
window of opportunity for intervention has been missed. Recent work from the 
Royal Free has identified that the development of peri-transplant AKI is associated 
with worse long term renal function up to 10 years post transplant. The more 
prolonged or severe the renal impairment is the worse the long-term renal function 
was. The measurement of NGALs in liver transplant patients will allow better 
diagnosis of this common complication and prompter initiation of therapy resulting 
in improved outcomes. Furthermore NGAL levels measured post-operatively would 
allow trials to be designed centered around early interventions to improve post-
operative renal function. A key limitation to this work was that NGAL levels were 
measured by standard ELISA which took 8 hours. There are several point of care 
testing kits available that can provide levels within the hour. These tests will need to 
be validated in liver transplant patients to allow for rapid measurements of urinary 
NGAL levels. A small grant application for this work is currently being submitted 
and urine samples are being collected. 
10.3: RIPC in liver transplant recipients. 
This was the first trial of remote ischaemic preconditioning in liver transplant 
recipients. As such, fundamental questions had to be answered including the ability 
to recruit liver transplant recipients, and the willingness of the transplant team for 
patients to undergo RIPC during the transplant procedure. A key issue was the safety 
of limb preconditioning in patients with end stage liver disease undergoing major 
surgery. The trial successfully achieved its primary endpoints of recruitment, 
retention and safety. 
Secondary endpoints had been identified as surrogate markers that may demonstrate 
evidence of clinical benefit in a smaller population. There was no evidence to 
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suggest that in its current form, RIPC of liver transplant donors improved outcomes 
post liver transplant. 
A key finding in this study was that despite the tourniquet being inflated for 5 
minutes, analysis of venous blood collected from the limb found that true ischaemic 
conditionings were not created in the limb during the preconditioning stimulus. This 
may be secondary to the administration of high flow oxygen during the transplant 
procedure and therefore during the preconditioning stimulus. A recent pilot study of 
RIPC in patients undergoing liver resection surgery used 10 minute preconditioning 
cycles and did demonstrate evidence of a reduction in liver injury as measured by 
reduced peak post-operative transaminases and improved post-operative idocyanine 
green clearance [12]. The next step in this study is to analyse a longer 
preconditioning stimulus. A major amendment is currently being submitted to the 
ethical board to include a cohort of 20 patients to undergo an altered RIPC protocol 
of 3 by 10 minute cycles. This cohort will be compared against both groups from the 
RIPCOLT trial. 
10.4: Cytokine and CD4+ T cell responses following liver IR injury 
in humans. 
Analysis of per-operative plasma samples collected from 28 patients undergoing 
liver transplant demonstrated significantly elevated circulating levels of CCL2, IL-6, 
IL-8, IL-10 and IL-17A. Patients who developed graft specific adverse outcomes or 
received an inferior graft from a donor following cardiac death had higher IL-10 
levels post reperfusion and this likely reflects toll like receptor 4 stimulation of 
monocytes. Patients with early allograft dysfunction had higher levels of CCL2 at 24 
hours post-reperfusion. Both these results suggest that monocyte recruitment and 
activation play a key role in graft injury and long term graft complication and 
identify this cell lineage as a putative target of immune modulation to reduce IR 
injury. 
Analysis of the CD4+ T cell population directly ex vivo in these patients 
demonstrated that although CD4+ T cell production of IL-6 and TNFα were 
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upregulated post reperfusion, the most striking upregulation was of IFNγ. IFNγ is a 
Th1 cytokine that has been shown to play a key role in activating monocytes and 
driving a M1 macrophage response which is dominated by tissue damage resulting 
from iNOS production of ROS. This finding may explain the role of CD4+ T cells in 
the pathogenesis of IR injury. Fresh cells were analysed and as such several key 
cytokines were not analysed as they were not included in the panel from the outset. A 
key chemokine identified is CCL2 and it would be of benefit to analyse patient cells 
to identify the cellular source of CCL2. If it were found to CD4+ T cells, this may 
further explain the role CD4+ T cells and the interplay between CD4+ T cells and 
monocytes. Ethical approval to allow for collection and analysis of these samples 
will be included in the further ethical amendment for the longer preconditioning 
stimulus. 
10.5: The effect of RIPC on CD4+ T cells in a murine model. 
CCL2, IL-6 and IL-10 were identified as key cytokines that were elevated post IR 
injury in patients undergoing liver transplant recruited to the RIPCOLT trial. Both 
CCL2 and IL-6 were elevated in plasma samples collected from mice at 2 hours post 
reperfusion and were significantly reduced in mice that underwent RIPC. IL-10 
levels were not elevated following IR injury. This is likely reflect in the fact that 
inflammatory monocytes in mice do not produce IL-10 when activated although they 
do in humans [222]. Further studies are now required to investigate the role of 
transiently inhibiting CCL2 in murine models and administering mice with CCL2 
post RIPC to investigate further the role of reduced CCL2 secretion in the protective 
mechanism of RIPC. 
Analysis of cells in mice demonstrated significant upregulation of TNFα production 
by intra-hepatic CD4+ T cells following IR injury and a significant reduction in 
TNFα production in mice that underwent RIPC. There was no upregulation of IFNγ 
by CD4+ T cells in mice following IR injury. A major recent advancement in IR 
injury has been the development of normothermic machine perfusion both as a 
preservation method and as a method for further researching modulation of IR injury 
in discarded or animal livers. This creates the ability to provide targeted 
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immunotherapy (infliximab) to the liver without subjecting the recipient to potential 
side-effects. Further studies of modulating IR injury by administrating immune 
therapy via machine perfusion could now be considered. 
10.6: Can RIPC modulate CD4+ T cell response following in vitro 
activation. 
Evidence from this study has shown that RIPC in healthy volunteers led to evidence 
of increased activation of CD4+ T cells and increased cytokine production upon in 
vitro stimulation. A major drawback was the use of OKT3 antibody which activated 
T cells through the T cell receptor. IR injury is likely independent of T cell receptor 
stimulation and therefore further studies of T cell stimulation via toll like receptor 4 
with high mobility group box 1 may provide a more accurate reflection of the in vivo 
process. Development of lab models of IR injury are of great importance as they 
would allow the early analysis of immune modulation whilst minimizing the use of 
laboratory animals.  
10.7: Hepatic recruitment of monocytes following liver IR injury. 
Results from this analysis clearly demonstrated recruitment of monocytes to the post 
ischaemic liver in both the murine and human models. Three recipient/donors had a 
mismatch at the HLA-A2/A3 alleles allowing us to confidently say that the recruited 
monocytes a derived from the recipient. Therefore investigation to transiently inhibit 
monocyte infiltration and activation should be focused on the recipient and not the 
donor. 
Retrospective analysis of the sample collected from 28 patients in the RIPCOLT trial 
showed significant upregulation if IFNγ and IL-2 by a cell population that was CD3-
ve and HLADR+ve. This cell is most likely to be dendritic cells as monocytes are 
not known to produce IL-2. Further analysis of this cell population with a panel 
specifically designed to identify these cells is paramount as this upregulation has to 
reflect a cell type that plays a key role in IR injury and could therefore be targeted. If 
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it is dendritic cells, they are similarly recruited by CCL2 and therefore CCL2 
inhibition remains warranted. 
10.8: Next key step. 
The key finding in this thesis is the identification of the role monocytes or monocyte 
derived dendritic cells in the pathogenesis of liver IR injury both in mice and 
humans. This is very exciting as it remains a relatively unexplored area of IR injury. 
The combination of further detailed analysis of IR injury in CCL2 knock out mice, 
transient inhibition of CCL2 in murine models of IR injury and the further analysis 
of this CD3-ve/HLADR+ve subset of cells in human patients would not only provide 
further knowledge of the pathways of the immune mediated reperfusion injury but 
would also lead to the development of a potential targeted therapy to reduce/treat IR 
injury. The work in this thesis has provided the background and skill set to make this 
future project feasible. 
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Appendix	1:	Patient	information	sheet	
and	consent	form	for	RIPCOLT	trial.	
PATIENT INFORMATION SHEET. 
Study title: Remote Ischaemic Preconditioning and Outcome of Liver Transplantation. 
Invitation  
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends and relatives if you wish. Ask us if there is anything that is not clear or 
if you would like more information. Take time to decide whether or not you wish to 
take part. 
Thank you for reading this. 
1. What is the purpose of the study? 
About 650 liver transplants are performed each year in the UK. During the transport 
period of the organs between the donor centre and recipient centre, the organs are 
damaged by the absence of blood flow (ischaemia) and when they are transplanted 
and blood flow is restored there is further damage (reperfusion injury). Brief 
reduction of blood flow to the arm or leg has been shown to reduce the effects of 
ischaemia and reperfusion injury (remote ischaemic preconditioning, RIPC) 
encountered after many types of surgery but has not been applied to liver 
transplantation. This study is aimed at determining whether RIPC is effective in 
decreasing ischaemia-reperfusion injury (I/R injury) in patients undergoing liver 
transplantation.  
2. Why have I been chosen? 
All patients waiting to undergo liver transplantation will be invited to take part in the 
study.  Once entered into the study you will be randomly allocated to RIPC group or 
no RIPC (control or standard treatment) group.  
3. Can I refuse to take part in the study or withdraw from the study?  
You do not have to take part in the study or you can withdraw at any stage. This will 
not affect your treatment in any way. If you refuse to participate in the study or 
choose to withdraw from the study before the intervention (RIPC or standard 
treatment) is carried out, we will provide you with the standard treatment. No further 
data will be collected. If you choose to withdraw from the study after the 
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intervention is carried out, we will use the data already collected while presenting the 
results, but will not collect any further data from the time of your withdrawal.  
4. What will happen to me if I take part? 
• While you are undergoing anaesthesia (being put to sleep for the purposes of 
the transplantation), a blood pressure cuff will be inflated around one of your 
legs for 5 minutes. This will then be deflated for a period of 5 minutes and 
then inflated again for a period of 5 minutes. This inflation and deflation 
cycles will be carried out thrice. The inflation pressure will not cause any 
damage to the legs or to the circulation, as frequently, bone doctors inflate the 
cuff for a continuous period of more than 1 hour while performing some 
operations. We perform this only for a 5 minute continuous period. Since you 
will be asleep during the procedure you will not feel any discomfort from the 
intervention. There will no increase in the time of the anaesthesia since this 
procedure will be carried out while other preparations for the surgery are 
performed.  Apart from this inflation and deflation of cuff, there will be no 
difference in the care that people who participate and do not participate 
receive.  
• As part of routine care, a bit of liver tissue (biopsy) is taken from you after 
liver transplantation. We will use some of that tissue for research purposes.  
• A second biopsy will be taken at the same time, which will be used for 
research purposes. 
• We will measure pressure in the portal vein (the vein carrying blood to the 
liver) at the end of liver transplant procedure. 
• Similarly, blood is routinely taken at the time of transplantation and after 
transplantation. The results of these blood tests will be collected as part of 
this research. In addition, data routinely collected by the NHS Blood and 
Transplant (NHSBT) to monitor your progress will also be used in this 
research. 
• We would measure markers of ischaemia-reperfusion injury in the blood 
samples collected routinely.  
• Similarly, we will measure markers of ischaemia-reperfusion injury in the 
urine. 
• Information will also be sought from routine biopsies in the post-operative 
period which is done to exclude suspected rejection. 
5. Will there be any changes to my treatment because of this research? 
Apart from this inflation and deflation of the blood pressure cuff, there will be no 
difference in the care that people who participate and do not participate receive.  
6. What do I have to do? 
There are no changes to your routine treatment or restrictions imposed on you from 
taking part in this research.   
7. What are the side effects of taking part? 
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We anticipate no disadvantages of having the cuff applied.  In a few patients where 
the tourniquet has been applied improperly or for more than half hour continuously, 
side effects have included pain in the leg, tingling and numbness and rarely damage 
to the blood vessel of the leg. However, we are applying the cuff for a continuous 
period of 5 minutes only.    
8. What are the possible disadvantages and risks of taking part? 
We do not anticipate any disadvantage or significant risks from taking part in this 
trial. Although this type of research has not been conducted in liver transplantation 
patients, cycles of brief inflation and deflation of the cuff has been performed in 
patients undergoing removal of part of liver, in patients donating their kidneys for 
their relatives, and in patients undergoing kidney transplantation with no reported 
disadvantages or risks. 
9. What are the possible benefits of taking part? 
RIPC may reduce the damage to your liver. The information we get from this study 
may help us to understand why livers get damaged during liver surgery and whether 
a simple interventional procedure will prevent this damage.   
10. Will my GP be informed of this research? 
We will not inform your GP routinely that you have participated in this research, as 
there will be no difference in the care that people who participate and do not 
participate receive, apart from this inflation and deflation of the blood pressure cuff.  
11. What if something goes wrong? 
Compression cuff is used routinely for some surgical procedures on the legs and has 
been shown to be safe and effective. If there was any complication as a result of this 
research, you would be treated under the NHS and will be covered under the NHS 
indemnity insurance. 
12. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you will stored using hospital 
numbers rather than using identifiable information names, address, and date of birth.   
13. What will happen to the results of the research study? 
The results from the study may be published in medical journals anytime between 6 
to 12 months following completion of the study, but you will not be identified.   
14. Who is organising and funding the research? 
The study is being supported by the Department of Hepatology at the Royal Free 
Hospital. There are no additional payments either to the doctor or patients for being 
involved in the study.  
15. Who has reviewed the study? 
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The study has been reviewed and approved by the Research Ethics Committee of the 
Royal Free Hospital.   
16. Contact for Further Information 
Prof Brian Davidson, MD, FRCS, 
Professor of HPB and Liver Transplantation Surgery 
 
We thank you for reading this information sheet.  Please keep a copy of this 
information sheet and the signed consent form for your records if you agree to 
participate in this study.     
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CONSENT FORM 
Title of Project:   Remote Ischaemic Preconditioning and Outcome of Liver Transplantation. 
Ethics approval number: 
Hospital number of the patient: 
1. I confirm that I have read and understand the information sheet dated 19th 
July 2011 (version 3) for the above study and have had the opportunity to 
ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals or from regulatory authorities where it  is relevant 
to my taking part in research.  I give permission for these individuals to 
have access to my records. 
4. I agree to take part in the above study.   
 
             
________________________ ________________ ________________ 
Name of patient Date  Signature 
 
_________________________ ________________ _________________ 
Name of person taking consent Date  Signature 
 
_________________________ ________________ _________________ 
Researcher Date  Signature 
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Appendix	 2:	 Supplementary	 data	
from	 analysis	 of	 samples	 from	
RIPCOLT	trial.	
 Age (S) Gender (M) Indication (KW) MELD (S) UKELD (S) 
CCL2 0.337 0.126 0.546 0.158 0.203 
CCL5 0.717 0.144 0.128 0.118 0.257 
IL-2 0.309 0.505 0.176 0.963 0.875 
IL-6 0.981 0.291 0.52 0.375 0.336 
IL-8 0.984 0.291 0.516 0.491 0.375 
IL-10 0.489 0.291 0.492 0.824 0.489 
IL-17 0.389 0.924 0.382 0.388 0.19 
IFNγ 0.16 0.975 0.379 0.588 0.713 
TNFα 0.165 0.681 0.294 0.893 0.902 
Table 1: Pre-operative cytokine levels and pre-operative characteristics. S= 
Spearman’ test, M= Mann-Whitney U test and KW = Kruskal-Wallis test. 
 Perfusate (%) Biopsy (%) P value 
CD3+ cells 43.4 (31.75-54.05) 36.8 (12.9-44.6) 0.282 
CD4+ cells 19.85 (13.9-34.4) 17.15(12.75-24.88) 0.143 
CD8+ cells 51.35 (39.03-58.98) 52.12 (36.8-59.88) 0.935 
Table 2: T cell populations in perfusate and biopsy as a percentage of the previous 
gate. 
  Control Preconditioned P value 
CD3+ 
cells 
Baseline 62.45 (44.45-73.13) 59.8 (41-66.6) 0.452 
Pre implantation 57.3 (35.93-74.9) 56.9 (34.2-66.7) 0.639 
Post reperfusion 40.05 (25.05-57.73) 47.2 (34.1-53.2) 0.926 
CD4+ 
cells 
Baseline 65.2 (57.28-75.15) 57.1 (53.7-71.77) 0.371 
Pre implantation 61.1 (42.73-71.48) 52.95 (46.7-73.1) 0.732 
Post reperfusion 37.4 (29.83-62.48) 47.9 (36.33-57.03) 0.552 
CD8+ 
cells 
Baseline 23.65 (18.78-31.55) 27.45 (13.9-38) 0.723 
Pre implantation 27.4 (20.7-37.58) 30 (15.43-40) 0.965 
Post reperfusion 42.05 (25.68-47.38) 30 (20.7-40.43) 0.239 
Table 3: T cells populations in preconditoned and control groups as a percentage of 
the previous gate. 
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  Control (%) Preconditioned (%) P value 
CD69 Baseline 0.52 (0.24-1.07) 0.52 (0.33-1.8) 0.661 
Pre implantation 1.22 (0.46-2.37) 0.62 (0.3-1.51) 0.267 
Post reperfusion 2.4 (1.24-3.54) 1.99 (0.69-3.44) 0.375 
CTLA-4 Baseline 5.89 (3.05-16.4) 7.45 (3.51-15.58) 0.894 
Pre implantation 8.31 (3.46-17.5) 9.33 (3.96-21.05) 0.726 
Post reperfusion 18.7 (9.61-30.2) 16.65 (8.88-25.48) 0.729 
HLADR Baseline 2.93 (1.6-3.83) 3.01 (2.25-9.31) 0.237 
Pre implantation 2.72 (2.07-4.21) 3.62 (1.95-10.85) 0.429 
Post reperfusion 5.77 (3.33-7.74) 4.39 (2.27-12.06) 0.76 
Table 4: T cells activation markers (CD69, CTLA-4 and HLADR) on CD4+ T cells. 
  Control (%) Preconditioned (%) P value 
CD69 Baseline 1.6 (0.71-5.56) 3.17 (1.1-6.49) 0.682 
Pre implantation 4.02 (1.46-10.2) 3.38 (1.45-10.27) 0.958 
Post reperfusion 12.6 (4.08-24.5) 8.11 (2.31-13.7) 0.510 
CTLA-4 Baseline 1.12 (0.53-1.99) 0.93 (0.48-1.64) 0.619 
Pre implantation 1.81 (0.49-3.84) 2.01 (0.42-3.4) 0.866 
Post reperfusion 4.21 (2.33-10) 4.17 (2.28-5.48) 0.641 
HLADR Baseline 3.58 (1.6-5.75) 3.96 (2.27-7.48) 0.623 
Pre implantation 2.59 (1.85-8.5) 3.12 (2.13-5.96) 0.673 
Post reperfusion 4.39 (2.16-10.3) 3.08 (1.81-4.46) 0.258 
Table 5: T cells activation markers (CD69, CTLA-4 and HLADR) on CD8+ T cells. 
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Appendix	 3:	 Supplementary	 data	
from	analysis	of	samples	from	healthy	
volunteers.	
  Pre RIPC Post RIPC 1 hour p 
C
ell type 
CD3 65.75 (57.38-73.05) 
72.7 (67.58-
74.83) 
70.35 (64.55-
77.65) 0.430 
CD4 52.7 (49.48-64.48) 
54.85 (49.8-
64.63) 
54.2 (50.58-
68.7) 0.052 
CD8 32.15 (21.38-36.48) 29.9 (22.2-35.08) 
28.45 (20.45-
34.4) 0.029 
Tregs 1.91 (0.36-7.18) 2.36 (0.6-6.68) 1.99 (0.22-6.5) 0.252 
C
D
4 T cells 
CD69 0.77 (0.26-1.43) 0.73 (0.42-1.28) 0.81 (0.39-1.49) 0.740 
CTLA-4 1.38 (1.13-3.41) 1.81 (1.28-4.44) 1.97 (1.53-5.1) 0.008 
HLADR 1.77 (1.33-2.03) 2.3 (1.59-2.91) 2.17 (1.36-2.39) 0.003 
IFNγ 0.11 (0.08-0.16) 0.14 (0.08-0.17) 0.11 (0.06-0.16) 0.913 
IL-2 0.04 (0.01-0.87) 0.04 (0.02-1.01) 0.02 (0.01-0.58) 0.430 
IL-10 0.22 (0.04-0.38) 0.17 (0.05-0.44) 0.06 (0.03-0.36) 0.643 
PD-1 0.39 (0.08-2.51) 0.95 (0.09-3.77) 0.74 (0.12-3.69) 0.142 
pS6 0.85 (0.52-0.91) 1.06 (0.58-3.33) 0.52 (0.38-0.92) 0.029 
TNFα 0.27 (0.21-0.53) 0.24 (0.17-0.53) 0.23 (0.11-0.42) 0.956 
Tregs 
CD69 12.75 (14.4-23.88) 
13.25 (8.79-
22.28) 
15.9 (13.63-
26.95) 0.430 
CTLA-4 41.6 (25.25-51.2) 39.2 (35.3-51.1) 49.0 (37.9-52.88) 0.052 
HLADR 19.4 (14.15-44.85) 
23.85 (13.65-
36.05) 
29.1 (11.83-
63.03) 0.740 
IL-10 3.03 (1.21-5.47) 3.79 (3.19-5.78) 4.83 (2.65-8.52) 0.838 
PD-1 6.77 (4.25-18.95) 8.37 (3.93-23.95) 7.96 (3.12-22.8) 0.956 
pS6 15.05 (13.23-20.53) 
24.65 (13.01-
31.93) 
15.0 (7.05-
25.55) 0.252 
Table 1: Ex vivo cell populations. Results expressed as median (IQR). Statistical 
significance measure by the Friedman test. 
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  Pre RIPC Post RIPC 1 hour p 
C
ell type 
CD3 70.85 (64.53-73.5) 
68.55 (62.65-
74.63) 
71.55 (59.2-
75.28) 0.956 
CD4 55.45 (51.48-62.3) 
56.2 (50.48-
66.33) 
58.75 (51.2-
67.3) 0.184 
CD8 28.2 (23.18-38.33) 27.3 (22.5-37.5) 
25.05 
(20.8535.58) 0.0001 
Tregs 3.17 (2.05-3.94) 3.1 (1.03-5.08) 2.81 (0.47-4.71) 0.430 
C
D
4 T cells 
CD69 66.95 (57.75-89.35) 
72.75 (64.6-
83.38) 
73.15 (65.83-
79.05) 0.274 
CTLA-4 17.05 (11.47-49.48) 
18.60 (12.65-
52.1) 
15.5 (8.75-
27.78) 0.252 
HLADR 1.57 (1.44-3.51) 2.07 (1.28-4.29) 2.71 (1.31-4.23) 0.956 
IFNγ 0.68 (0.22-4.21) 0.61 (0.39-6.02) 0.82 (0.30-6.81) 0.142 
IL-2 0.06 (0.03-5.91) 0.08 (0.02-8.14) 0.45 (0.02-7.86) 0.571 
IL-10 0.29 (0.11-0.41) 0.33 (0.14-0.47) 0.32 (0.16-0.6) 0.571 
PD-1 1.50 (0.48-4.36) 1.61 (0.65-5.69) 2.0 (1.27-5.33) 0.012 
pS6 2.44 (1.39-3.23) 1.37 (1.27-5.69) 1.39 (0.47-3.75) 0.931 
TNFα 4.28 (1.79-11.15) 5.26 (2.51-14.75) 
6.31 (2.54-
13.53) 0.012 
Tregs 
CD69 45.75 (30.98-67.63) 
45.25 (37.05-
65.1) 
40.25 (34.23-
70.13) 0.956 
CTLA-4 54.15 (28.1-76.45) 
63.05 (18.88-
81.2) 
45.65 (23.83-
60.95) 0.653 
HLADR 31.1 (12.62-44.28) 
37.8 (7.37-
54.38) 
52.95 (7.76-
60.73) 0.571 
IL-10 3.3 (1.79-7.0) 5.12 (3.06-8.22) 4.71 (2.23-8.33) 0.142 
PD-1 24.15 (21.43-29.78) 
28.65 (26.13-
32.78) 
32.4 (21.08-
36.98) 0.052 
pS6 27.65 (20.53-37.48) 
26.25 (18.23-
45.83) 
22.25 (16.95-
28.68) 0.571 
Table 2: Cell populations following in vitro activation. Results expressed as median 
(IQR). Statistical significance measure by the Friedman test. 
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Appendix	4:	Students	supervised,	and	
manuscripts	 published	 during	 the	
time	of	this	PhD.	
Students supervised. 
MSc in Surgical Sciences. 
2016: A Ahmed, MSc in Surgical Science (UCL)  
          Investigating the role of inflammatory monocytes and macrophages in  
          early ischaemia reperfusion in a liver transplant recipient. 
2015: A Yeung, MSc in Surgical Science (UCL) – awarded with distinction 
          Use of neutrophil gelatinase-associated lipocalin in predicting acute kidney  
          injury post orthotopic liver transplantation. 
Intercalated BSc in Surgical Sciences. 
2016: A Weiss, iBSc in Surgical Science (UCL) – awarded 2:1 
          The use of plasma and urinary NGAL levels in predicting acute kidney  
           injury post liver transplantation. 
2015: O Swann, iBSc in Surgical Science (UCL) – awarded 2:1 
          Urine albumin as a diagnostic marker for renal failure in post orthotopic   
          liver transplantation patients: generating a standard operating protocol for  
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          sandwich ELISA of human urine albumin. 
Published Manuscripts. 
Manuscripts directly from trial 
1. An Evaluation of Ischaemic Preconditioning as a Method of Reducing 
Ischaemia Reperfusion Injury in Liver Surgery and Transplantation. 
Robertson FP, Fuller BJ, Davidson BR. (2017) 
           Journal of Clinical Medicine 6(7) E69. 
2. Remote ischaemic preconditioning in orthotopic liver transplantation 
(RIPCOLT trial): a pilot randomized controlled feasibility study. 
Robertson FP, Goswami R, Wright GP, Imber C, Sharma D, Malago M, 
Fuller BJ, Davidson BR. (2017) 
            HPB (Oxford) 19(9) pp 757-767. 
3. A systematic review and meta-analysis of donor ischaemic 
preconditioning in liver transplantation. Robertson FP, Magill LJ, 
Wright GP, Fuller B, Davidson BR. (2016) 
            Transplant International 29(11) pp 1147-1154. 
4. Protocol for a prospective randomized controlled trial of recipient 
remote ischaemic preconditioning in orthotopic liver transplantation 
(RIPCOLT trial). Robertson FP, Goswami R, Wright GP, Fuller B, 
Davidson BR. (2016) 
            Transplant Research 6; 5:4. 
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5. High serum Aspartate transaminase levels of day 3 post liver 
transplantation correlates with graft and patient survival and would be a 
valid surrogate for outcome in liver transplantation clinical trials. 
Robertson FP, Bessell PR, Diaz-Nieto R, Thomas N, Rolando N, Fuller B, 
Davidson BR. (2016) 
            Transplant International 29(3), pp 323-30. 
 
Additional manuscripts published. 
1. Determining the outcomes of post-mastectomy radiation therapy 
delivered to the definitive implant in patients undergoing one- and two-
stage implant-based breast reconstruction: A systematic review and 
meta-analysis. Magill LJ, Robertson FP, Jell G, Mosahebi, Keshtgar M. 
(2017) 
            Journal of Plastic, Resconstructive and Aesthetic Surgery 70(10) pp 1329-   
            1335. 
2. IL-2high tissue-resident T cells in the human liver: Sentinels for 
hepatotropic infection. Pallett LJ, Davies J, Colbeck EJ, Robertson FP, 
Hansi N, Easom NJ, Burton AR, Stegmann KA, Schurich A, Swadling L, 
Gill US, Male V, Luong T, Gander A, Davidson BR, Kennedy PT, Maini 
MK. (2017) 
            Journal of Experimental Medicine 214(6) pp 1567-1580. 
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3. T cells Infiltrating Diseased Liver Express Ligands for the NKG2D 
Stress Surveillance System. Huang WC, EasomNJ, Tang XZ, Gill US, 
Sing H, Robertson FP, Chang C, Trowsdale J, Davidson BR, Rosenberg 
WM, Fusai G, Toubert A, Kennedy PT, Peppa D, Maini MK. (2017) 
             Journal of Immunology 198(3) pp 1172-1182. 
4. Effect of Remote Ischaemic Preconditioning on Liver Injury in patients 
Undergoing Major Hepatectomy for Colorectal Liver Metastesis: A Pilot 
Randomised Controlled Feasibility Trial. Kanoria S, Robertson FP, 
Mehta NN, Fusai G, Sharma D, Davidson BR. (2017) 
            World Journal of Surgery 41(5) pp 1322-1330. 
5. Eomes hi NK Cells in Human Liver Are Long-Lived and Do Not 
Recirculate but Can Be Replenished from the Circulation. Cuff AO, 
Robertson FP, Stegmann KA, Pallett LJ, Maini MK, Davidson BR, Male 
V. (2016) 
           Journal of Immunology 197911) pp 4283-4291. 
6. CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells 
residing in human liver. Stegmann KA, Robertson FP, Hansi N, Gill U, 
Pallant C, Christophides T, Pallet LJ, Peppa D, Dunn C, Fusai G, Male 
V, Davidson BR, Kennedy P, Maini MK. (2016) 
            Scientific Reports 6; 26157. 
7. A network meta-analysis comparing perioperative outcomes of 
interventions aiming to decrease ischaemia reperfusion injury during 
elective liver resection. Simillis C, Robertson FP, Afxentiou T, Davidson 
BR, Gurusamy KS. (2016) 
            Surgery 159(4), pp 1157-69. 
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8. A diaphragmatic retroperitoneal cyst. Robertson FP, Tsironis D, 
Davidson BR. (2015) 
            The Annals of the Royal College of Surgeons of England, Vol 97:5, e77-78. 
Published Abstracts. 
1. Recruitment of inflammatory monocytes after liver transplantation and 
correlation with outcomes. Robertson FP, Male V, Wright G, Fuller B, 
Davidson BR (2017). 
            The Lancet, Vol 389 S84. 
2. Circulating cytokine levels and outcome following human orthotopic 
liver transplantation. Robertson FP, Male V, Wright G, Fuller B, 
Davidson BR (2016). 
            Transplant International, Vol 29 S2. 
3. Inflammatory monocytes are the main producers of TNFα a key cytokine 
in hepatic IR injury. Robertson FP, Male V, Magill LJ, Wright G, Fuller 
B, Davidson BR (2016). 
            Transplant International, Vol 29 S2. 
4. The effect of remote ischaemic preconditioning prior to hepatic ischaemi 
reperfusion injury on CT4+ T cell cytokine production. Robertson FP, 
Male V, Magill LJ, Wright G, Fuller B, Davidson BR (2016). 
            Transplant International, Vol 29 S2. 
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5. Preoperative renal failure predicts reduce survival following liver 
transplantation but not liver specific graft failure or death. Robertson 
FP, Siriwardana P, Bessell P, Diaz-Nieto R, Rolando N, Davidson BR 
(2014). 
           Hepatology, Vol 1 S1. 
6. Evolving renal failure in the post-operative period correlates with overall 
graft survival following liver transplantation. Robertson FP, 
Siriwardana P, Bessell P, Diaz-Nieto R, Rolando N, Davidson BR (2014). 
           Hepatology, Vol 1 S1. 
7. Serum aspartate transaminase levels on the third post-operative day 
correlate with overall survival and liver specific survival at 10 years 
following liver transplantation. Robertson FP, Bessell P, Diaz-Nieto R, 
Rolando N, Davidson BR (2014). 
            Hepatology, Vol 1 S1. 
Published Book Chapters. 
1. Cyanoacrylate tissue glues for cutaneous wound closure. Robertson FP, 
Magill LJ, Davidson C, Mitchell H, Davidson BR (2016) 
            Wound Healing Biomaterials (Volume 2), Woodhead Publishing (UK). 
2. Causes of SIRS in surgery: Pancreatitis. Robertson FP. (2012) 
            Critical Care Handbook for Global Surgery, Alba (UK). 
 
 
